WO2005023260A1 - 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses - Google Patents

1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses Download PDF

Info

Publication number
WO2005023260A1
WO2005023260A1 PCT/EP2004/009665 EP2004009665W WO2005023260A1 WO 2005023260 A1 WO2005023260 A1 WO 2005023260A1 EP 2004009665 W EP2004009665 W EP 2004009665W WO 2005023260 A1 WO2005023260 A1 WO 2005023260A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
alkyl
piperazine
fluoro
piperazin
Prior art date
Application number
PCT/EP2004/009665
Other languages
French (fr)
Inventor
Daniela Alberati-Giani
Synese Jolidon
Robert Narquizian
Matthias Heinrich Nettekoven
Roger David Norcross
Emmanuel Pinard
Henri Stalder
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP04764631A priority Critical patent/EP1663232B1/en
Priority to CN2004800321632A priority patent/CN1874777B/en
Priority to NZ545454A priority patent/NZ545454A/en
Priority to PL04764631T priority patent/PL1663232T3/en
Priority to MXPA06002727A priority patent/MXPA06002727A/en
Priority to BRPI0414209A priority patent/BRPI0414209B8/en
Priority to DE602004009323T priority patent/DE602004009323T2/en
Priority to DK04764631T priority patent/DK1663232T3/en
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to JP2006525694A priority patent/JP4563386B2/en
Priority to CA2537292A priority patent/CA2537292C/en
Priority to AU2004269889A priority patent/AU2004269889B2/en
Publication of WO2005023260A1 publication Critical patent/WO2005023260A1/en
Priority to IL173768A priority patent/IL173768A0/en
Priority to NO20060768A priority patent/NO20060768L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to compounds of the general formula I
  • Ar is unsubstituted or substituted aryl or 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups are substituted by one or more substituents selected from the group consisting of hydroxy, halogen, NO 2 , CN, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl substituted by halogen, ( - -alkoxy, (C C 6 )-alkoxy substituted by halogen, NR 7 R 8 , C(0)R 9 or SO 2 R 10 ;
  • R 1 is hydrogen or (C ⁇ -C 6 )-alkyl
  • R 2 and R 2 are independently from each other hydrogen, (CR 2 ) n -hydroxy for R being hydrogen or Ci-C 6 )-alkyl, or are (C ⁇ -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C C 6 )-alkyl substituted by halogen, (CH 2 ) n -(C 3 -C 6 )-cycloaIkyl, (CH 2 ) n -heterocycloalkyl, (CH 2 ) n -0-(C 1 -C 6 )-alkyl or (CH 2 ) n -aryl or R 2 and R 2 form together with the N atom to which they are attach a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O, which rings are unsubstituted or substituted by (CH 2 ) n -hydroxy, (CrC 6 )
  • R 5 is N0 2 , CN, C(O)R 9 , S-(C 1 -C 6 )-alkyl, SO 2 R 10 or is NR ⁇ R 12 ;
  • R 7 and R 8 are independently from each other hydrogen, (CH 2 ) n -(C 3 -C 6 )-cycloalkyl or (C 1 -C 6 )-alkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
  • R 9 is hydroxy, (C ⁇ -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (C 1 -C 6 )-alkoxy or NR 7 R 8 ;
  • R 10 is (C C 6 )-alkyl, (CH 2 ) admir-(C 3 -C 6 )-cycloalkyl or NR 7 R 8 ;
  • R 11 and R 12 are independently from each other hydrogen, C(O)-(C 1 -C 6 )-alkyl, SO 2 -(Cr )-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, ( -Q ⁇ -alkyl or (CH 2 ) n (C 3 -C 6 )-cycloalkyl;
  • n 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof, with the proviso that l-[5-(aminosulfonyl)-2-(4-morpholinyl)benzoyl]-4-phenyl-piperazine, l-(4-methoxyphenyl)-4-[2-(4-morpholinyl)-5-nitrobenzoyl]-piperazine, l-[2-(4-morpholinyl)-5-nitrobenzoyl]-4-[2-nitro-4-(trifluoromethyl)phenyl]- piperazine,
  • the compound 1 - [ 5- (aminosulfonyl) -2- (4-morpholinyl)benzoyl] -4-phenyl-piperazine has been described specifically in US 4,244,871, which possess tyrosine-paralyzing activity, and the other compounds mentioned above are commercially available products.
  • the present invention relates to compounds of general formula I, to pharmaceutical composition containing them and their use in the treatment of neurological and neuropsychiatric disorders. It has surprisingly been found that the compounds of general formula I are good inhibitors of the glycine transporter 1 (GlyT- 1), and that they have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors.
  • Schizophrenia is a progressive and devastating neurological disease characterized by episodic positive symptoms such as delusions, hallucinations, thought disorders and psychosis and persistent negative symptoms such as flattened affect, impaired attention and social withdrawal, and cognitive impairments (Lewis DA and Lieberman JA, Neuron, 28:325-33, 2000).
  • episodic positive symptoms such as delusions, hallucinations, thought disorders and psychosis and persistent negative symptoms such as flattened affect, impaired attention and social withdrawal, and cognitive impairments
  • For decades research has focused on the "dopaminergic hyperactivity" hypothesis which has led to therapeutic interventions involving blockade of the dopaminergic system (Vandenberg RJ and Aubrey KR., Exp. Opin. Ther. Targets, 5(4): 507-518, 2001; Nakazato A and Okuyama S, et al., Exp. Opin. Ther. Patents, 10(1): 75-98, 2000).
  • transgenic mice expressing reduced levels of the NMDAR1 subunit displays behavioral abnormalities similar to those observed in pharmacologically induced models of schizophrenia, supporting a model in which reduced NMDA receptor activity results in schizophrenia-like behavior (Mohn AR et al., Cell, 98: 427-236, 1999).
  • Glutamate neurotransmission, in particular NMDA receptor activity plays a critical role in synaptic plasticity, learning and memory, such as the NMDA receptors appears to serve as a graded switch for gating the threshold of synaptic plasticity and memory formation (Wiley, NY; Bliss TV and Collingridge GL, Nature, 361: 31-39, 1993).
  • mice overexpressing the NMDA NR2B subunit exhibit enhanced synaptic plasticity and superior ability in learning and memory (Tang JP et al., Natur, 401- 63-69, 1999).
  • enhancing glutamate transmission in particular via NMDA receptor activation, would be predicted to produce both anti-psychotic and cognitive enhancing effects.
  • the amino acid glycine is known to have at least two important functions in the CNS. It acts as an inhibitory amino acid, binding to strychnine sensitive glycine receptors, and it also influences excitatory activity, acting as an essential co-agonist with glutamate for N-methyl-D-aspartate (NMDA) receptor function. While glutamate is released in an activity-dependent manner from synaptic terminals, glycine is apparently present at a more constant level and seems to modulate/control the receptor for its response to glutamate. One of the most effective ways to control synaptic concentrations of neurotransmitter is to influence their re-uptake at the synapses.
  • Neurotransmitter transporters by removing neurotransmitters from the extracellular space, can control their extracellular lifetime and thereby modulate the magnitude of the synaptic transmission (Gainetdinov RR et al, Trends in Pharm. ScL, 23(8): 367-373, 2002).
  • Glycine transporters which form part of the sodium and chloride family of neurotransmitter transporters, play an important role in the termination of post- synaptic glycinergic actions and maintenance of low extracellular glycine concentration by re- uptake of glycine into presynaptic nerve terminals and surrounding fine glial processes.
  • GlyT-1 and GlyT-2 Two distinct glycine transporter genes have been cloned (GlyT-1 and GlyT-2) from mammalian brain, which give rise to two transporters with ⁇ 50 % amino acid sequence homology.
  • GlyT-1 presents four isoforms arising from alternative splicing and alternative promoter usage (la, lb, lc and Id). Only two of these isoforms have been found in rodent brain (GlyT-la and GlyT-lb).
  • GlyT-2 also presents some degree of heterogeneity.
  • Two GlyT-2 isoforms (2a and 2b) have been identified in rodent brains.
  • GlyT-1 is known to be located in CNS and in peripheral tissues, whereas GlyT-2 is specific to the CNS.
  • GlyT-1 has a predominantly glial distribution and is found not only in areas corresponding to strychnine sensitive glycine receptors but also outside these areas, where it has been postulated to be involved in modulation of NMDA receptor function (Lopez-Corcuera B et al., Mol. Mem. Biol, 18: 13-20, 2001).
  • one strategy to enhance NMDA receptor activity is to elevate the glycine concentration in the local microenvironment of synaptic NMDA receptors by inhibition of GlyT-1 transporter (Bergereon R. et al., Proc. Natl. Acad. Sci. USA, 95: 15730-15734, 1998; Chen L. et al., /. NeurophysioL, 89(2): 691-703, 2003).
  • Glycine transporters inhibitors are suitable for the treatment of neurological and neuropsychiatric disorders.
  • the majority of diseases states implicated are psychoses, schizophrenia (Armer RE and Miller DJ, Exp. Opin. Ther. Patents, 11 (4): 563-572, 2001), psychotic mood disorders such as severe major depressive disorder, mood disorders associated with psychotic disorders such as acute mania or depression, associated with bipolar disorders and mood disorders, associated with schizophrenia, (Pralong ET et al., Prog. Neurobiol, 67: 173-202, 2002), autistic disorders (Carlsson ML, J. Neural Trans,.
  • cognitive disorders such as dementias, including age related dementia and senile dementia of the Alzheimer type, memory disorders in a mammal, including a human, attention deficit disorders and pain (Armer RE and Miller DJ, Exp. Opin. Ther. Patents, 11 (4): 563-572, 2001).
  • AD disorders such as dementias, including age related dementia and senile dementia of the Alzheimer type, memory disorders in a mammal, including a human, attention deficit disorders and pain (Armer RE and Miller DJ, Exp. Opin. Ther. Patents, 11 (4): 563-572, 2001).
  • increasing activation of NMDA receptors via GlyT-1 inhibition may lead to agents that treat psychosis, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
  • Objects of the present invention are the compounds of formula I per se, the use of compounds of formula I and their pharmaceutically acceptable salts for the manufacture of medicaments for the treatment of diseases related to activation of NMDA receptors via Glyt-1 inhibition, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula I in the control or prevention of illnesses such as psychoses, disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
  • the preferred indications using the compounds of the present invention are schizophrenia, cognitive impairment and Alzheimer's disease.
  • alkyl denotes a saturated straight- or branched-chain group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl and the like.
  • Preferred alkyl groups are groups with 1 - 4 carbon atoms.
  • alkenyl denotes an unsaturated straight- or branched-chain group containing from 2 to 6 carbon atoms. Preferred alkenyl group is allyl.
  • halogen denotes chlorine, iodine, fluorine and bromine.
  • aryl denotes a monovalent cyclic aromatic hydrocarbon radical consisting of one or more fused rings in which at least one ring is aromatic in nature, for example phenyl or naphthyl.
  • 6-membered heteroaryl containing one, two or three nitrogen atoms denotes a monovalent aromatic carbocyclic radical, for example pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl or triazinyl.
  • 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three further nitrogen atoms denotes a monovalent aromatic carbocyclic radical, for example pyrrolyl, 2,5-dihydro-pyrrol-l-yl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl.
  • heterocycloalkyl denotes a non aromatic hydrocarbon radical, for example azepanyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl; pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or thiomorphoUnyl.
  • pharmaceutically acceptable acid addition salts embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.
  • Preferred compounds of formula I are those of formula 1-1
  • R' is hydroxy, halogen, NO 2 , CN, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl substituted by halogen, (C C 6 )-alkoxy, (C C 6 )-alkoxy substituted by halogen, NR 7 R 8 , C(O)R 9 or SO 2 R 10 ; m is 0, 1, 2 or 3; R 1 is hydrogen or (C 1 -C 6 )-alkyl;
  • R 2 and R 2 are independently from each other hydrogen, (CR 2 ) n -hydroxy for R being hydrogen or -Q -alkyl, or are (C C 6 )-alkyl, (C 2 -C 6 ) -alkenyl, ( -C ⁇ -alkyl substituted by halogen, (CH 2 ) n - (C 3 -C 6 )-cycloalkyl, (CH 2 ) n -heterocycloalkyl, (CH 2 ) favor-O-(C 1 -C 6 )-alkyl or (CH 2 ) n -aryl;
  • R 3 , R 4 and R 6 are independently from each other hydrogen, halogen, (CrQ -alkyl or (C C 6 )-alkoxy;
  • R 5 is NO 2 , CN, C(O)R 9 , S-(C ⁇ -C 6 )-alkyl, SO 2 R 10 or is NR n R 12 ;
  • R 7 and R 8 are independently from each other hydrogen, (CH 2 ) n -(C 3 -C 6 )-cycloalkyl or (C C 6 )-alkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
  • R 9 is hydroxy, (C r C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (CrC 6 )-alkoxy or NR 7 R 8 ;
  • R 10 is (CrC 6 )-alkyl, (CH 2 ) n -(C 3 -C 6 )-cycloalkyl or NR 7 R 8 ;
  • R 11 and R 12 are independently from each other hydrogen, C(O)-(C 1 -C 6 )-alkyl, SO 2 -(C 1 -C 6 )-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, (C 1 -C 6 )-alkyl or (CH 2 ) n (C 3 -C 6 )-cycloalkyl;
  • n 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof.
  • R' is hydroxy, halogen, N0 2 , CN, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl substituted by halogen, (C ⁇ -C 6 )-alkoxy, (C 1 -C 6 )-alkoxy substituted by halogen, NR 7 R 8 , C(O)R 9 or S0 2 R 10 ; m is 0, 1, 2 or 3;
  • R 1 is hydrogen or (C 1 -C 6 )-alkyl; is a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O, which rings are unsubstituted or substituted by (CH 2 ) n -hydroxy, (CH 2 ) n -O-(C 1 -C 6 )-alkyl, or form together with the N atom a 5-membered heteroaryl group, optionnally containing in addition to the N atom one, two or three further nitrogen atoms and wherein the heteroaryl group is optionally substituted by (Q- C 6 )-alkyl;
  • R 3 , R 4 and R 6 are independently from each other hydrogen, halogen, (CrQ -alkyl or ( -C ⁇ -alkoxy;
  • R 5 is NO 2 , CN, C(O)R 9 , S-(C 1 -C 6 )-alkyl, SO 2 R 10 or is NR U R 12 ;
  • R 7 and R 8 are independently from each other hydrogen, (CH 2 ) ⁇ -(C 3 - )-cycloalkyl or (C 1 -C 6 )-alkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
  • R 9 is hydroxy, (C ⁇ -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (C C 6 )-alkoxy or NR 7 R 8 ;
  • R 10 is (Q-Q -alkyl, (CH 2 ) n -(C 3 -C 6 )-cycloalkyl or NR 7 R 8 ;
  • R 11 and R 12 are independently from each other hydrogen, C(0)-(Ci-Q)-alkyl, SO 2 -(C ⁇ -C 6 )-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, (CrC 6 )-alkyl or (CH 2 ) n (C 3 -C 6 )-cycloalkyl;
  • n 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof.
  • hetaryl is a 6-membered heteroaryl, containing one, two or three nitrogen atoms, optionally substituted by one or more substituents selected from the group consisting of hydroxy, halogen, NO 2 , CN, (CrC ⁇ -alkyl, (CrC 6 )-alkyl substituted by halogen, (C 1 -C 6 )-alkoxy, (C 1 -C 6 )-alkoxy substituted by halogen, NR 7 R 8 , C(O)R 9 or SO 2 R 10 ;
  • R 1 is hydrogen or (C C 6 )-alkyl
  • R 2 and R 2 are independently from each other hydrogen, (CR 2 ) n -hydroxy for R being hydrogen or C 1 -C 6 )-alkyl, or are (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 1 -C 6 )-alkyl substituted by halogen, (CH 2 ) n -(C 3 -C 6 )-cycloalkyl, (CH 2 ) n -heterocycloalkyl, (CH 2 ) favor-O-(C 1 -C 6 )-a ⁇ kyl or (CH 2 ) n -aryl or R , R 4 and R 6 are independently from each other hydrogen, halogen, (C ⁇ - )-alkyl or (C 1 -C 6 )-alkoxy;
  • R 5 is NO 2 , CN, C(O)R 9 , S-(C ⁇ -C 6 )-alkyl, SO 2 R 10 or is NR n R 12 ;
  • R 7 and R 8 are independently from each other hydrogen, (CH 2 ) n -(C 3 -C 6 )-cycloalkyl or (CrC 6 )-alkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
  • R 9 is hydroxy, (C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloall yl, (C ⁇ -C 6 )-alkoxy or NR 7 R 8 ;
  • R 10 is (C 1 -C 6 )-alkyl, (CH 2 ) n -(C 3 -C 6 )-cycloalkyl or NR 7 R 8 ;
  • R 11 and R 12 are independently from each other hydrogen, C(O)-(C ⁇ -C 6 )-alkyl, SO 2 -(CrC 6 )-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, (C 1 -C 6 )-alkyl or (CH 2 ) favour(C 3 -C 6 )-cycloalkyl;
  • n 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof.
  • hetaryl is a 6-membered heteroaryl, containing one, two or three nitrogen atoms, optionally substituted by one or more substituents selected from the group consisting of hydroxy, halogen, NO 2 , CN, (C C 6 )-alkyl, (C C 6 )-alkyl substituted by halogen, (C ⁇ - )-alkoxy, (C ⁇ -C 6 )-alkoxy substituted by halogen, NR 7 R 8 , C(O)R 9 or S0 2 R 10 ;
  • R 1 is hydrogen or (C ⁇ -C 6 )-alkyl
  • heterocycloalkyl ring optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O, which rings are unsubstituted or substituted by (CH 2 ) n -hydroxy, (C 1 -C 6 )-alkyl, (Q-C ⁇ -alkoxy, (CH 2 ) n -0-(C 1 -C 6 )-alkyl, or form together with the N atom a 5-membered heteroaryl group, optionnally containing in addition to the N atom one, two or three further nitrogen atoms and wherein the heteroaryl group is optionally substituted by (Q- C 6 )-alkyl;
  • R 3 , R 4 and R 6 are independently from each other hydrogen, halogen, (C 1 -C 6 )-alkyl or (C C 6 )-alkoxy;
  • R 5 is NO 2 , CN, C(0)R 9 , S-(C C 6 )-alkyl, S0 2 R 10 or is NR U R 12 ;
  • R 7 and R 8 are independently from each other hydrogen, (CH 2 ) n -(C 3 -C 6 )-cycloalkyl or (C 1 -C 6 )-alkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
  • R 9 is hydroxy, (C ⁇ -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (C ⁇ -C 6 )-alkoxy or NR 7 R 8 ;
  • R 10 is (CrQ -alkyl, (CH 2 ) n -(C 3 -C 6 )-cycloalkyl or NR 7 R 8 ;
  • R 11 and R 12 are independently from each other hydrogen, C(0)-(C ⁇ -C 6 )-alkyl, SO 2 -(CrC 6 )-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, (C 1 -C 6 )-alkyl or (CH 2 ) n (C 3 -C 6 )-cycloalkyl; n is 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof.
  • Ar is unsubstituted or substituted aryl or 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups are substituted by one or more substituents selected from the group consisting of hydroxy, halogen, N0 2 , CN, (Ci-C 6 )-alkyl, (C 1 -C 6 )-alkyl substituted by halogen, ( -C ⁇ -alkoxy, (Ci-C 6 )-alkoxy substituted by halogen, NR 7 R 8 , C(O)R 9 or SO 2 R 10 ; R 1 is hydrogen or (C ⁇ -Q)-alkyl;
  • R 2 and R 2 are independently from each other hydrogen, hydroxy, (C C 6 )-alkyl, (C 3 -C 6 )-alkenyl, (C 2 -C6)-alkyl substituted by halogen, (C 3 -C 6 )-cycloalkyl, heterocycloalkyl, (C 1 -C 6 )-alkyl-(C 3 -C 6 )-cycloalkyl, (CrC 6 )-alkyl-heterocycloalkyl, (C I -C 6 )-alkyl-C(0)-R 9 , (Q-C 6 )-alkyl-CN, (C 2 -C 6 )-alkyl-0-R 13 , (C 2 -C 6 )-alkyl- NR 7 R 8 , aryl or 6-membered heteroaryl containing one, two or three nitrogen atoms, (C ⁇ -C 6 )-alkyl-aryl or (C ⁇ -C 6
  • R 3 , R 4 and R 6 are independently from each other hydrogen, hydroxy, halogen, CN, (Q-Q -alkyl, (C 1 -C 6 )-alkoxy or NR 7 R 8 ;
  • R 5 is NO 2 , CN, C(O)R 9 , S-(C 1 -C 6 )-alkyl, SO 2 R 10 or is NR ⁇ R 12 ;
  • R 7 and R 8 are independently from each other hydrogen, (C ⁇ -C6)-alkyl-(C 3 -C6)-cycloalkyl, (C ⁇ -C 6 )-alkyl, or (C 3 -C6)-cycloalkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
  • R 9 is hydroxy, (C C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (C 1 -C 6 )-alkoxy or NR 7 R 8 ;
  • R 10 is ( -Q -alkyl, (C 3 -C 6 )-cycloalkyl, (C 1 -C 6 )-alkyl-(C 3 -C 6 )-cycloalkyl or NR 7 R 8 ;
  • R 11 and R 12 are independently from each other hydrogen, C(0)-(C 1 -C 6 )-alkyl, SO 2 -(CrC 6 )-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, ( - C 6 )-alkyl, (Q-C 6 )-aikyl substituted by halogen or (C 3 -C 6 )-cycloalkyl;
  • R 13 is hydrogen, (C C 6 )-alkyl or (C 3 -C 6 )-cycloalkyl; and pharmaceutically acceptable acid addition salts thereof, with the proviso that l-[5-(aminosulfonyl)-2-(4-morpholinyl)benzoyl]-4-phenyl-piperazine,
  • Ar is unsubstituted or substituted phenyl or 6-membered heteroaryl, containing one or two nitrogen atoms, and wherein the phenyl and the heteroaryl groups are optionally substituted by one or two substituents selected from the group consisting of halogen, NO 2 , CN, (Ci-Cg)-alkyl, (C 1 -C 6 )-alkyl substituted by halogen, (C ⁇ -C 5 )-alkoxy, (C 1 -C 6 )-alkoxy substituted by halogen, NR 7 R 8 , C(O)R 9 or SO 2 R 10 ;
  • R 1 is hydrogen or (C ⁇ -C 6 )-alkyl
  • R 2 and R 2 are independently from each other hydrogen, hydroxy, (C ⁇ -C 6 )-alkyl, (C 3 -C 6 )-alkenyl, (C 3 -Q)-cycloalkyl, heterocycloalkyl, (C 1 -C 6 )-alkyl-(C 3 -C 6 )-cycloalkyl, (Q-C 6 )-alkyl-aryl, (C 2 -C 6 )-alkyl-O-R 13 , or R 2 and R 2 form together with the N atom to which they are attach a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O, which rings are unsubstituted or substituted by hydroxy, (C 1 -C 6 )-alkyl, ( -C ⁇ -alkoxy, (Q-C 6 )-alkyl-0-R 13 , or form together with the N atom
  • R 5 is NO 2 , CN, C(O)R 9 , S-(C r C 6 )-alkyl, SO 2 R 10 or is NR ⁇ R 12 ;
  • R 7 and R 8 are independently from each other hydrogen, (C 1 -C 6 )-alkyl-(C 3 -C 6 )-cycloalkyl, (Ci-C 6 )-alkyl or form together with the N atom to which they are attach a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of oxygen;
  • R 9 is (CrQ -alkyl, (C ⁇ -C 6 )-alkoxy or NR 7 R 8 ;
  • R 10 is (C ⁇ -C 6 )-alkyl, (C 1 -C 6 )-a ⁇ kyl-(C 3 -C 6 )-cycloalkyl or NR 7 R 8 ;
  • R ⁇ and R 12 are independently from each other SO 2 -(C 1 -C 6 )-alkyl, or form together with the N-atom a 5-membered heteroaryl group containing in addition to the N atom one, two or three nitrogen atoms;
  • R 13 is hydrogen or (C 1 -C 6 )-alkyl; and pharmaceutically acceptable acid addition salts thereof, with the proviso that 1 - [5-(aminosulfonyl)-2-(4-morpholinyl)benzoyl] -4-phenyl-piperazine, l-(4-methoxyphenyl)-4-[2-(4-morpholinyl)-5-nitrobenzoyl]-piperazine,
  • Ar is unsubstituted or substituted phenyl, pyridyl or pyrimidinyl, optionally substituted by one or two substituents selected from the group consisting of halogen, NO 2 , CN, methyl, CF 3 , methoxy, OCF 3 , NH 2 , C(O)CH 3 , C(O)OCH 3 , C(O)OCH 2 CH 3 , SO 2 NH 2 or SO 2 CH 3 ;
  • R 1 is hydrogen or methyl
  • R 2 and R 2 form together with the N atom to which they are attach a heterocycloalkyl ring, selected from the group consisting of morpholinyL fhiomorpholinyl, azetidinyl, pyrrolidinyl, piperidinyl or azepanyl, which rings are unsusbtituted or substituted by hydroxy, methyl, methoxy, ethoxy, CH 2 OH, or form together with the N atom a 5- membered heteroaryl ring, selected from the group consisting of imidazolyl, triazolyl or di-hydro-pyrrolyl;
  • R 5 is NO 2 , CN, -C(0)NH 2 , -C(O)NHCH 3 , .C(0)N(CH 3 ) 2 , -C(O)CH 3 , -SCH 3 , -S0 2 -(C C 6 )-alkyl, -SO 2 -NH-(CrC 6 )-alkyl, -SO 2 -N-[(C ⁇ -C 6 )-alkyl] 2 , -SO 2 NH 2 , -NHSO 2 CH 3 , -S0 2 -NHCH 2 -cycloalkyl, -SO 2 -CH 2 -cycloalkyl, -SO 2 -pyrrolidin-l-yl, -S0 2 -morpholidin-l-yl, imidazolyl or tetrazolyl;
  • Still another embodiment are compounds, wherein R 2 and R 2 form together with the N atom to which they are attach a morpholine ring, for example the following compounds: l- ⁇ 4-[4-(2-morpholin-4-yl-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl ⁇ -ethanone, N-methyl-4-morpholin-4-yl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]- benzenesulfonamide or
  • R 2 and R 2 form together with the N atom to which they are attach a pyrrolidin- or 2,5-dihydropyrrol ring, which are optionally substituted by methyl or CH 2 OH, for example the following compounds: l- ⁇ 3-fluoro-4-[4-(5-nitro-2-pyrrolidin-l-yl-benzoyl)-piperazin-l-yl]-phenyl ⁇ -ethanone, l-(3-fluoro-4- ⁇ 4-[2-(2-methyl-pyrrolidin-l-yl)-5-nitro-benzoyl]-piperazin-l-yl ⁇ - phenyl) -ethanone, l-(4- ⁇ 4-[2-(2,5-dihydro-pyrrol-l-yl)-5-nitro-benzoyl]-piperazin-l-yl ⁇ -3-fluoro-phenyl)- ethanone, l- ⁇ 3-fluoro-4
  • Still another embodiment are further those compounds, wherein R and R 2 form together with the N atom to which they are attach a piperidine ring, which is optionally substituted by methyl or hydroxy, for example the following compounds: l- ⁇ 3-fluoro-4-[4-(5-nitro-2-piperidin-l-yl-benzoyl)-piperazin-l-yl]-phenyl ⁇ -ethanone, l-(3-fluoro-4- ⁇ 4-[2-(2-methyl-piperidin-l-yl)-5-nitro-benzoyl]-piperazin-l-yl ⁇ - phenyl)-ethanone, l-(3-fluoro-4- ⁇ 4-[2-(4-methyl-piperidin-l-yl)-5-nitro-benzoyl]-piperazin-l-yl ⁇ - phenyl) -ethanone, l-(3-fluoro-4- ⁇ 4-[2-(4-methyl-piperidin-l-
  • An embodiment of the invention are further those compounds, wherein R 2 and R 2 form together with the N atom to which they are attach a azepane ring, for example the following compounds: l- ⁇ 4-[4-(2-azepan-l-yl-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl ⁇ -ethanone or l- ⁇ 4-[4-(2-azepan-l-yl-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl ⁇ - ethanone.
  • a further embodiment of the invention are further those compounds, wherein R 2 or R 2 is CH 2 -cycloalkyl or cycloalkyl, for example the following compounds: l-(4- ⁇ 4-[2-(cyclopropylmethyl-amino)-5-nitro-benzoyl]-piperazin-l-yl ⁇ -3-fluoro- phenyl) -ethanone, l- ⁇ 4-[4-(2-cyclohexylamino-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl ⁇ - ethanone, l- ⁇ 4-[4-(2-cyclobutylamino-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-
  • An embodiment of the invention are further those compounds, wherein one of R 2 or R 2 is (C 1 -C 6 )-alkyl, and the other is hydrogen or both of R 2 or R 2 are (C 1 -C 6 )-alkyl, for example the following compounds: l- ⁇ 3-fluoro-4-[4-(2-isopropylamino-5-nitro-benzoyl)-piperazin-l-yl]-phenyl ⁇ - ethanone, l- ⁇ 3-fluoro-4-[4-(2-isobutylamino-5-nitro-benzoyl)-piperazin-l-yl]-phenyl ⁇ -ethanone, l- ⁇ 3-fluoro-4-[4-(2-tert.-butylamino-5-nitro-benzoyl)-piperazin-l-yl]-phenyl ⁇ - ethanone or l- ⁇ 4-[4-(2-diethylamino-5-nitro-benzoyl)
  • R 2 or R is (C 2 -C 6 ) -alkenyl, and the other is (C ⁇ -C 6 )-alkyl, for example the following compound: l-(4- ⁇ 4-[2-(allyl-methyl-amino)-5-nitro-benzoyl]-piperazin-l-yl ⁇ -3-£luoro-phenyl)- ethanone.
  • the present compounds of formula I and their pharmaceutically acceptable salts can be prepared by methods known in the art, for example, by processes described below, which process comprises a) reacting a compound of formula
  • R 15 is hydrogen, halogen, (C ⁇ -C6)-alkyl, (C ⁇ -C 6 )-alkyl substituted by halogen or (C3-C6)-cycloalkyl and the other substituents are as defined above, g) reacting a compound of formula
  • R is (C C 6 )-alkyl
  • R 16 is (C C 6 )-alkyl or (C 3 -C 6 )-cycloalkyl and the other substituents are as defined above, j) reacting a compound of formula
  • X is CH or N and the heteroaryl ring is selected from the group consisting of imidazole, pyrazole or triazole
  • R 15 is hydrogen, halogen, (CrC ⁇ -alkyl, (C 1 -C 6 )-alkyl substituted by halogen or (C 3 -C 6 )-cycloalkyl and the other substituents are as defined above,
  • the compounds of formula I may be prepared in accordance with process variants a) to j) and with the following schemes 1 to 6.
  • X halogen i.e GDI, TBTU
  • Compounds of general formula I can be prepared by reacting of a piperazine of formula II with a compound of formula III (Z: Cl) or III (Z: OH) in the presence of an activating agent like CDI (N,N-carbonyldiimidazole) or TBTU (2-(lH-benzotriazole-l-yl)-l, 1,3,3- tetramethyluroniumtetrafluoroborate).
  • an activating agent like CDI (N,N-carbonyldiimidazole) or TBTU (2-(lH-benzotriazole-l-yl)-l, 1,3,3- tetramethyluroniumtetrafluoroborate).
  • a compound of formula III (Z: Cl) can be prepared from a compound of formula III (Z: OH) in the presence of an activating agent like thionylchloride.
  • the acid of formula III (Z: OH) can be prepared by heating a mixture of an acid of formula IV and an amino derivative of formula R 2 R NH.
  • the piperazine of formula II can be prepared by heating of a corresponding piperazine with ArX or by reacting of a N-protected piperazine with ArX in the presence of palladium catalyst followed by cleavage of the protective group.
  • the protective group is typically tert-butoxycarbonyl (Boc).
  • halogen Z OH, halogen (i.e: Cl)
  • compounds of general formula I can be prepared by reaction of a derivative of formula V with a corresponding amine of formula R 2 R 2 NH.
  • Compounds of formula V can be prepared by reacting of derivatives of formula II with compounds of formula IV (Z: Cl) or with compounds of formula IV(Z: OH) in the presence of an activating agent like GDI (N-carbonyldiimidazole) or TBTU (2-(lH-benzotriazoIe-l-yl)-l,l,3,3- tetramethyluroniumtetrafluoroborate).
  • halogen Y H
  • Z OH
  • halogen i.e: Cl
  • compounds of general formula I can be prepared by reaction of a compound of formula VII with ArX.
  • a compound of formula VII can be prepared by reacting of a
  • a compound of formula VI can be prepared by reacting of a piperazine of formula II with a compound of formula IV (Z: Cl) or with a compound of formula IV (Z: OH) in the presence of an activating agent like CDI (N-carbonyldiimidazole) or TBTU (2- ( 1 H-benzotriazole- 1 -yl) - 1 , 1 ,3 ,3 -tetramethylur oniumtetrafluoroborate) .
  • an activating agent like CDI (N-carbonyldiimidazole) or TBTU (2- ( 1 H-benzotriazole- 1 -yl) - 1 , 1 ,3 ,3 -tetramethylur oniumtetrafluoroborate
  • IC (A is -CO-) and IC (A is -S0 2 -) can be prepared respectively by carbonylation or sulfonylation of a corresponding amino derivative IB in the presence of a compound of formula R 14 AX.
  • a compound of formula IB can be prepared by hydrogenation of a compound of formula IA.
  • Heterocyclic compounds of formula ID can be prepared by reaction of a compound of formula IB with a substituted triethyl orthoformate derivative of formula R 15 -C(OEt) 3 in the presence of sodium azide.
  • Compounds of formula IG can be prepared by reaction of an acid derivative of formula IF with an amine of formula R 7 R 8 NH in the presence of an activating agent like CDI (N- carbonyldiimidazole) or TBTU (2-(lH-benzotriazoIe-l-yl)-l, 1,3,3- tetramethyluroniumtetrafluoroborate).
  • an activating agent like CDI (N- carbonyldiimidazole) or TBTU (2-(lH-benzotriazoIe-l-yl)-l, 1,3,3- tetramethyluroniumtetrafluoroborate).
  • a compound of formula IF can be prepared by hydrolysis of a compound of formula IE in the presence of base like sodium hydroxide.
  • a compound of formula IH can be prepared by reacting under Stille conditions with an aryl-bromo derivative of formula X and with a corresponding vinyl stannane of formula XI in the presence of a palladium catalyst like dichlorobis(triphenylphosphine) palladium(II).
  • a compound of formula 1 1 can be prepared by reacting of a compound of formula X with a compound of formula XII in the presence of a Cu catalyst like Cul.
  • a compound of formula X can be prepared by coupling an acid chloride III with a piperazine derivative of formula II.
  • the acid addition salts of the basic compounds of formula I maybe converted to the corresponding free bases by treatment with at least a stoichiometric equivalent of a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like.
  • a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like.
  • the compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention are good inhibitors of the glycine transporter I (GlyT-1).
  • DMEM complete medium Nutrient mixture F-12 (Gibco Life-technologies), fetal bovine serum (FBS) 5 %, (Gibco life technologies), Penicillin/Streptomycin 1 % (Gibco life technologies), Hygromycin 0.6 mg/ml (Gibco life technologies), Glutamine 1 mM Gibco life technologies)
  • Uptake buffer 150 mM NaCl, 10 mM Hepes-Tris, pH 7.4, 1 mM CaCl 2 , 2.5 mM KC1, 2.5 mM MgSO 4 , 10 mM (+) D-glucose.
  • Flp-inTM-CHO (Invitrogen Cat n° R758-07)ceUs stably transfected with mGlyTlb cDNA.
  • mammalian cells (Flp-inTM-CHO), transfected with mGlyT-lb cDNA , were plated at the density of 40,000 cells/well in complete F-12 medium, without hygromycin in 96-well culture plates.
  • the medium was aspirated and the cells were washed twice with uptake buffer (UB).
  • the cells were then incubated for 20 min at 22°C with either (i) no potential competitor, (ii) 10 mM non-radioactive glycine , (iii) a concentration of a potential inhibitor.
  • a range of concentrations of the potential inhibitor was used to generate data for calculating the concentration of inhibitor resulting in 50 % of the effect (e.g.
  • the compounds of formula I and the pharmaceutically acceptable salts of the compounds of formula I can be used as medicaments, e.g. in the form of pharmaceutical preparations.
  • the pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions.
  • the administration can, however, also be effected rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions.
  • the compounds of formula I can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations.
  • Lactose,corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules.
  • Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are however usually required in the case of soft gelatine capsules.
  • Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like.
  • Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
  • the pharmaceutical preparations can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • Medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable acid addition salts and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.
  • the most preferred indications in accordance with the present invention are those, which include disorders of the central nervous system, for example the treatment or prevention of schizophrenia, cognitive impairment and Alzheimer's disease.
  • the dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case.
  • the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof.
  • the daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.
  • RT room temperature
  • n-Boc-piperazine tert-Butyl 1-piperazinecarboxylate
  • oxone® (potassium peroxymonosulfate) 2KHSO 5 *KHS0 « K 2 S0 ,
  • THF tetrahydrofuran
  • TBTU 2-(lH-benzotriazole-l-yl)-l,l,3,3-tetramethyluroniumtetrafluoroborate
  • DIPEA diisopropylethylamine
  • Example 1 According to the procedure described for the synthesis of Example 1 further derivatives have been synthesised and comprise Examples 179,180, 189, 190, 191, 196, 197, 198 in Table 1.
  • Example 2 further derivatives have been synthesised from l- ⁇ 3-Fluoro-4-[4-(2-fluoro-5-nitro-benzoyl)-piperazin-l- yl] -phenyl ⁇ -ethanone and amines and comprise Examples 2-45 in Table 1.
  • step 1 2-Morpholin-4-yl-5-nitro-benzoic acid
  • step 1 4-(2-Chloro-4-trifluoromethyl-phenyl -piperazine-l-carboxylic acid tert-butyl ester
  • Boc-piperazine 41 mg (0.04 mmol) Tris(dibenzylideneacetone)dipalladium chloroform complex, 0.44 g ( 4.43 mmol) sodium-t-butoxide and 48 mg (0.16 mmol) tri-o- tolylphosphine in 6 ml dioxane was heated overnight at 100 °C. The solution was allowed to cool to room temperature, taken up in ether (30ml) and washed with brine (25ml).
  • Step 2 l-(2-Chloro-4-trifluoromethyl-phenyl)-piperazine
  • step 1 4-(2-Cvano-4-trifluoromethyl-phenyl)-piperazine-l-carboxylic acid tert-butyl ester
  • Example 46 further derivatives have been synthesised from 2-morpholin-4-yl-5-nitro-benzoyl chloride and piperazine derivatives and comprise Examples 46-74, 177, 184, 185, 186,187,188, 192, 200, 201 in Table 1.
  • step 1 2-Chloro-5-methanesulfonyl-benzoic acid
  • Step 2 l- ⁇ 4- 4-(2-Chloro-5-methanesulfonyl-benzoyl)-piperazin-l-yl1 -3-fluoro- phenvU-ethanone
  • Example 75 further derivatives have been synthesised from l- ⁇ 4-[4-(2-Chloro-5-methanesulfonyl-benzoyl)-piperazin-l- yl]-3-fluoro-phenyl ⁇ -ethanone and amines and comprise Examples 75-89 in Table 1.
  • step 1 2-bromo-5-cyano-benzoic acid
  • Step 2 3-[4-(4-ace1yl-2-fluoro-phenyl)-piperazine-l-carbonyl1-4-bromo benzonitrile
  • Example 90 further derivatives have been synthesised from 3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4- bromo-benzonitrile and amines and comprise Examples 90-103 in Table 1.
  • Example 104 According to the procedure described for the synthesis of Example 104 further derivatives have been synthesised from 2-Morpholin-4-yl-5-nitro-benzoyl chloride and piperazine derivatives and comprise Examples 104-122 in Table 1.
  • Example M
  • Example 123 further derivatives have been synthesised from acid derivatives and piperazine derivatives and comprise Examples 123-173 in Table 1.
  • Example 174 further derivatives have been synthesised from l- ⁇ 3-fluoro-4-[4-(2-fluoro-5-nitro-benzoyl)- piperazin- l-yl]-phenyl ⁇ -ethanone and amines and comprise Examples 174 to 176 in Table 1.
  • Example AR
  • the titie compound was prepared according to the procedure described for example K step 2 from 4'-piperazino-acetophenone and 2-fluoro-5-nitrobenzoic acid (16%, yellow solid, MS (m/e): 372.1 (M+H, 100%)
  • Example 189
  • the titie compound was prepared according to the procedure described for example 1 from l- ⁇ 4- [4-(2-Fluoro-5-nitro-benzoyl)-piperazin-l-yl] -phenyl ⁇ -ethanone and morpholine (85%, yellow solid, MS (m/e): 439.3 (M+H, 100%)
  • the titie compound was prepared according to the procedure described for example 46 from 2-Fluoro-5-nitro-benzoyl chloride and l-(2-fluorophenyl)-piperazine (52%, orange solid, MS (m/e): 348.1 (M+H, 100%)
  • Example 190
  • PdCl 2 (PPh 3 ) 2 (5 mg, 0.0065 mmol) and tributyl(l-ethoxyvinyl)tin (125 ul, 0.36 mmol). The mixture was heated to 100°C for 6 hours. The mixture was cooled in an ice bath and 2N HCl (0.55 ml) was added. The mixture was stirred at room temperature overnight. The mixture was filtered. The organic layer was separated and 10% aqueous KF solution was added. The mixture was stirred at room temperature for 3 hours and filtered. The organic layer was dried over Na 2 SO 4 , filtered and the solvent was removed in vacuo.
  • the titie compound was prepared according to the procedure described for example K step 2 from 5-Methylsulfanyl-2-morpholin-4-yl-benzoic acid and l-(3-Fluoro-4- piperazin-l-yl-phenyl)-ethanone (8%, white solid), MS (m/e): 458.2 (M+, 100%)
  • the titie compound was prepared according to the procedure described for example 1 from 3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-bromo-benzonirrile (example L) and morpholine (71%, white solid), MS (m/e): 437.2 (M+H, 100%)
  • Example 197
  • the titie compound was prepared according to the procedure described for example K/ step2 from l-(3-Fluoro-4-piperazin-l-yl-phenyl)-ethanone and 2-Chloro-5-sulfamoyl- benzoic acid (CAS: 97-04-1; Basu; D.-G.; J.Indian Chem.Soc; 16; 1939; 100, 106) (42%, white solid), MS (m/e): 438.1 (M-H, 100%)
  • the titie compound was prepared according to the procedure described for example 1 from 3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-chloro- benzenesulfonamide and morpholine (39%, yellow solid), MS (m/e): 489.4 (M-H, 100%)
  • Example 199
  • the titie compound was prepared according to the procedure described for example AX from l-bromo-2-chloro-4-fluorobenzene and N-Boc-piperazine (10%, off white solid, MS (m/e): 315.1(M+H, 100%)
  • Example BN
  • the titie compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid (Example Y) from 2- Chloro-5-methanesulfonyl-benzoic acid and rac-pyrrolidin-3-yl-methanol and obtained in 39 % yield. MS (m/e): 298.1 (M-H, 100%).
  • the titie compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid (Example S) from 2-
  • Example S The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid (Example S) from 2- Chloro-5-methylsulfamoyl-benzoic acid and piperidine and obtained in 48 % yield. MS (m/e): 297.4 MH- (100%).
  • the titie compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin-l-yl-benzoic acid (Example S) from 2- Chloro-5-sulfamoyl-benzoic acid (CAS: 97-04-1; Basu; D.-G.; JJndian Chem.Soc; 16; 1939; 100, 106) and pyrrolidine and obtained in 19% yield. MS (m/e): 269.4 (MH " 100%).
  • the titie compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid (Example S) from 2- Chloro-5-sulfamoyl-benzoic acid (CAS: 97-04-1; Basu; D.-G.; JTndian Chem.Soc; 16; 1939; 100, 106) and morpholine and obtained in 85% yield. MS (m/e): 285.1 (MH " 100%).
  • Example 123 further derivatives have been synthesised from acid derivatives and piperazine derivatives and comprise Examples 206-279 in Table 2.
  • the titie compound was prepared according to the procedure described for example 202 from (2-Cl loro-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l- yl] -methanone (example BO) and thiomorpholine to yield the title compound as a pale yellow solid. MS (m/e): 514.5 (M+H, 100%).
  • Example CF was prepared in analogy to Example CE using 2,4,5-trifluorobenzonitrile. MS (m/e): 224.3 (M+H + , 100%).
  • Example 123 According to the procedure described for the synthesis of Example 123 further derivatives have been synthesised from acid derivatives and piperazine derivatives and comprise Examples 283-289 in Table 3. Table 3
  • Example CK was prepared in analogy to Example 123 from 2-Iodo-5-methanesulfonyl- benzoic acid (example BQ) and l-(4-Trifluoromethyl-phenyl)-piperazine (commercial). MS (m/e): 539.1 (M+H + , 100%).
  • Example CL Example CL
  • Example CL was prepared in analogy to Example 123 from 2-Iodo-5-methanesulfonyl- benzoic acid (example BQ) and 3-Fluoro-4-piperazin-l -yl-benzonitrile (WO9625414). MS (m/e): 514.0 (M+H + , 100%).
  • Example CM was prepared in analogy to Example 123 from 2-Iodo-5-methanesulfonyl- benzoic acid (example BQ) and l-(2-Fluoro-4-methanesulfonyl-phenyl)-piperazine (commercial). MS (m/e): 567.0 (M+H + , 100%).
  • Example CN was prepared in analogy to Example 123 from 2-Iodo-5-methanesulfonyl- benzoic acid (example BQ) and l-(2-Fluoro-4-trifluoromethyl-phenyl)-piperazine (example H). MS (m/e): 574.2 (M+NH 4 + , 100%).
  • Example CR
  • Example CR was prepared in analogy to Example 46 from 5-Bromo-2-morpholin-4-yl- benzoyl chloride (example Bl) and l-(4-Trifluoromethyl-phenyl)-piperazine (commercial). MS (m/e): 500.1 (M+H + , 100%).
  • the reaction mixture was cooled to room temperature and quenched with water/dichloromethane.
  • the aqueous layer was extracted twice with dichloromethane.
  • the organic layers were combined, dried over Na 2 SO , filtered and the solvent was removed in vacuo.
  • the crude oil was chromatographed over silicagel: eluent: heptane/ethylacetate: 0-5% to provide the titie compound as a light grey powder (19 mg, 21%), MS (m/e): 479.1 (M+H, 100%)
  • the titie compound was prepared according to the procedure described for example 294 . from 3-Fluoro-4-[4-(2-iodo-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-benzonitrile (compound CL) and 4-Methyl-lH-pyrazole (20% yield, white foam , MS (m/e): 468.3 (M+H, 100%)
  • the titie compound was prepared in analogy to Example H from 4-(2-trifluoromethyl- pyrimidin-5-yl)-piperazine-l-carboxylic acid tert-butyl ester MS (m/e): 233.0 (M+H + , 100%)
  • Example 123 The title compound was prepared in analogy to Example CS (b-c) from 2-Bromo-5- trifluoromethyl-pyrazine MS (m/e): 233.0 (M+H + , 100%) According to the procedure described for the synthesis of Example 123 further derivatives have been synthesised from acid derivatives and piperazine derivatives and comprise Examples 305-318 in Table 4.
  • Item Ingredients mg/capsule Compound of formula I 5 25 100 500 Hydrous Lactose 159 123 148 — Corn Starch 25 35 40 70 Talc 10 15 10 25 Magnesium Stearate 1 2 2 5 Total 200 200 300 600

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A compound of formula (I) wherein the substituents are described in claim 1 for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

Description

1- (2-AMINO-BENZOL) -PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES
The present invention relates to compounds of the general formula I
Figure imgf000002_0001
wherein
Ar is unsubstituted or substituted aryl or 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups are substituted by one or more substituents selected from the group consisting of hydroxy, halogen, NO2, CN, (C1-C6)-alkyl, (C1-C6)-alkyl substituted by halogen, ( - -alkoxy, (C C6)-alkoxy substituted by halogen, NR7R8, C(0)R9 or SO2R10;
R1 is hydrogen or (Cι-C6)-alkyl;
R2 and R2 are independently from each other hydrogen, (CR2)n-hydroxy for R being hydrogen or Ci-C6)-alkyl, or are (Cι-C6)-alkyl, (C2-C6)-alkenyl, (C C6)-alkyl substituted by halogen, (CH2)n-(C3-C6)-cycloaIkyl, (CH2)n-heterocycloalkyl, (CH2)n-0-(C1-C6)-alkyl or (CH2)n-aryl or R2 and R2 form together with the N atom to which they are attach a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O, which rings are unsubstituted or substituted by (CH2)n-hydroxy, (CrC6)-alkyl, (C1-C6)-alkoxy, (CH2)n-O-(C1-C6)-alkyl, or form together with the N atom a 5-membered heteroaryl group, optionnally containing in addition to the N atom one, two or three further nitrogen atoms and wherein the heteroaryl group is optionally substituted by (Cι-C6)-alkyl; R3, R4 and R6 are independently from each other hydrogen, halogen, (C1-C6)-alkyl or (CrC^-alkoxy;
R5 is N02, CN, C(O)R9, S-(C1-C6)-alkyl, SO2R10 or is NRπR12;
R7 and R8 are independently from each other hydrogen, (CH2)n-(C3-C6)-cycloalkyl or (C1-C6)-alkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
R9 is hydroxy, (Cι-C6)-alkyl, (C3-C6)-cycloalkyl, (C1-C6)-alkoxy or NR7R8;
R10 is (C C6)-alkyl, (CH2)„-(C3-C6)-cycloalkyl or NR7R8;
R11 and R12 are independently from each other hydrogen, C(O)-(C1-C6)-alkyl, SO2-(Cr )-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, ( -QΛ-alkyl or (CH2)n(C3-C6)-cycloalkyl;
n is 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof, with the proviso that l-[5-(aminosulfonyl)-2-(4-morpholinyl)benzoyl]-4-phenyl-piperazine, l-(4-methoxyphenyl)-4-[2-(4-morpholinyl)-5-nitrobenzoyl]-piperazine, l-[2-(4-morpholinyl)-5-nitrobenzoyl]-4-[2-nitro-4-(trifluoromethyl)phenyl]- piperazine,
1 -(4-methoxyphenyl)-4- [5-nitro-2-( 1 -pyrrolidinyl)benzoyl] -piperazine, l-[2-[4-(2-hydroxyethyl)-l-piperazinyl]-5-nitrobenzoyl]-4-(4-methoxyphenyl)- piperazine,
1 - [ 2-fluoro-4- ( 1 -oxopropyl)phenyl] -4- [ 5-nitro-2- ( 1 -piperidinyl)benzoyl] -piperazine, l-[2-fluoro-4-(l-oxopropyl)phenyl]-4-[5-nitro-2-(l-pyrrolidinyl)benzoyl]-piperazine> l-[2-fluoro-4-(l-oxopropyl)phenyl]-4-[2-(4-methyl-l-piperidinyl)-5-nitrobenzoyl]- piperazine, l-[2-fluoro-4-(l-oxopropyl)phenyl]-4-[2-(4-methyl-l-piperazinyl)-5-nitrobenzoyl]- piperazine,
1- [2-fluoro-4-( l-oxopropyl)phenyl] -4- [2-(4-morpholinyl)-5-nitrobenzoyl] -piperazine, 1- [5- [ [methyl(phenylmethyl)amino] sulfonyl] -2-(4-morpholinyl)benzoyl] -4-(4- nitrophenyl) -piperazine and
1 - (4-acetyl-2-fluorophenyl) -4- [2- (4-morphohnyl)-5-nitrobenzoyl] - piperazine, are excluded.
The compound 1 - [ 5- (aminosulfonyl) -2- (4-morpholinyl)benzoyl] -4-phenyl-piperazine has been described specifically in US 4,244,871, which possess tyrosine-paralyzing activity, and the other compounds mentioned above are commercially available products. The present invention relates to compounds of general formula I, to pharmaceutical composition containing them and their use in the treatment of neurological and neuropsychiatric disorders. It has surprisingly been found that the compounds of general formula I are good inhibitors of the glycine transporter 1 (GlyT- 1), and that they have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors. Schizophrenia is a progressive and devastating neurological disease characterized by episodic positive symptoms such as delusions, hallucinations, thought disorders and psychosis and persistent negative symptoms such as flattened affect, impaired attention and social withdrawal, and cognitive impairments (Lewis DA and Lieberman JA, Neuron, 28:325-33, 2000). For decades research has focused on the "dopaminergic hyperactivity" hypothesis which has led to therapeutic interventions involving blockade of the dopaminergic system (Vandenberg RJ and Aubrey KR., Exp. Opin. Ther. Targets, 5(4): 507-518, 2001; Nakazato A and Okuyama S, et al., Exp. Opin. Ther. Patents, 10(1): 75-98, 2000). This pharmacological approach poorly address negative and cognitive symptoms which are the best redictors of functional outcome (Sharma T., Br.J. Psychiatry, 174(suppl 28): 44-51, 1999). A complementary model of schizophrenia was proposed in the mid- 1960' based upon the psychotomimetic action caused by the blockade of the glutamate system by compounds like phencyclidine (PCP) and related agents (ketamine) which are non- competitive NMDA receptor antagonists. Interestingly in healthy volunteers, PCP- induced psychotomimetic action incorporates positive and negative symptoms as well as cognitive dysfunction, thus closely resembling schizophrenia in patients (Javitt DC et al., Biol. Psychiatry, 45: 668-679, 1999). Furthermore transgenic mice expressing reduced levels of the NMDAR1 subunit displays behavioral abnormalities similar to those observed in pharmacologically induced models of schizophrenia, supporting a model in which reduced NMDA receptor activity results in schizophrenia-like behavior (Mohn AR et al., Cell, 98: 427-236, 1999). Glutamate neurotransmission, in particular NMDA receptor activity, plays a critical role in synaptic plasticity, learning and memory, such as the NMDA receptors appears to serve as a graded switch for gating the threshold of synaptic plasticity and memory formation (Wiley, NY; Bliss TV and Collingridge GL, Nature, 361: 31-39, 1993). Transgenic mice overexpressing the NMDA NR2B subunit exhibit enhanced synaptic plasticity and superior ability in learning and memory (Tang JP et al., Natur, 401- 63-69, 1999). Thus, if a glutamate deficit is implicate in the pathophysiology of schizophrenia, enhancing glutamate transmission, in particular via NMDA receptor activation, would be predicted to produce both anti-psychotic and cognitive enhancing effects.
The amino acid glycine is known to have at least two important functions in the CNS. It acts as an inhibitory amino acid, binding to strychnine sensitive glycine receptors, and it also influences excitatory activity, acting as an essential co-agonist with glutamate for N-methyl-D-aspartate (NMDA) receptor function. While glutamate is released in an activity-dependent manner from synaptic terminals, glycine is apparently present at a more constant level and seems to modulate/control the receptor for its response to glutamate. One of the most effective ways to control synaptic concentrations of neurotransmitter is to influence their re-uptake at the synapses. Neurotransmitter transporters by removing neurotransmitters from the extracellular space, can control their extracellular lifetime and thereby modulate the magnitude of the synaptic transmission (Gainetdinov RR et al, Trends in Pharm. ScL, 23(8): 367-373, 2002). Glycine transporters, which form part of the sodium and chloride family of neurotransmitter transporters, play an important role in the termination of post- synaptic glycinergic actions and maintenance of low extracellular glycine concentration by re- uptake of glycine into presynaptic nerve terminals and surrounding fine glial processes. Two distinct glycine transporter genes have been cloned (GlyT-1 and GlyT-2) from mammalian brain, which give rise to two transporters with ~50 % amino acid sequence homology. GlyT-1 presents four isoforms arising from alternative splicing and alternative promoter usage (la, lb, lc and Id). Only two of these isoforms have been found in rodent brain (GlyT-la and GlyT-lb). GlyT-2 also presents some degree of heterogeneity. Two GlyT-2 isoforms (2a and 2b) have been identified in rodent brains. GlyT-1 is known to be located in CNS and in peripheral tissues, whereas GlyT-2 is specific to the CNS. GlyT-1 has a predominantly glial distribution and is found not only in areas corresponding to strychnine sensitive glycine receptors but also outside these areas, where it has been postulated to be involved in modulation of NMDA receptor function (Lopez-Corcuera B et al., Mol. Mem. Biol, 18: 13-20, 2001). Thus, one strategy to enhance NMDA receptor activity is to elevate the glycine concentration in the local microenvironment of synaptic NMDA receptors by inhibition of GlyT-1 transporter (Bergereon R. et al., Proc. Natl. Acad. Sci. USA, 95: 15730-15734, 1998; Chen L. et al., /. NeurophysioL, 89(2): 691-703, 2003).
Glycine transporters inhibitors are suitable for the treatment of neurological and neuropsychiatric disorders. The majority of diseases states implicated are psychoses, schizophrenia (Armer RE and Miller DJ, Exp. Opin. Ther. Patents, 11 (4): 563-572, 2001), psychotic mood disorders such as severe major depressive disorder, mood disorders associated with psychotic disorders such as acute mania or depression, associated with bipolar disorders and mood disorders, associated with schizophrenia, (Pralong ET et al., Prog. Neurobiol, 67: 173-202, 2002), autistic disorders (Carlsson ML, J. Neural Trans,. 105: 525-535, 1998), cognitive disorders such as dementias, including age related dementia and senile dementia of the Alzheimer type, memory disorders in a mammal, including a human, attention deficit disorders and pain (Armer RE and Miller DJ, Exp. Opin. Ther. Patents, 11 (4): 563-572, 2001). Thus, increasing activation of NMDA receptors via GlyT-1 inhibition may lead to agents that treat psychosis, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
Objects of the present invention are the compounds of formula I per se, the use of compounds of formula I and their pharmaceutically acceptable salts for the manufacture of medicaments for the treatment of diseases related to activation of NMDA receptors via Glyt-1 inhibition, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula I in the control or prevention of illnesses such as psychoses, disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease. The preferred indications using the compounds of the present invention are schizophrenia, cognitive impairment and Alzheimer's disease.
Furthermore, the invention includes all racemic mixtures, all their corresponding enantiomers and/or optical isomers. As used herein, the term "alkyl" denotes a saturated straight- or branched-chain group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl and the like. Preferred alkyl groups are groups with 1 - 4 carbon atoms.
The term "alkenyl" denotes an unsaturated straight- or branched-chain group containing from 2 to 6 carbon atoms. Preferred alkenyl group is allyl. The term "halogen" denotes chlorine, iodine, fluorine and bromine.
The term "aryl" denotes a monovalent cyclic aromatic hydrocarbon radical consisting of one or more fused rings in which at least one ring is aromatic in nature, for example phenyl or naphthyl. The term "6-membered heteroaryl containing one, two or three nitrogen atoms" denotes a monovalent aromatic carbocyclic radical, for example pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl or triazinyl.
The term "5-membered heteroaryl group optionally containing in addition to the N atom one, two or three further nitrogen atoms" denotes a monovalent aromatic carbocyclic radical, for example pyrrolyl, 2,5-dihydro-pyrrol-l-yl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl.
The term "heterocycloalkyl" denotes a non aromatic hydrocarbon radical, for example azepanyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl; pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or thiomorphoUnyl. The term "pharmaceutically acceptable acid addition salts" embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.
Preferred compounds of formula I are those of formula 1-1
Figure imgf000007_0001
wherein
R' is hydroxy, halogen, NO2, CN, (C1-C6)-alkyl, (C1-C6)-alkyl substituted by halogen, (C C6)-alkoxy, (C C6)-alkoxy substituted by halogen, NR7R8, C(O)R9 or SO2R10; m is 0, 1, 2 or 3; R1 is hydrogen or (C1-C6)-alkyl;
R2 and R2 are independently from each other hydrogen, (CR2)n-hydroxy for R being hydrogen or -Q -alkyl, or are (C C6)-alkyl, (C2-C6) -alkenyl, ( -C^-alkyl substituted by halogen, (CH2)n- (C3-C6)-cycloalkyl, (CH2)n-heterocycloalkyl, (CH2)„-O-(C1-C6)-alkyl or (CH2)n-aryl;
R3, R4 and R6 are independently from each other hydrogen, halogen, (CrQ -alkyl or (C C6)-alkoxy;
R5 is NO2, CN, C(O)R9, S-(Cι-C6)-alkyl, SO2R10 or is NRnR12;
R7 and R8 are independently from each other hydrogen, (CH2)n-(C3-C6)-cycloalkyl or (C C6)-alkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
R9 is hydroxy, (CrC6)-alkyl, (C3-C6)-cycloalkyl, (CrC6)-alkoxy or NR7R8;
R10 is (CrC6)-alkyl, (CH2)n-(C3-C6)-cycloalkyl or NR7R8;
R11 and R12 are independently from each other hydrogen, C(O)-(C1-C6)-alkyl, SO2-(C1-C6)-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, (C1-C6)-alkyl or (CH2)n(C3-C6)-cycloalkyl;
n is 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof.
The following compounds of formula 1-1 are preferred: l-(4-{4-[2-(cyclopropylmethyl-amino)-5-nitro-benzoyl]-piperazin-l-yl}-3-fluoro- phenyl) -ethanone, l-{4-[4-(2-cyclohexylamino-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone, l-{4-[4-(2-diethylamino-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}-ethanone, l-{3-fluoro-4-[4-(2-isobutylamino-5-nitro-benzoyl)-piperazin-l-yl]-phenyl}-ethanone, l-{4-[4-(2-cyclobutylamino-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone, 1 - { - [4- ( 2-cyclobutylamino-5-nitro-benzoyl) -piperazin- 1 -yl] -3 -fluoro-phenyl} - ethanone, l-{4-[4-(2-cyclopentylamino-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone or l-(4-{4-[2-(allyl-methyl-amino)-5-nitro-benzoyl]-piperazin-l-yl}-3-fluoro-phenyl)- ethanone.
Further preferred are compounds of formula 1-2
Figure imgf000009_0001
wherein
R' is hydroxy, halogen, N02, CN, (C1-C6)-alkyl, (C1-C6)-alkyl substituted by halogen, (Cι-C6)-alkoxy, (C1-C6)-alkoxy substituted by halogen, NR7R8, C(O)R9 or S02R10; m is 0, 1, 2 or 3;
R1 is hydrogen or (C1-C6)-alkyl;
Figure imgf000009_0002
is a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O, which rings are unsubstituted or substituted by (CH2)n-hydroxy,
Figure imgf000009_0003
(CH2)n-O-(C1-C6)-alkyl, or form together with the N atom a 5-membered heteroaryl group, optionnally containing in addition to the N atom one, two or three further nitrogen atoms and wherein the heteroaryl group is optionally substituted by (Q- C6)-alkyl;
R3, R4 and R6 are independently from each other hydrogen, halogen, (CrQ -alkyl or ( -C^-alkoxy; R5 is NO2, CN, C(O)R9, S-(C1-C6)-alkyl, SO2R10 or is NRUR12;
R7 and R8 are independently from each other hydrogen, (CH2)π-(C3- )-cycloalkyl or (C1-C6)-alkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
R9 is hydroxy, (Cι-C6)-alkyl, (C3-C6)-cycloalkyl, (C C6)-alkoxy or NR7R8;
R10 is (Q-Q -alkyl, (CH2)n-(C3-C6)-cycloalkyl or NR7R8;
R11 and R12 are independently from each other hydrogen, C(0)-(Ci-Q)-alkyl, SO2-(Cι-C6)-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, (CrC6)-alkyl or (CH2)n(C3-C6)-cycloalkyl;
n is 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof.
The following compounds of formula 1-2 are preferred: l-{4-[4-(2-morpholin-4-yl-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}-ethanone, 1 - { 3-fluoro-4- [4- ( 5-nitro-2-pyrrolidin- 1 -yl-benzoyl) -piperazin- 1 -yl] -phenyl}-ethanone, 1 - { 3 -fluoro-4- [4- ( 5-nitro-2 -piperidin- 1 -yl-benzoyl) -piperazin- 1 -yl] -phenyl } -ethanone, l-{4-[4-(2-azepan-l-yl-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}-ethanone, l-(3-fluoro-4-{4-[2-(2-methyl-piperidin-l-yl)-5-nitro-benzoyl]-piperazin-l-yl}- phenyl) -ethanone, l-(3-fluoro-4-{4-[2-(4-methyl-piperidin-l-yl)-5-nitro-benzoyI]-piperazin-l-yl}- phenyl) -ethanone, l-(3-fluoro-4-{4-[2-(3-methyl-piperidin-l-yl)-5-nitro-benzoyl]-piperazin-l-yl}- phenyl)-ethanone, l-(3-fluoro-4-{4-[2-(2-methyl-pyrrolidin-l-yl)-5-nitro-benzoyl]-piperazin-l-yl}- phenyl ) -ethanone, l-(4-{4-[2-(2,5-dihydro-pyrrol-l-yI)-5-nitro-benzoyl]-piperazin-l-yl}-3-fluoro-phenyl)- ethanone, l-{3-fluoro-4- [4-(5-nitro-2~thiomorpholin-4-yl-benzoyl)-piperazin- 1-yl] -phenyl}- ethanone, l-(3-fluoro-4-{4-[2-(3-hydroxy-piperidin-l-yl)-5-nitro-benzoyl]-piperazin-l-yl}- phenyl) -ethanone, l-{4-[4-(2-azepan-l-yl-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone, l-{3-fluoro-4- [4-(5-methanesulfonyl-2-pyrrolidin-l-yl~benzoyl)-piperazin-l-yl] - phenyl}-ethanone, N-methyl-4-pyrrolidin- l-yl-3- [4-(4-trifluoromethyl-phenyl)-piperazine- 1-carbonyl] - benzenesulfonamide, N-methyl-4-morpholin-4-yl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]- benzenesulfonamide,
3-[4-(4-acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-N-methyl-4-pyrrolidin-l-yl- benzenesulfonamide, 1 - (3-fluoro-4-{4- [2- (3-hydroxymethyl-pyrrolidin- 1 -yl)-5-nitro-benzoyl] -piperazin- 1 - yl}-phenyl)-ethanone, 2- [4- (2-morpholin-4-yl-5-nitro-benzoyl) -piperazin- 1-yl] -5-trifluoromethyl- benzonitrile, 3-fluoro-4- [4- (5-methanesulfonyl-2-piperidin- 1 -yl-benzoyl) -piperazin- 1 -yl] - benzonitrile, 2-fluoro-4-[4-(5-methanesulfonyl-2-piperidin-l-yl-benzoyl)-piperazin-l-yl]- benzonitrile,
[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-(5-methanesulfonyl-2-piperidin- 1 -yl-phenyl) -methanone, [4-(3-fluoro-4-trifluoromethyl-ρhenyl)-piperazin-l-yl]-(5-methanesulfonyl-2-piperidin- l-yl-phenyl)-methanone, 3- [4- (4-cyano-phenyl)-piperazine- 1-carbonyl] -N-methyl-4-pyrrolidin- 1 -yl- benzenesulfonamide, 3-[4-(4-cyano-2-fluoro-phenyl)-piperazine-l-carbonyl]-N-methyl-4-pyrrolidin-l-yl- benzenesulfonamide, 3-[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]-N-methyl-4- pyrrolidin- 1-yl-benzenesulfonamide,
3- [4- (3-fluoro-4-trifluoromethyl-phenyl)-piperazine- 1-carbonyl] -N-methyl-4- pyrrolidin- 1 -yl-benzenesulfonamide, 3-[4-(4-acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-N-methyl-4-piperidin-l-yl- benzenesulfonamide, 3-[4-(4-cyano-phenyl)-piperazine-l-carbonyl]-N-methyl-4-piperidin-l-yl- benzenesulfonamide, 3- [4-(4-cyano-2-fluoro-phenyl) -piperazine- 1-carbonyl] -N-methyl-4-piperidin- 1 -yl- benzenesulfonamide, 3-[4-(4-cyano-3-fluoro-phenyl)-piperazine-l-carbonyl]-N-methyl-4-piperidin-l-yl- benzenesulfonamide, N-methyl-4-piperidin-l-yl-3-[4-(4-trifIuoromethyl-phenyl)-piperazine-l-carbonyl]- benzenesulfonamide, 3-[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]-N-methyl-4- piperidin- 1 -yl-benzenesulfonamide, 3-[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]-N-methyl-4- piperidin- 1 -yl-benzenesulfonamide,
3- [4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazine- 1-carbonyl] -N-methyl-4- morpholin-4-yl-benzenesulfonamide or 3-[4-(3-fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]-N-methyl-4- morpholin-4-yl-benzenesulfonamide.
Further preferred are compounds of formula 1-3
Figure imgf000012_0001
wherein
hetaryl is a 6-membered heteroaryl, containing one, two or three nitrogen atoms, optionally substituted by one or more substituents selected from the group consisting of hydroxy, halogen, NO2, CN, (CrC^-alkyl, (CrC6)-alkyl substituted by halogen, (C1-C6)-alkoxy, (C1-C6)-alkoxy substituted by halogen, NR7R8, C(O)R9 or SO2R10;
R1 is hydrogen or (C C6)-alkyl;
R2 and R2 are independently from each other hydrogen, (CR2)n-hydroxy for R being hydrogen or C1-C6)-alkyl, or are (C1-C6)-alkyl, (C2-C6)-alkenyl, (C1-C6)-alkyl substituted by halogen, (CH2)n-(C3-C6)-cycloalkyl, (CH2)n-heterocycloalkyl, (CH2)„-O-(C1-C6)-aιkyl or (CH2)n-aryl or R , R4 and R6 are independently from each other hydrogen, halogen, (Cι- )-alkyl or (C1-C6)-alkoxy;
R5 is NO2, CN, C(O)R9, S-(Cι-C6)-alkyl, SO2R10 or is NRnR12;
R7 and R8 are independently from each other hydrogen, (CH2)n-(C3-C6)-cycloalkyl or (CrC6)-alkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
R9 is hydroxy, (C1-C6)-alkyl, (C3-C6)-cycloall yl, (Cι-C6)-alkoxy or NR7R8;
R10 is (C1-C6)-alkyl, (CH2)n-(C3-C6)-cycloalkyl or NR7R8;
R11 and R12 are independently from each other hydrogen, C(O)-(Cι-C6)-alkyl, SO2-(CrC6)-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, (C1-C6)-alkyl or (CH2)„(C3-C6)-cycloalkyl;
n is 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof.
Further preferred are compounds of formula 1-4
Figure imgf000013_0001
wherein hetaryl is a 6-membered heteroaryl, containing one, two or three nitrogen atoms, optionally substituted by one or more substituents selected from the group consisting of hydroxy, halogen, NO2, CN, (C C6)-alkyl, (C C6)-alkyl substituted by halogen, (Cι- )-alkoxy, (Cι-C6)-alkoxy substituted by halogen, NR7R8, C(O)R9 or S02R10;
R1 is hydrogen or (Cι-C6)-alkyl;
Figure imgf000014_0001
is a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O, which rings are unsubstituted or substituted by (CH2)n-hydroxy, (C1-C6)-alkyl, (Q-C^-alkoxy, (CH2)n-0-(C1-C6)-alkyl, or form together with the N atom a 5-membered heteroaryl group, optionnally containing in addition to the N atom one, two or three further nitrogen atoms and wherein the heteroaryl group is optionally substituted by (Q- C6)-alkyl;
R3, R4 and R6 are independently from each other hydrogen, halogen, (C1-C6)-alkyl or (C C6)-alkoxy;
R5 is NO2, CN, C(0)R9, S-(C C6)-alkyl, S02R10 or is NRUR12;
R7 and R8 are independently from each other hydrogen, (CH2)n-(C3-C6)-cycloalkyl or (C1-C6)-alkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
R9 is hydroxy, (Cι-C6)-alkyl, (C3-C6)-cycloalkyl, (Cι-C6)-alkoxy or NR7R8;
R10 is (CrQ -alkyl, (CH2)n-(C3-C6)-cycloalkyl or NR7R8;
R11 and R12 are independently from each other hydrogen, C(0)-(Cι-C6)-alkyl, SO2-(CrC6)-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, (C1-C6)-alkyl or (CH2)n(C3-C6)-cycloalkyl; n is 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof.
The following compounds of formula 1-4 are preferred:
3-[4-(3-fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]-N-methyl-4- morpholin-4-yl-benzenesulfonamide (2-morpholin-4-yl-5-nitro-phenyl)- [4-(5-trifluoromethyl-pyridin-2-yl)-piperazin- 1-yl] - methanone [4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-(2-morpholin-4-yl-5- nitro-phenyl) -methanone 6- [4- (2-morpholin-4-yl-5-nitro-benzoyl) -piperazin- 1 -yl] -nicotinonitrile [4-(3-chloro-pyridin-2-yl)-piperazin-l-yl]-(2-morpholin-4-yl-5-nitro-phenyl)- methanone (2-morpholin-4-yl-5-nitro-phenyl)-[4-(4-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]- methanone (2-morpholin-4-yl-5-nitro-phenyl)-[4-(6-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]- methanone [4- ( 5-bromo-pyrimidin-2-yl) -piperazin- 1 -yl] -(2-morpholin-4-yl-5-nitro-phenyl) - methanone
[4-(6-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-(2-morpholin-4-yl-5- nitro-phenyl)-methanone (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(2-trifluoromethyl-pyrimidin-4-yl)- piperazin- 1 -yl] -methanone (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(6-trifluoromethyl-pyrimidin-4-yl)- piperazin- 1 -yl] -methanone (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(5-trifluoromethyl-pyrimidin-2-yl)- piperazin- 1 -yl] -methanone 6- [4- ( 5-methanesulfonyl-2-morpholin-4-yl-benzoyl)-piρerazin- 1 -yl] -nicotinonitrile (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(5-trifluoromethyl-pyridin-2-yl)- piperazin- 1 -yl] -methanone [4-(3-cUoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-(5-methanesulfonyl-2- morpholin-4-yl-phenyl) -methanone [4-(5-chloro-pyridin-2-yl)-piperazin-l-yl]-(5-mefhanesulfonyl-2-morpholin-4-yl- phenyl) -methanone
(5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(6-trifluoromethyl-pyridin-3-yl)- piperazin- 1 -yl] -methanone [4- (3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin- 1 -yl] - (5-methanesulfonyl-2- morpholin-4-yl-phenyl)-methanone (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(6-methyl-pyridin-3-yl)-piperazin-l- yl] -methanone (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(5-methyl-pyridin-2-yl)-piperazin-l- yl] -methanone (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(4-trifluoromethyl-pyridin-2-yl)- piperazin- 1 -yl] -methanone (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(6-trifluoromethyl-pyridin-2-yl)- piperazin- 1-yl] -methanone
(5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(2-trifluoromethyl-pyrimidin-5-yl)- piperazin- 1 -yl] -methanone (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(6-trifluoromethyl-pyridazin-3-yl)- piperazin- 1 -yl] -methanone [4-(4-dimethylamino-[l,3,5]triazin-2-yl)-piperazin-l-yl]-(5-methanesulfonyl-2- morpholin-4-yl-phenyl)-methanone or (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-(5'-trifluoromethyl-2,3,5,6-tetrahydro- [ 1 ,2' ] bipyrazinyl-4-yl) -methanone. One embodiment of the invention are compounds of formula
Figure imgf000016_0001
wherein
Ar is unsubstituted or substituted aryl or 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups are substituted by one or more substituents selected from the group consisting of hydroxy, halogen, N02, CN, (Ci-C6)-alkyl, (C1-C6)-alkyl substituted by halogen, ( -C^-alkoxy, (Ci-C6)-alkoxy substituted by halogen, NR7R8, C(O)R9 or SO2R10; R1 is hydrogen or (Cι-Q)-alkyl;
R2 and R2 are independently from each other hydrogen, hydroxy, (C C6)-alkyl, (C3-C6)-alkenyl, (C2-C6)-alkyl substituted by halogen, (C3-C6)-cycloalkyl, heterocycloalkyl, (C1-C6)-alkyl-(C3-C6)-cycloalkyl, (CrC6)-alkyl-heterocycloalkyl, (CI-C6)-alkyl-C(0)-R9, (Q-C6)-alkyl-CN, (C2-C6)-alkyl-0-R13, (C2-C6)-alkyl- NR7R8, aryl or 6-membered heteroaryl containing one, two or three nitrogen atoms, (Cι-C6)-alkyl-aryl or (Cι-C6)-aIkyl-5 or-6-membered heteroaryl containing one, two or three heteroatoms, selected from the group consisting of oxygen, sulphur or nitrogen, wherein aryl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen, (Cι-C6)-alkyl or (C1-C6)-alkoxy; or R2 and R2 form together with the N atom to which they are attach a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O, which rings are unsubstituted or substituted by hydroxy, (CrC6)-alkyl, (Q-C^-alkoxy, (C1-C6)-alkyl-0-R13, or form together with the N atom a 5-membered heteroaryl group, optionnally containing in addition to the N atom one, two or three further nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, (Cι- )-alkyl, (Cj-C6)-alkyl substituted by halogen or (C3-C6)-cycloalkyl;
R3, R4 and R6 are independently from each other hydrogen, hydroxy, halogen, CN, (Q-Q -alkyl, (C1-C6)-alkoxy or NR7R8;
R5 is NO2, CN, C(O)R9, S-(C1-C6)-alkyl, SO2R10 or is NRπR12;
R7 and R8 are independently from each other hydrogen, (Cι-C6)-alkyl-(C3-C6)-cycloalkyl, (Cι-C6)-alkyl, or (C3-C6)-cycloalkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
R9 is hydroxy, (C C6)-alkyl, (C3-C6)-cycloalkyl, (C1-C6)-alkoxy or NR7R8;
R10 is ( -Q -alkyl, (C3-C6)-cycloalkyl, (C1-C6)-alkyl-(C3-C6)-cycloalkyl or NR7R8;
R11 and R12 are independently from each other hydrogen, C(0)-(C1-C6)-alkyl, SO2-(CrC6)-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, ( - C6)-alkyl, (Q-C6)-aikyl substituted by halogen or (C3-C6)-cycloalkyl;
R13 is hydrogen, (C C6)-alkyl or (C3-C6)-cycloalkyl; and pharmaceutically acceptable acid addition salts thereof, with the proviso that l-[5-(aminosulfonyl)-2-(4-morpholinyl)benzoyl]-4-phenyl-piperazine,
1 - (4-mefhoxyphenyl) -4- [2 - (4-morpholinyl) -5-nitrobenzoyl] -piperazine, l-[2-(4-morpholinyl)-5-nitrobenzoyl]-4-[2-nitro-4-(trifluoromethyl)phenyl]- piperazine, l-(4-methoxyphenyl)-4-[5-nitro-2-(l-pyrrolidinyl)benzoyl]-piperazine, l-[2-[4-(2-hydroxyethyl)-l-piperazinyl]-5-nitrobenzoyl]-4-(4-methoxyphenyl)- piperazine,
1 - [2-fluoro-4-( 1 -oxopropyl)phenyl] -4- [5-nitro-2-( 1 -piperidinyl)benzoyl] -piperazine,
1 - [2-fluoro-4- ( 1 -oxopropyl)phenyl] -4- [5-nitro-2- ( 1 -pyrrolidinyl)benzoyl] -piperazine,
1 - [2-fluoro-4- ( 1 -oxopropyl)phenyl] -4- [2- (4-methyl- 1 -piperidinyl)-5-nitrobenzoyl] - piperazine,
1 - [2-fluoro-4- ( 1 -oxopropyl)phenyl] -4- [2- (4-methyl-l -piperazinyl)-5-nitrobenzoyl] - piperazine,
1 - [2-fluoro-4- ( 1 -oxopropyl)phenyl] -4- [2- (4-morpholinyl) -5-nitrobenzoyl] -piperazine, l-[5-[[methyl(phenylmethyl)amino]sulfonyl]-2-(4-morpholinyl)benzoyl]-4-(4- nitrophenyl) -piperazine and l-(4-acetyl-2-fluorophenyl)-4-[2-(4-morpholinyl)-5-nitrobenzoyl]- piperazine, are excluded.
One embodiment of the invention are compounds of formula la
Figure imgf000018_0001
wherein
Ar is unsubstituted or substituted phenyl or 6-membered heteroaryl, containing one or two nitrogen atoms, and wherein the phenyl and the heteroaryl groups are optionally substituted by one or two substituents selected from the group consisting of halogen, NO2, CN, (Ci-Cg)-alkyl, (C1-C6)-alkyl substituted by halogen, (Cι-C5)-alkoxy, (C1-C6)-alkoxy substituted by halogen, NR7R8, C(O)R9 or SO2R10;
R1 is hydrogen or (Cι-C6)-alkyl;
R2 and R2 are independently from each other hydrogen, hydroxy, (Cι-C6)-alkyl, (C3-C6)-alkenyl, (C3-Q)-cycloalkyl, heterocycloalkyl, (C1-C6)-alkyl-(C3-C6)-cycloalkyl, (Q-C6)-alkyl-aryl, (C2-C6)-alkyl-O-R13, or R2 and R2 form together with the N atom to which they are attach a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O, which rings are unsubstituted or substituted by hydroxy, (C1-C6)-alkyl, ( -C^-alkoxy, (Q-C6)-alkyl-0-R13, or form together with the N atom a 5-membered heteroaryl group optionnally containing in addition to the N atom one or two nitrogen atoms;
R5 is NO2, CN, C(O)R9, S-(CrC6)-alkyl, SO2R10 or is NRπR12;
R7 and R8 are independently from each other hydrogen, (C1-C6)-alkyl-(C3-C6)-cycloalkyl, (Ci-C6)-alkyl or form together with the N atom to which they are attach a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of oxygen;
R9 is (CrQ -alkyl, (Cι-C6)-alkoxy or NR7R8;
R10 is (Cι-C6)-alkyl, (C1-C6)-aιkyl-(C3-C6)-cycloalkyl or NR7R8;
Rπ and R12 are independently from each other SO2-(C1-C6)-alkyl, or form together with the N-atom a 5-membered heteroaryl group containing in addition to the N atom one, two or three nitrogen atoms; R13 is hydrogen or (C1-C6)-alkyl; and pharmaceutically acceptable acid addition salts thereof, with the proviso that 1 - [5-(aminosulfonyl)-2-(4-morpholinyl)benzoyl] -4-phenyl-piperazine, l-(4-methoxyphenyl)-4-[2-(4-morpholinyl)-5-nitrobenzoyl]-piperazine,
1 - [2-(4-morpholinyl)-5-nitrobenzoyl] -4- [2-nitro-4-(trifluoromethyl)phenyl] - piperazine,
1 -(4-methoxyphenyl)-4- [5-nitro-2-( 1 -pyrrolidinyl)benzoyl] -piperazine, l-[2-[4-(2-hydroxyethyl)-l-piperazinyl]-5-nitrobenzoyl]-4-(4-methoxyphenyl)- piperazine,
1 - [2-fluoro-4-( 1 -oxopropyl)phenyl] -4- [5-nitro-2- ( 1 -piperidinyl)benzoyl] -piperazine,
1 - [2-fluoro-4-( l-oxopropyl)phenyl] -4- [5-nitro-2-( 1 -pyrrolidinyl)benzoyl] -piperazine,
1 - [2-fluoro-4- ( 1 -oxopropyl)phenyl] -4- [2-(4-methyl- 1 -piperidinyl) -5-nitrobenzoyl] - piperazine,
1 - [2-fluoro-4- ( 1 -oxopropyl)ρhenyl] -4- [2- (4-methyl-l -piperazinyl)-5-nitrobenzoyl] - piperazine,
1 - [2-fluoro-4-( 1 -oxopropyl)phenyl] -4- [2- (4-morpholinyl) -5-nitrobenzoyl] -piperazine, l-[5-[[methyl(phenylmethyl)amino]sulfonyl]-2-(4-morpholinyl)benzoyl]-4-(4- nitrophenyl) -piperazine and l-(4-acetyl-2-fluorophenyl)-4-[2-(4-morpholinyl)-5-nitrobenzoyl]- piperazine, are excluded.
Another embodiment are those compounds of formula la, wherein
Figure imgf000020_0001
wherein
Ar is unsubstituted or substituted phenyl, pyridyl or pyrimidinyl, optionally substituted by one or two substituents selected from the group consisting of halogen, NO2, CN, methyl, CF3, methoxy, OCF3, NH2, C(O)CH3, C(O)OCH3, C(O)OCH2CH3, SO2NH2 or SO2CH3;
R1 is hydrogen or methyl;
R2 and R2 are independently from each other hydrogen, hydroxy, (Cι- )-alkyl, -CH2CH=CH2, -CH2CH2OH, -CH(CH3)CH2OH, cyclopropyl, cyclopentyl, cyclohexyl, tetrahydropyranyl, -CH2-cyclopropyl, (CH2)2OCH3, benzyl, or
R2 and R2 form together with the N atom to which they are attach a heterocycloalkyl ring, selected from the group consisting of morpholinyL fhiomorpholinyl, azetidinyl, pyrrolidinyl, piperidinyl or azepanyl, which rings are unsusbtituted or substituted by hydroxy, methyl, methoxy, ethoxy, CH2OH, or form together with the N atom a 5- membered heteroaryl ring, selected from the group consisting of imidazolyl, triazolyl or di-hydro-pyrrolyl;
R5 is NO2, CN, -C(0)NH2, -C(O)NHCH3, .C(0)N(CH3)2, -C(O)CH3, -SCH3, -S02-(C C6)-alkyl, -SO2-NH-(CrC6)-alkyl, -SO2-N-[(Cι-C6)-alkyl]2, -SO2NH2, -NHSO2CH3, -S02-NHCH2-cycloalkyl, -SO2-CH2-cycloalkyl, -SO2-pyrrolidin-l-yl, -S02-morpholidin-l-yl, imidazolyl or tetrazolyl;
and pharmaceutically acceptable acid addition salts thereof, with the proviso that
1 - [5- ( aminosulfonyl) -2- (4-morpholinyl)benzoyl] -4-phenyl-piperazine, l-(4-methoxyphenyl)-4-[2-(4-morpholinyl)-5-nitrobenzoyl]-piperazine, l-[2-(4-morpholinyl)-5-nitrobenzoyl]-4-[2-nitro-4-(trifluoromethyl)phenyl]- piperazine,
1 - [2- [4- (2-hydroxyethyl) - 1-piperazinyl] -5-nitrobenzoyl] -4-(4-methoxyphenyl) - piperazine and l-(4-acetyl-2-fluorophenyI)-4- [2-(4-morpholinyl)-5-nitrobenzoyl] - piperazine, are excluded.
Still another embodiment are compounds, wherein R2 and R2 form together with the N atom to which they are attach a morpholine ring, for example the following compounds: l-{4-[4-(2-morpholin-4-yl-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}-ethanone, N-methyl-4-morpholin-4-yl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]- benzenesulfonamide or
2-[4-(2-morpholin-4-yl-5-nitro-benzoyl)-piperazin-l-yl]-5-trifluoromethyl- benzonitrile.
Another embodiment are compounds, wherein R2 and R2 form together with the N atom to which they are attach a pyrrolidin- or 2,5-dihydropyrrol ring, which are optionally substituted by methyl or CH2OH, for example the following compounds: l-{3-fluoro-4-[4-(5-nitro-2-pyrrolidin-l-yl-benzoyl)-piperazin-l-yl]-phenyl}-ethanone, l-(3-fluoro-4-{4-[2-(2-methyl-pyrrolidin-l-yl)-5-nitro-benzoyl]-piperazin-l-yl}- phenyl) -ethanone, l-(4-{4-[2-(2,5-dihydro-pyrrol-l-yl)-5-nitro-benzoyl]-piperazin-l-yl}-3-fluoro-phenyl)- ethanone, l-{3-fluoro-4-[4-(5-methanesulfonyl-2-pyrrolidin-l-yl-benzoyl)-piperazin-l-yl]- phenyl} -ethanone,
N-methyl-4-pyrrolidin-l-yl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]- benzenesulfonamide,
3-[4-(4-acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-N-methyl-4-pyrrolidin-l-yl- benzenesulfonamide or l-(3-fluoro-4-{4-[2-(3-hydroxymethyl-pyrrolidin-l-yl)-5-nitro-benzoyl]-piperazin-l- yl}-phenyl)-ethanone. Still another embodiment are further those compounds, wherein R and R2 form together with the N atom to which they are attach a piperidine ring, which is optionally substituted by methyl or hydroxy, for example the following compounds: l-{3-fluoro-4-[4-(5-nitro-2-piperidin-l-yl-benzoyl)-piperazin-l-yl]-phenyl}-ethanone, l-(3-fluoro-4-{4-[2-(2-methyl-piperidin-l-yl)-5-nitro-benzoyl]-piperazin-l-yl}- phenyl)-ethanone, l-(3-fluoro-4-{4-[2-(4-methyl-piperidin-l-yl)-5-nitro-benzoyl]-piperazin-l-yl}- phenyl) -ethanone, l-(3-fluoro-4-{4-[2-(3-methyl-piperidin-l-yl)-5-nitro-benzoyl]-piperazin-l-yl}- phenyl)-ethanone or l-(3-fluoro-4-{4-[2-(3-hydroxy-piperidin-l-yl)-5-nitro-benzoyl]-piperazin-l-yl}- phenyl) -ethanone.
An embodiment of the invention are further those compounds, wherein R2 and R2 form together with the N atom to which they are attach a azepane ring, for example the following compounds: l-{4-[4-(2-azepan-l-yl-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}-ethanone or l-{4-[4-(2-azepan-l-yl-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone.
Compounds of the invention are further those, wherein R2 and R2 form together with the N atom to which they are attach a thiomorpholine ring, for example the following compound:
1 - { 3-fluoro-4- [4- (5-nitro-2-thiomorpholin-4-yl-benzoyl)-piperazin- 1 -yl] -phenyl} - ethanone. A further embodiment of the invention are further those compounds, wherein R2 or R2 is CH2-cycloalkyl or cycloalkyl, for example the following compounds: l-(4-{4-[2-(cyclopropylmethyl-amino)-5-nitro-benzoyl]-piperazin-l-yl}-3-fluoro- phenyl) -ethanone, l-{4-[4-(2-cyclohexylamino-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone, l-{4-[4-(2-cyclobutylamino-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone or l-{4-[4-(2-cyclopentylamino-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone.
An embodiment of the invention are further those compounds, wherein one of R2 or R2 is (C1-C6)-alkyl, and the other is hydrogen or both of R2 or R2 are (C1-C6)-alkyl, for example the following compounds: l-{3-fluoro-4-[4-(2-isopropylamino-5-nitro-benzoyl)-piperazin-l-yl]-phenyl}- ethanone, l-{3-fluoro-4-[4-(2-isobutylamino-5-nitro-benzoyl)-piperazin-l-yl]-phenyl}-ethanone, l-{3-fluoro-4-[4-(2-tert.-butylamino-5-nitro-benzoyl)-piperazin-l-yl]-phenyl}- ethanone or l-{4-[4-(2-diethylamino-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}-ethanone.
Compounds of the invention are further those, wherein one of R2 or R is (C2-C6) -alkenyl, and the other is (Cι-C6)-alkyl, for example the following compound: l-(4-{4-[2-(allyl-methyl-amino)-5-nitro-benzoyl]-piperazin-l-yl}-3-£luoro-phenyl)- ethanone. The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by methods known in the art, for example, by processes described below, which process comprises a) reacting a compound of formula
Figure imgf000024_0001
with a compound of formula
Figure imgf000024_0002
to a compound of formula
Figure imgf000024_0003
wherein Z is OH or halogen and the other substituents are as defined above, or b) reacting a compound of formula
Figure imgf000024_0004
with a compound of formula
R2R2NH
to a compound of formula
Figure imgf000024_0005
wherein X is halogen and the other substituents are as defined above, c) reacting a compound of formula
Figure imgf000025_0001
with a compound of formula
ArX
to a compound of formula
Figure imgf000025_0002
wherein X is halogen and the other substituents are as defined above, d) reacting a compound of formula
Figure imgf000025_0003
with hydrogen on Pd/C to a compound of formula
Figure imgf000025_0004
wherein the substituents are as defined above, e) reacting a compound of formula
Figure imgf000026_0001
with a compound of formula
R1 AX
to a compound of formula
Figure imgf000026_0002
wherein X is halogen, A is -C(O)- or -SO -, R14 is (Q-C^-alkyl and the other substituents are as defined above, f) reacting a compound of formula
Figure imgf000026_0003
with a compound of formula
R15C(OEt)3
to a compound of formula
Figure imgf000027_0001
wherein R15 is hydrogen, halogen, (Cι-C6)-alkyl, (Cι-C6)-alkyl substituted by halogen or (C3-C6)-cycloalkyl and the other substituents are as defined above, g) reacting a compound of formula
Figure imgf000027_0002
with a base
to a compound of formula
Figure imgf000027_0003
wherein the substituents are as defined above, h) reacting a compound of formula
Figure imgf000027_0004
with a compound of formula
R7R8NH
to a compound of formula
Figure imgf000028_0001
wherein the substituents are as defined above, i) reacting a compound of formula
Figure imgf000028_0002
with a compound of formula
Figure imgf000028_0003
to a compound of formula
Figure imgf000028_0004
wherein R is (C C6)-alkyl, R16 is (C C6)-alkyl or (C3-C6)-cycloalkyl and the other substituents are as defined above, j) reacting a compound of formula
Figure imgf000029_0001
with a compound of formula
Figure imgf000029_0002
to a compound of formula
Figure imgf000029_0003
wherein X is CH or N and the heteroaryl ring is selected from the group consisting of imidazole, pyrazole or triazole, R15 is hydrogen, halogen, (CrC^-alkyl, (C1-C6)-alkyl substituted by halogen or (C3-C6)-cycloalkyl and the other substituents are as defined above,
and if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts. The compounds of formula I may be prepared in accordance with process variants a) to j) and with the following schemes 1 to 6.
The starting material is commercially available or may be prepared in accordance with known methods. Scheme 1
Figure imgf000030_0001
ded:
X: halogen i.e GDI, TBTU
Y: H, protective group (i.e.boc)
Z: OH, halogen (i.e.: Cl)
Figure imgf000030_0002
Figure imgf000030_0003
Compounds of general formula I can be prepared by reacting of a piperazine of formula II with a compound of formula III (Z: Cl) or III (Z: OH) in the presence of an activating agent like CDI (N,N-carbonyldiimidazole) or TBTU (2-(lH-benzotriazole-l-yl)-l, 1,3,3- tetramethyluroniumtetrafluoroborate).
A compound of formula III (Z: Cl) can be prepared from a compound of formula III (Z: OH) in the presence of an activating agent like thionylchloride. In turn the acid of formula III (Z: OH) can be prepared by heating a mixture of an acid of formula IV and an amino derivative of formula R2R NH.
The piperazine of formula II can be prepared by heating of a corresponding piperazine with ArX or by reacting of a N-protected piperazine with ArX in the presence of palladium catalyst followed by cleavage of the protective group. The protective group is typically tert-butoxycarbonyl (Boc). Scheme 2
X: halogen Z: OH, halogen (i.e: Cl)
Figure imgf000031_0002
Aternatively, compounds of general formula I can be prepared by reaction of a derivative of formula V with a corresponding amine of formula R2R2 NH. Compounds of formula V can be prepared by reacting of derivatives of formula II with compounds of formula IV (Z: Cl) or with compounds of formula IV(Z: OH) in the presence of an activating agent like GDI (N-carbonyldiimidazole) or TBTU (2-(lH-benzotriazoIe-l-yl)-l,l,3,3- tetramethyluroniumtetrafluoroborate). Scheme 3
Figure imgf000032_0001
X: halogen Y: H, protective group (i.e.boc) Z: OH, halogen (i.e: Cl)
Figure imgf000032_0002
Aternatively, compounds of general formula I can be prepared by reaction of a compound of formula VII with ArX. A compound of formula VII can be prepared by reacting of a
N-protected derivative of formula VI with an amine of formula R2R2 NH, followed by cleavage of the protective group. The protective group is typically tert-butoxycarbonyl (Boc). In turn, a compound of formula VI can be prepared by reacting of a piperazine of formula II with a compound of formula IV (Z: Cl) or with a compound of formula IV (Z: OH) in the presence of an activating agent like CDI (N-carbonyldiimidazole) or TBTU (2- ( 1 H-benzotriazole- 1 -yl) - 1 , 1 ,3 ,3 -tetramethylur oniumtetrafluoroborate) .
Scheme 4
Figure imgf000033_0001
Compounds of formula IC (A is -CO-) and IC (A is -S02-) can be prepared respectively by carbonylation or sulfonylation of a corresponding amino derivative IB in the presence of a compound of formula R14AX. In turn, a compound of formula IB can be prepared by hydrogenation of a compound of formula IA.
Heterocyclic compounds of formula ID can be prepared by reaction of a compound of formula IB with a substituted triethyl orthoformate derivative of formula R15-C(OEt)3 in the presence of sodium azide.
Scheme 5
Figure imgf000034_0001
Compounds of formula IG can be prepared by reaction of an acid derivative of formula IF with an amine of formula R7R8NH in the presence of an activating agent like CDI (N- carbonyldiimidazole) or TBTU (2-(lH-benzotriazoIe-l-yl)-l, 1,3,3- tetramethyluroniumtetrafluoroborate). A compound of formula IF can be prepared by hydrolysis of a compound of formula IE in the presence of base like sodium hydroxide.
Scheme 6
Figure imgf000035_0001
Z is CI
Figure imgf000035_0002
or
Figure imgf000035_0003
H i N X' Nχ : substituted imidazole, R9 χ-X pyrazole, triazole
X: C, N
A compound of formula IH can be prepared by reacting under Stille conditions with an aryl-bromo derivative of formula X and with a corresponding vinyl stannane of formula XI in the presence of a palladium catalyst like dichlorobis(triphenylphosphine) palladium(II). A compound of formula 1 1 can be prepared by reacting of a compound of formula X with a compound of formula XII in the presence of a Cu catalyst like Cul. A compound of formula X can be prepared by coupling an acid chloride III with a piperazine derivative of formula II. The acid addition salts of the basic compounds of formula I maybe converted to the corresponding free bases by treatment with at least a stoichiometric equivalent of a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like.
The compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention are good inhibitors of the glycine transporter I (GlyT-1).
The compounds were investigated in accordance with the test given hereinafter.
Solutions and materials DMEM complete medium: Nutrient mixture F-12 (Gibco Life-technologies), fetal bovine serum (FBS) 5 %, (Gibco life technologies), Penicillin/Streptomycin 1 % (Gibco life technologies), Hygromycin 0.6 mg/ml (Gibco life technologies), Glutamine 1 mM Gibco life technologies)
Uptake buffer (UB): 150 mM NaCl, 10 mM Hepes-Tris, pH 7.4, 1 mM CaCl2, 2.5 mM KC1, 2.5 mM MgSO4, 10 mM (+) D-glucose.
Flp-in™-CHO (Invitrogen Cat n° R758-07)ceUs stably transfected with mGlyTlb cDNA.
Glycine uptake inhibition assay (mGlyT-lb)
On day 1 mammalian cells, (Flp-in™-CHO), transfected with mGlyT-lb cDNA , were plated at the density of 40,000 cells/well in complete F-12 medium, without hygromycin in 96-well culture plates. On day 2, the medium was aspirated and the cells were washed twice with uptake buffer (UB). The cells were then incubated for 20 min at 22°C with either (i) no potential competitor, (ii) 10 mM non-radioactive glycine , (iii) a concentration of a potential inhibitor. A range of concentrations of the potential inhibitor was used to generate data for calculating the concentration of inhibitor resulting in 50 % of the effect (e.g. IC50, the concentration of the competitor inhibiting glycine uptake of 50 %). A solution was then immediately added containing [3H]-glycine 60 nM (11-16 Ci/mmol) and 25 μM non-radioactive glycine. The plates were incubated with gentle shaking and the reaction was stopped by aspiration of the mixture and washing (three times) with ice-cold UB. The cells were lysed with scintillation liquid, shaken 3 hours and the radioactivity in the cells was counted using a scintillation counter.
The compounds in the above table show an IC50 (μM) at mGlyT-1 < 0.02 (μM)
Figure imgf000037_0001
Figure imgf000038_0001
The compounds of formula I and the pharmaceutically acceptable salts of the compounds of formula I can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions.
The compounds of formula I can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose,corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are however usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
The pharmaceutical preparations can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
Medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable acid addition salts and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.
The most preferred indications in accordance with the present invention are those, which include disorders of the central nervous system, for example the treatment or prevention of schizophrenia, cognitive impairment and Alzheimer's disease. The dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.
The following examples illustrate the present invention without limiting it. All temperatures are given in degree Celsius.
The following abbreviations were used in the examples: RT: room temperature; n-Boc-piperazine: tert-Butyl 1-piperazinecarboxylate, oxone®: (potassium peroxymonosulfate) 2KHSO5*KHS0 «K2S0 ,
EtOAc: ethyl acetate;
THF: tetrahydrofuran; TBTU: 2-(lH-benzotriazole-l-yl)-l,l,3,3-tetramethyluroniumtetrafluoroborate;
DIPEA: diisopropylethylamine,
DMF: N,N-dimetyhylformamide
Example A
l-{3-Fluoro-4-[4-(2-fluoro-5-nitro-benzoyl)-piperazin-l-yl]-phenyl}-ethanone
Figure imgf000039_0001
A solution of 2-Fluoro-5-nitro-benzoyl chloride (CAS: 7304-32-7; Feng, Y.; Burgess, K.; Chem.Europ.J.; EN; 5; 11; 1999; 3261 - 3272) (0.054 g, 0.261 mmol) in dioxane (1ml) was treated with triethylamine (0.073 ml, 0.522 mmol) and then with a solution of l-(3- Fluoro-4-piperazin-l-yl-phenyl)-ethanone (CAS: 189763-57-3; WO9714690) (58 mg, 0.261 mmol) in dioxane ( 1 ml). The mixture was stirred at room temperature for 30 minutes. The solvent was removed in vacuo. The crude oil was taken in water. The aqueous layer was extracted 3 times with CH2C12. The combined extracts were dried over Na2SO , filtered and the solvent was removed in vacuo. The crude gum was purified on silicagel (eluent: heptane/ethylacetate 0%-20% (10 minutes) to provide the title compound (69 mg, 68%) as a light yellow solid, MS (m/e): 390.2 (MH+, 100%) Example 1
l-{4-[4-(2-Morphol -4-yl-5-mtro-benzoyl)-piperazm-l-yl]-3-fluoro-phenyl}-ethanone (known compound, RN 310415)
A solution of l-{3-Fluoro-4-[4-(2-fluoro-5-nitro-benzoyl)-piperazin-l-yl]-phenyl}- ethanone (0.065 g, 0.167 mmol) in morpholine (0.29 ml) was heated for 30 minutes at 100 °C then cooled to room temperature and diluted with water. The resulting solid was filtered and dried to provide the title compound (71 mg, 93%) as a yellow solid, MS (m/e): 457.3 (M+H+, 100%)
According to the procedure described for the synthesis of Example 1 further derivatives have been synthesised and comprise Examples 179,180, 189, 190, 191, 196, 197, 198 in Table 1.
Example 2
l-{4-[4-(2-Ethylamino-5-nitro-benzoyl)-ρiperazin-l-yl]-3-fluoro-phenyl}-ethanone
A mixture of 27.4 mg (0.07 mmol) l-{3-Fluoro-4-[4-(2-fluoro-5-nitro-benzoyl)- piperazin- 1-yl] -phenyl}-ethanone, 91 ul (0.091 mmol) of a IN solution of ethylamine in DMF and 30 ul (0.175 mmol) DIPEA in 2 ml THF was heated to 80 °C for 16 h. After evaporation of the volatiles the residue was taken up in 2 ml methanol / formic acid 6/1 and subjected to preparative HPLC purification on reversed phase eluting with an acetonitrile / water gradient to yield after evaporation of the product fractions 20.2 mg (70%) of the title compound. MS (m/e): 415.2 (MH+, 100%)
According to the procedure described for the synthesis of Example 2 further derivatives have been synthesised from l-{3-Fluoro-4-[4-(2-fluoro-5-nitro-benzoyl)-piperazin-l- yl] -phenyl} -ethanone and amines and comprise Examples 2-45 in Table 1.
Example B
2-Morpholin-4-yl-5-nitro-benzoyl chloride
Figure imgf000040_0001
step 1: 2-Morpholin-4-yl-5-nitro-benzoic acid
Figure imgf000041_0001
To a solution of 2-Fluoro-5-nitrobenzoic acid (4.86 g, 26.2 mmol) in dioxane (50 ml) was added morpholine (11.5 ml). The mixture was stirred at room temperature for 2 hours. The solvent was removed in vacuo. The residue was dissolved in water and the mixture was acidified with HC12N. The solid was filtered, washed with water and dried to provide the title compound (6.2 g, 93%) as a yellow solid, MS (m/e): 251.2 (M-H, 100%).
Step 2: 2-Morpholin-4-yl-5-nitro-benzoyl chloride
Figure imgf000041_0002
To a suspension of 2-Morpholin-4-yl-5-nitro-benzoic acid (4.0 g, 16 mmol) in toluene were added 2 drops of DMF and thionylchloride (5.7 ml, 79.3 mmol). The mixture was heated to 80°C for 50 minutes. The solvent was removed in vacuo, and the resulting solid was stirred in ether, filtered and dried to provide the title compound (4.0 g, 93%) as a yellow solid.
Example C
l-(3-Chloro-4-piperazin-l-yl-phenyl)-ethanone
Figure imgf000041_0003
A mixture of 5.0 g (29 mmol) 3-Chloro-4-fluoroacetophenon and 12.5 g (145 mmol) piperazine in 10 ml N,N-dimethyl-acetamide was heated to 120 °C for 23 h. All volatiles were removed under vacuum and the residue was purified by flash column chromatography on silica eluting with a mixture of DCM / methanol / 5% NH3 aq. to yield 3.47 g (50 %) of the title compound as yellow amorphous solid.
1-H-NMR (300 MHz, CDC13) δ= 7.96 (d, =8.4 Hz, J2=2.1 Hz, H-2, IH), 7.82 (dd,
Figure imgf000042_0001
Hz, H-5, IH), 3.03 (m, 4H, piperazine), 2.88 (m, 4H, piperazine), 2.55 (s, 3H, COMe). MS (m/e): 239.2 (MH+, 100%)
Example D
l-(2-Chloro-4-trifluoromethyl-phenyI)-piperazme
Figure imgf000042_0002
step 1: 4-(2-Chloro-4-trifluoromethyl-phenyl -piperazine-l-carboxylic acid tert-butyl ester
A mixture of 0.5 g (1.6 mmol) of 3-chloro-4-iodobenzotrifluoride 0.7 g (3.8 mmol), N-
Boc-piperazine, 41 mg (0.04 mmol) Tris(dibenzylideneacetone)dipalladium chloroform complex, 0.44 g ( 4.43 mmol) sodium-t-butoxide and 48 mg (0.16 mmol) tri-o- tolylphosphine in 6 ml dioxane was heated overnight at 100 °C. The solution was allowed to cool to room temperature, taken up in ether (30ml) and washed with brine (25ml).
The organic layer was dried over Na2SO , filtered and the solvent was removed in vacuo.
The crude oil was chromatographed over on silica gel: Eluent: Heptane-AcOEt 0-10% over 15min to provide the title compound (0.06g, 10%) as a brown oil, MS (m/e): 365.1
(MH+, 100%).
Step 2: l-(2-Chloro-4-trifluoromethyl-phenyl)-piperazine
Figure imgf000043_0001
A solution of 4-(2-Chloro-4-trifiuoromethyl-phenyl)-piperazine-l-carboxylic acid tert- butyl ester (60 mg, 0.164 mmol) in MeCl2 (0.8 ml) was treated with trifluoroacetic acid (63μl), heated up to 40°C and stirred for 4h. The solvent was removed in vacuo. The residue was dissolved in water and basified with NaOH IN. The aqueous layer was extracted twice with MeCl2. The combined organic layers were dried over Na2SO4, filtered and the solvent was removed in vacuo to provide the title compound (20 mg, 46%) as a yellow oil, MS (m/e): 265.0 (MH+, 100%).
Example E
2-Piperazin- l-yl-5-trifluoromethyl-benzonitrile
Figure imgf000043_0002
step 1: 4-(2-Cvano-4-trifluoromethyl-phenyl)-piperazine-l-carboxylic acid tert-butyl ester
Figure imgf000043_0003
Title compound was prepared according to the procedure described in example G from N-Boc-piperazine and 2-Chloro-5-trifluoromethylbenzonitrile ( CAS: 328-87-0)(15% yield, yellow oil, MS (m/e): 373.1 (M+NH4+, 100%).
Step 2: 2-Piperazin-l-yl-5-trifluoromethyl-benzonitrile
Figure imgf000044_0001
Title compound was prepared according to procedure described in example D/ step2, (82% yield, yellow oil, MS (m/e): 256.0 (M+H+, 100%).
Example F
1- (2-Bromo-5-trifluoromethyl-phenyl)-piperazine
Figure imgf000044_0002
A mixture of 2 g (8 mmol)l-Bromo-2-fluoro-4-frifluoromethyl-benzene and 2.13 g ( 25 mmol) piperazine in 2 ml N,N-dimethylacetamide was heated to 100 °C for 2 h and subsequently all volatiles were removed under vacuum. The residue was purified by flash column chromatography on silica eluting with DCM / methanol / 1% NH3 aq. to yield 0.765 g (37 %) of the title compound as colourless oil.
1-H-NMR (300 MHz, CDC13) δ= 7.81 (d, J = 8 Hz, IH, H-4), 7.30 (m, 2H, H-3 / H-6), 3.2-3.5 (s, br, IH, NH), 2.93 (m, 4H, piperazine) 2.86 (m, 4H, piperazine). MS (m/e): 309.1 (MH+, 100%) Example G
4-(2-Fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carboxylic acid tert-butyl ester
Figure imgf000044_0003
A mixture of 5 g (20 mmol) l-Bromo-2-fluoro-4-trifluoromethyl-benzene , 4.6 g (24.7 mmol) n-Boc-piperazine, 106 mg (0.1 mmol) Tris(dibenzylideneacetone)dipalladium chloroform complex 2.77 g ( 28.8 mmol) sodium-t-butoxide and 144 mg (0.4 mmol) 2- (Dicyclohexylphosphino)biphenyl in 50 ml toluene was heated for 16 h at 80 °C. After cooling to room temperature the mixture was treated with 15 g Isolute HM-N and all volatiles were removed under vacuum. The residue was purified on silica eluting with a gradient of heptane / EtOAc to yield after evaporation 4.54 g (63%) of the title compound as white amorphous solid.
1-H-NMR (300 MHz, CDC13) δ= 7.50 (d, J = 12 Hz, IH, H-3), 7.48 (d, J = 8 Hz, IH, H-
5), 7.2 (dd, = 8 Hz, J2 = 8 Hz, IH, H-6), 3.49 (m, 4H, piperazine), 3.08 (m, 4H, piperazine).
MS (m/e): 349.2 (MH+, 100%) Example H
l-(2-Fluoro-4-trifluoromethyl-phenyl)-piperazine
Figure imgf000045_0001
A mixture of 3.11 g (9 mmol) 4-(2-Fluoro-4-trifluoromethyl-phenyl)-piperazine-l- carboxylic acid tert-butyl ester in 20 ml dioxane was treated with 8.93 ml 4N HC1 in dioxane for 2 h at 80 °C. The mixture was concentrated and treated with 20 ml water, 20 ml 2M Na2C03 and extracted with 50 ml EtOAc. The organic phase was washed with 30 ml saturated NaCl. All aqueous phases were combined and extracted with 50 ml EtOAc. The combined organic phases were dried with MgSO4 and evaporated to yield 2.1 g (95 %) of the title compound as brownish crystals.
1-H-NMR (300 MHz, CDCI3) δ= 7.50 (d, J = 13.3 Hz, IH, H-3), 7.45 (d, J = 8.8 Hz, IH, H-5), 7.16 (dd, Ji = 8.8 Hz, J2 = 8.8 Hz, IH, H-6), 3.5-3.2 (s, br, IH, NH), 3.04 (m, 4H, piperazine), 2.87 (m, 4H, piperazine). MS (m/e): 249.2 (MH+, 100%)
Example I
3-Fluoro-4-piperazin- 1-yl-benzoic acid ethyl ester
Figure imgf000046_0001
A mixture of 5 g (27 mmol)3,4-Difluoro-benzoic acid ethyl ester and 11.56 g (134 mmol) piperazine in 15 ml N,N-dimethylacetamide was heated to 120 °C for 1.5 h and subsequently all volatiles were removed under vacuum. The residue was purified by flash column chromatography on silica eluting with DCM / methanol to yield 6.19 g (91 %) of the title compound as white amorphous solid.
1-H-NMR (300 MHz, DMSO-d6) δ= 7.69(dd, Jx= 8.4 Hz, J2=1.9 Hz, IH, H-6), 7.57(dd, Jι=12.1Hz, J2=2.0Hz, IH, H-2), 7.07(dd, Jι=8.7 Hz, J2=8.7 Hz, IH, H-5), 4.26(q, J1=-7.1 Hz, 2H, 0-CH2), 3.06(m, 4H, piperazine), 2.83(m, 4H, piperazine), 1.30(t, Jι=7.1Hz, 3H, CH3).
MS (m/e): 253.2 (MH+, 100%)
Example J
3-Fluoro-4-piperazin- 1 -yl-benzenesulfonamide
Figure imgf000046_0002
A mixture of 0.5 g (3 mmol) 3,4-Difluoro-benzenesulfonamide and 1.15 g (13 mmol) piperazine in 2.3 ml water was heated to 110 °C for 3 h and subsequently the precipitate was filtered off and washed with water and toluene. The residue was dried under high vacuum to yield 0.578 g (86 %) of the title compound as white crystals.
1-H-NMR (300 MHz, DMSO-d6) δ= 7.53 (dd, J =8.6 Hz, J2=2Hz, IH, H-6), 7.48(dd, Jι=15 Hz, J2=2 Hz, IH, H-2), 7.2-7.4(s, br, 2H, NH2), 7.13(dd, h=8.6 Hz, J2=8.6 Hz IH, H-5), 3.2-3.5(s, br, IH, NH), 3.03(m, 4H, piperazine), 2.83(m, 4H, piperazine). MS (m/e): 260.0 (MH+, 100%)
Example 46
[4-(2-Chloro-phenyl)-piperazin-l-yl]-(2-morpholin-4-yl-5-nitro-phenyl)-methanone A mixture of 18.9 mg (0.07 mmol) 2-Morpholin-4-yl-5-nitro-benzoyl chloride, 16.5 mg (0.084 mmol) l-(2-Chloro-phenyl)-piperazine and 34 ul (0.245 mmol) NEt3 in 2 ml DCM was stirred at room temperature for 16 h. After evaporation of the volatiles the residue was taken up in 2 ml CH3CN/MeOH/HCOOH 2/2/1 and subjected to preparative HPLC purification on reversed phase eluting with an acetonitrile / water gradient to yield after evaporation of the product fractions 23.2 mg (77%) of the title compound. MS (m/e): 431.2 (MH+, 100%)
According to the procedure described for the synthesis of Example 46 further derivatives have been synthesised from 2-morpholin-4-yl-5-nitro-benzoyl chloride and piperazine derivatives and comprise Examples 46-74, 177, 184, 185, 186,187,188, 192, 200, 201 in Table 1.
Example K
l-{4-[4-(2-Chloro-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone
Figure imgf000047_0001
step 1: 2-Chloro-5-methanesulfonyl-benzoic acid
Figure imgf000047_0002
A solution of 2-Chloro-5-(methylthio)benzoic acid (CAS: 51546-12-4; 2.5 g, 11.8 mmol) was dissolved in methanol (50 ml) and cooled to 0°C. Oxone (21.9 g, 35.5 mmol) was added portionwise within 5 minutes. The mixture was stirred at 0°C for 30 minutes and then at room temperature for 22 hours. The mixture was filtered. The filtrate was poured onto water (200 ml). The aqueous layer was extracted with dichloromethane (5x50 ml). The combined extracts were dried over Na2SO , filtered and the solvent was removed in vacuo. The solid was stirred in ether (30 ml), filtered and dried to provide the title compound (1.96 g, 70%) as a beige solid, MS (m/e): 232.9 (M-H+, 100%).
Step 2: l-{4- 4-(2-Chloro-5-methanesulfonyl-benzoyl)-piperazin-l-yl1 -3-fluoro- phenvU-ethanone
Figure imgf000048_0001
To a solution of 2-Chloro-5-methanesulfonyl-benzoic acid (200 mg, 0.852 mmol) in DMF (3 ml) was added dropwise l, -Carbonyldiimidazole (142 mg, 0.852 mmol). When the CO2 evolution ceased, the mixture was heated to 50 °C for 15 minutes. The mixture was cooled to room temperature. l-(3-Fluoro-4-piperazin-l-yl-phenyl)-efhanone (189 mg, 0.852 mmol) was added portionwise. The mixture was stirred at room temperature for 1 hour. The solvent was removed in vacuo. The residue was dissolved in ethyl acetate. The solution was washed twice with water, dried over Na2SO , filtered and the solvent was removed in vacuo. The crude oil was purified on silica gel (Heptane/ AcOEt 0%-50% (15 minutes) to provide the title compound (185 mg, 49 %) as a white solid, MS (m/e): 439.1 (M+H+, 100%).
Example 75
1 - (3-Fluoro-4- {4- [ 5-methanesulfonyl-2- (2-methyl-pyrrolidin- 1 -yl)-benzoyl] -piperazin- l-yl}-phenyl)-ethanone
A mixture of 30.7 mg (0.7 mmol) l-{4-[4-(2-Chloro-5-methanesulfonyl-benzoyl)- piperazin- l-yl]-3-fluoro-phenyl} -ethanone, 30 ul (0.175 mmol) DIPEA and 91 ul (0.91 mmol) of a 1M solution of 2-Methyl-pyrrolidine in DMF was heated to 100 °C for 24 h.
After removal of THF 2 ml dioxane, 180 ul of a 1M solution of 2-Methyl-pyrrolidine in
DMF and 30 ul (0.175 mmol) DIPEA were added and the mixture was heated to 120 °C for 16 h. After evaporation of all volatiles the residue was taken up in 1 ml MeOH / formic acid 6 / 1 and subjected to reversed phase HPLC purification eluting with an acetonitrile / water gradient to yield after evaporation of the product fractions 4.7 mg (14
%) of the title compound. MS (m/e): 488.2 (MH+, 100%) According to the procedure described for the synthesis of Example 75 further derivatives have been synthesised from l-{4-[4-(2-Chloro-5-methanesulfonyl-benzoyl)-piperazin-l- yl]-3-fluoro-phenyl}-ethanone and amines and comprise Examples 75-89 in Table 1.
Example L
3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-bromo-benzonitrile
Figure imgf000049_0001
step 1: 2-bromo-5-cyano-benzoic acid
Figure imgf000049_0002
To a suspension of copper (II) bromide (1.6 g, 7.1 mmol) in acetonitrile (30 ml) was added dropwise tert-butylnitrite (1.15 ml, 8.63 mmol) at 0 °C within 2 minutes. 2- Amino-5-cyano-benzoic acid (CAS: 99767-45-0; WO9518097) (1.0 g, 6.17 mmol) was added portionwise within 10 minutes at 0 °C. The mixture was stirred at 0 °C for 2 hours and then at room temperature overnight. Half of the solvent was removed in vacuo. The residue was taken in HCl IN (15 ml) and ethyl acetate (30 ml). The organic layer was extracted with NaOH IN (3x10 ml). The aqueous layer was acidified with HCl 2N. The resulting solid was filtered, washed with water and dried (high vacum, 50 °C) to provide the title compound (0.92 g, 66%) as a yellow solid.
Step 2: 3-[4-(4-ace1yl-2-fluoro-phenyl)-piperazine-l-carbonyl1-4-bromo benzonitrile
Figure imgf000049_0003
Title compound was prepared according to procedure described in example K/ step2 from l-(3-Fluoro-4-piperazin-l-yl-phenyl)-ethanone and 2-bromo-5-cyano-benzoic acid , (49% yield, white solid, MS (m/e): 430 (M+, 100%).
Example 90
3- [4- (4- Acetyl-2-fluoro-phenyl)-piperazine- 1-carbonyl] -4-azepan- 1-yl-benzonitrile
A mixture of 30.1 mg (0.7 mmol) 3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l- carbonyl]-4-bromo-benzonitrile, 30 ul (0.175 mmol) DIPEA and 91 ul (0.91 mmol) of a 1M solution of azepane in DMF was heated to 100 °C for 24 h. After removal of THF 2 ml dioxane, 180 ul of a 1M solution of azepane in DMF and 30 ul (0.175 mmol) DIPEA were added and the mixture was heated to 120 °C for 16 h. After evaporation of all volatiles the residue was taken up in 1 ml MeOH / formic acid 6 / 1 and subjected to reversed phase HPLC purification eluting with an acetonitrile / water gradient to yield after evaporation of the product fractions 9.3 mg (30 %) of the title compound. MS (m/e): 449.2 (MH+, 100%)
According to the procedure described for the synthesis of Example 90 further derivatives have been synthesised from 3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4- bromo-benzonitrile and amines and comprise Examples 90-103 in Table 1.
Example 104
3-Chloro-4-[4-(2-morphoUn-4-yl-5-nitro-benzoyl)-piperazin-l-yl]-benzonitrile
A mixture of 40.6 mg (0.15 mmol) 2-Morpholin-4-yl-5-nitro-benzoyl chloride, 39.9 mg (0.18 mmol) 3-Chloro-4-piperazin-l-yl-benzonitrile (WO9625414) and 62.5 ul (0.45 mmol) NEt in 1 ml DCM was stirred at room temperature for 16 h. After evaporation of the volatiles the residue was taken up in 1 ml CH3CN/DMF/HCOOH 3/5/2 and subjected to preparative HPLC purification on reversed phase eluting with an acetonitrile / water gradient to yield after evaporation of the product fractions 4.9 mg (8 %) of the title compound. MS (m/e): 456.2 (MH+, 100%)
According to the procedure described for the synthesis of Example 104 further derivatives have been synthesised from 2-Morpholin-4-yl-5-nitro-benzoyl chloride and piperazine derivatives and comprise Examples 104-122 in Table 1. Example M
2-CWoro-5-sulfino-benzoic acid
Figure imgf000051_0001
A solution of 33.59 g (267 mmol) sodium sulfite in 100 ml water at 0 °C is treated with 21.2 g (89 mmol) 2-Chloro-5-fluorosulfonyl-benzoic acid and 26.6 ml of a 10M aqueous NaOH solution (267 mmol). The mixture was allowed to stirr for 3 h at room temperature, acidified with HCl cone. (pH = 4) and water was removed under vacuum. Methanol was added, the precipitate filtered off and the filtrate concentrated. Methanol and diethylether were added and the precipitate was filtered off washed with ether and dried to yield 15 g (76.5%) of the title compound as white gum. MS (m/e): 219.1 (MH' » 100%)
Example N
2-Chloro-5-methanesulfonyl-benzoic acid
Figure imgf000051_0002
A mixture of 1 g (4 mmol ) 2-Chloro-5-sulfino-benzoic acid in 20 ml Methanol and 20 ml water was treated with ION NaOH to pH = 9 before adding 1.7 g (12 mmol) Methyliodide. The mixture was heated for 48 h to 80 °C with occasional addition of NaOH to maintain pH = 9. After removal of all volatiles HCl cone, was added and the mixture was extracted with ethyl acetate. The combined organic layers were dried with MgSO4 and evaporated to dryness. The residue was taken up in methanol and subjected to reversed phase HPLC purification eluting with an acetonitrile / water gradient to yield after evaporation of the product fractions 323 mg (34 %) of the title compound. MS (m/e): 233.0 (MH", 100%).
Example O
2-Chloro-5-ethanesulfonyl-benzoic acid
Figure imgf000052_0001
The title compound was synthesised according to the procedure described for the synthesis of 2-Chloro-5-methanesulfonyl-benzoic acid from 2-Chloro-5-sulfino-benzoic acid and ethyl iodide in 20 ml ethanol / 20 ml water and obtained in 27% yield. MS (m/e): 247.1 (MH\ 100%).
Example P
2-Chloro-5-(propane-2-sulfonyl)-benzoic acid
Figure imgf000052_0002
The title compound was synthesised according to the procedure described for the synthesis of 2-Chloro-5-methanesulfonyl-benzoic acid from 2-Chloro-5-sulfino-benzoic acid and 2-iodopropane in 20 ml isopropanol/ 20 ml water and obtained in 42% yield. MS (m/e): 261.1 (MH\ 100%).
Example Q
2-Chloro-5-cyclopropylmethanesulfonyl-benzoic acid
Figure imgf000052_0003
The title compound was synthesised according to the procedure described for the synthesis of 2-Chloro-5-methanesulfonyl-benzoic acid from 2-Chloro-5-sulfino-benzoic acid and Bromomethyl-cyclopropane (+catalytic amount I2) in 20 ml cyclopropyl methanol/ 20 ml water and obtained in 8% yield. MS (m/e): 273.1 (MH", 100%). Example R
2-Chloro-5-(propane-l-suιfonyl)-benzoic acid
Figure imgf000053_0001
The title compound was synthesised according to the procedure described for the synthesis of 2-Chloro-5-methanesulfonyl-benzoic acid from 2-Chloro-5-sulfino-benzoic acid and 1-iodopropane in 20 ml propanol/ 20 ml water and obtained in 3% yield. MS (m/e): 261.1 (MH", 100%).
Example S
2-Chloro-5-methylsulfamoyl-benzoic acid
Figure imgf000053_0002
A mixture of 1 g (4 mmol ) 2-Chloro-5-sulfino-benzoic acid and 0.62 g (20 mmol) Methylamine in 10 ml dioxane was stirred for 3 h at room temperature. After evaporation of the volatiles 15 ml 5N HCl was added and the mixture was extracted 3x with ethylacetate. The solvent was removed under vacuum to yield 0.724 g (72 %) of the title compound as amorphous white solid. MS (m/e): 248.1 (MH", 100%).
Example T
2-Chloro-5-ethylsulfamoyl-benzoic acid
Figure imgf000053_0003
The title compound was synthesised according to the procedure described for 2-Chloro- 5-methylsulfamoyl-benzoic acid from 2-Chloro-5-sulfino-benzoic acid and ethylamine and obtained in 78 % yield. MS (m/e): 262.2 (MH", 100%).
Example U
2-Chloro-5-isopropylsulfamoyl-benzoic acid
Figure imgf000054_0001
The title compound was synthesised according to the procedure described for 2-Chloro- 5-methylsulfamoyl-benzoic acid from 2-Chloro-5-sulfino-benzoic acid and isopropylamine and obtained in 74 % yield. MS (m/e): 276.1 (MH", 100%). Example V
2-CUoro-5-(cyclopropylmethyl-sulfamoyl)-benzoic acid
Figure imgf000054_0002
The title compound was synthesised according to the procedure described for 2-Chloro- 5-methylsulfamoyl-benzoic acid from 2-Chloro-5-sulfino-benzoic acid and cyclopropylmethylamine and obtained in 81 % yield. MS (m/e): 288.0 (MH", 100%).
Example W
2-Chloro-5-(pyrrolidine-l-sulfonyl)-benzoic acid
Figure imgf000055_0001
The title compound was synthesised according to the procedure described for 2-Chloro- 5-methylsulfamoyl-benzoic acid from 2-Chloro-5-sulfino-benzoic acid and pyrrolidine and obtained in 91 % yield. MS (m/e): 288.0 (MH", 100%).
Example X
2-Chloro-5- (morpholine-4-sulfonyl)-benzoic acid
Figure imgf000055_0002
The title compound was synthesised according to the procedure described for 2-Chloro- 5-methylsulfamoyl-benzoic acid from 2-Chloro-5-sulfino-benzoic acid and morpholine and obtained in 100 % yield. MS (m/e): 304.0 (MH", 100%).
Example Y
5-Methanesulfonyl-2-pyrrolidin-l-yl-benzoic acid
Figure imgf000055_0003
A mixture of 163.8 mg (0.7 mmol) 2-Chloro-5-methanesulfonyl-benzoic acid in 2 ml pyrrolidine was heated for 16 h to 100 °C. After evaporation of all volatiles the residue was taken up in 2 ml methanol/formic acid 3/1 and subjected to reversed phase HPLC purification eluting with an acetonitrile / water gradient to yield after evaporation of the product fractions 143.4 mg (77 %) of the title compound. MS (m/e): 268.1 (MH", 100%). Example Z
5-Et anesulfonyl-2-pyrroUdin- 1-yl-benzoic acid
Figure imgf000056_0001
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid from 2-Chloro-5-(ethane- 2-sulfonyl)-benzoic acid and pyrrolidine and obtained in 73 % yield. MS (m/e): 282.2 (MH", 100%).
Example AA
5-(Propane-l-sulfonyl)-2-pyrrolidin-l-yl-benzoic acid
Figure imgf000056_0002
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid from 2-Chloro-5- (propane-2-sulfonyl)-benzoic acid and pyrrolidine and obtained in 63 % yield. MS (m/e): 296.2 (MH", 100%). Example AB
5- (Propane-2-sulfonyl)-2-pyrrolidin- 1-yl-benzoic acid
Figure imgf000056_0003
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrroHdin-l-yl-benzoic acid from 2-Chloro-5- (propane-2-sulfonyl)-benzoic acid and pyrrolidine and obtained in 72 % yield. MS (m/e): 296.2 (MH", 100%). Example AC
5-Methylsulfamoyl-2-pyrrolidin- 1-yl-benzoic acid
Figure imgf000057_0001
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid from 2-Chloro-5- methylsulfamoyl-benzoic acid and pyrrolidine and obtained in 45 % yield. MS (m/e): 283.1 (MH", 100%).
Example AD
5-Ethylsulfamoyl-2-pyrrolidin- 1-yl-benzoic acid
Figure imgf000057_0002
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid from 2-Chloro-5- ethylsulfamoyl-benzoic acid and pyrrolidine and obtained in 43 % yield. MS (m/e): 202.2 (MH", 100%).
Example AE
5-Isopropylsulfamoyl-2-pyrrolidin-l-yl-benzoic acid
Figure imgf000058_0001
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid from 2-Chloro-5- isopropylsulfamoyl-benzoic acid and pyrrolidine and obtained in 40 % yield. MS (m/e): 311.2 (MH", 100%).
Example AF
5- (Cyclopropylmethyl-sulfamoyl)-2-pyrrolidin- 1-yl-benzoic acid
Figure imgf000058_0002
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid from 2-Chloro-5-
(cyclopropylmethyl-sulfamoyl)-benzoic acid and pyrrolidine and obtained in 38 % yield. MS (m/e): 323.2 (MH", 100%).
Example AG
5-Melhanesulfonyl-2-morpholin-4-yl-benzoic acid
Figure imgf000058_0003
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid from 2-Chloro-5- (methane-2-sulfonyl)-benzoic acid and morpholine and obtained in 80 % yield. MS (m/e): 284.1 (MH", 100%). Example AH
5-Ethanesulfonyl-2-morpholin-4-yl-benzoic acid
Figure imgf000059_0001
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid from 2-Chloro-5-(ethane- 2-sulfonyl)-benzoic acid and morpholine and obtained in 77 % yield. MS (m/e): 298.2 (MH", 100%).
Example Al
2-Morpholin-4-yl-5- (propane-2-sulfonyl)-benzoic acid
Figure imgf000059_0002
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid from 2-Chloro-5- (isopropane-2-sulfonyl)-benzoic acid and morpholine and obtained in 53 % yield. MS (m/e): 312.1 (MH", 100%). Example AJ
5-Cyclopropylmethanesulfonyl-2-morpholin-4-yl-benzoic acid
Figure imgf000059_0003
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid from 2-Chloro-5- cyclopropylmethanesulfonyl-benzoic acid and morpholine and obtained in 27 % yield. MS (m/e): 324.2 (MH", 100%). Example AK
2-Morpholin-4-yl-5- (propane- l-sulfonyl)-benzoic acid
Figure imgf000060_0001
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid from 2-Chloro-5- (propane-2-sulfonyl)-benzoic acid and morpholine and obtained in 62 % yield. MS (m/e): 312.2 (MH", 100%).
Example AL
5-Methylsulfamoyl-2-morpholin-4-yl-benzoic acid
Figure imgf000060_0002
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid from 2-Chloro-5- methylsulfamoyl-benzoic acid and morpholine and obtained in 40 % yield. MS (m/e): 299.2 (MH", 100%).
Example AM 5-Ethylsulfamoyl-2-morpholin-4-yl-benzoic acid
Figure imgf000061_0001
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin-l-yl-benzoic acid from 2-Chloro-5- ethylsulfamoyl-benzoic acid and morpholine and obtained in 42 % yield. MS (m/e): 313.2 (MH", 100%).
Example AN
5-Isopropylsulfamoyl-2-morpholin-4-yl-benzoic acid
Figure imgf000061_0002
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid from 2-Chloro-5- isopropylsulfamoyl-benzoic acid and morpholine and obtained in 38 % yield. MS (m/e): 327.2 (MH", 100%).
Example AO
5- (Cyclopropylmethyl-sulfamoyl)-2-morpholin-4-yl-benzoic acid
Figure imgf000061_0003
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid from 2-Chloro-5- (cyclopropylmethyl-sulfamoyl)-benzoic acid and morpholine and obtained in 33 % yield. MS (m/e): 339.2 (MH", 100%).
Example AP
2-MorphoUn-4-yl-5-(pyιτoh<lme-l-sulfonyl)-benzoic acid
Figure imgf000062_0001
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid from 2-Chloro-5- (pyrrolidine-l-sulfonyl)-benzoic acid and morpholine and obtained in 34 % yield. MS (m/e): 339.2 (MH", 100%). Example AQ
5- (Morpholine-4-sulfonyl) -2-morpholin-4-yl-benzoic acid
Figure imgf000062_0002
The title compound was synthesised according to the procedure described for the synthesis of 5-Mefhanesulfonyl-2-pyrrolidin-l-yl-benzoic acid from 2-Chloro-5- (morpholine- l-sulfonyl)-benzoic acid and morpholine and obtained in 22 % yield. MS (m/e): 355.2 (MH", 100%).
Example 123
4-Fluoro-2-[4-(5-methanesulfonyl-2-pyrrolidin-l-yl-benzoyl)-piperazin-l-yl]- benzonitrile
A mixture of 13.6 mg (0.05 mmol) 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid, 15.7 mg (0.06 mmol) 2-Fluoro-4-piperazin-l-yl-benzonitrile (Org. Proc. Res. Dev. 1999, 460), 17.9 mg (0.06 mmol) TBTU and 43 ul (0.25 mmol) DIPEA in 1 ml DMF was stirred for 16 h at room temperature. After addition of lOOul formic acid the mixture was subjected to preparative HPLC purification on reversed phase eluting with an acetonitrile / water gradient to yield after evaporation of the product fractions 10.6 mg (33%) of the title compound. MS (m/e): 457.2 (MH+, 100%)
According to the procedure described for the synthesis of Example 123 further derivatives have been synthesised from acid derivatives and piperazine derivatives and comprise Examples 123-173 in Table 1.
Example 174
l-(4-{4-[2-(4-Methyl-piperazin-l-yl)-5-nitro-benzoyl]-piperazin-l-yl}-phenyl)- ethanone
A stirred mixture of 150 mg (0.39 mmol) l-{3-fluoro-4-[4-(2-fluoro-5-nitro-benzoyl)- piperazin-l-yl]-phenyl}-ethanone, 200 mg (2.0 mmol) 1-methylpiperazine in 4 ml THF was heated to 80 °C for lh. Water was added to the reaction mixture, the precipitate isolated, dried and purified by flash-chromatography on silica gel with heptane/ AcOEt as eluent. The title compound was obtained as a light yellow powder, MS (m/e): 471.2 (MH+, 100%).
According to the procedure described for the synthesis of Example 174 further derivatives have been synthesised from l-{3-fluoro-4-[4-(2-fluoro-5-nitro-benzoyl)- piperazin- l-yl]-phenyl}-ethanone and amines and comprise Examples 174 to 176 in Table 1. Example AR
4-(2-Fluoro-4-methyl-phenyl)-piperazine-l-carboxylic acid tert-butyl ester
Figure imgf000063_0001
Title compound was prepared according to the procedure described in example G from N-Boc-piperazine and 4-bromo-3-fluorotoluene (40% yield, yellow oil, MS (m/e): 295.2 (M+H+, 100%). Example AS
1 - (2-Fluoro-4-methyl-phenyl)-piperazine
Figure imgf000064_0001
Title compound was prepared according to procedure described in example D/ step 2, (99% yield, yellow oil, MS (m/e): 195.3 (M+H+, 100%).
Example 177
[4- (2-Fluoro-4-methyl-phenyl) -piperazin- 1 -yl] - (2-morpholin-4-yl-5-nitro-phenyl)- methanone
Title compound was prepared according to procedure described in example 46 from 1- (2-Fluoro-4-methyl-phenyl)-piperazine and 2-morpholin-4-yl-5-nitro-benzoyl chloride (70% yield, yeUow oil, MS (m/e): 429.2 (M+H+, 100%).
Example AT
(5-Ammo-2-morphoUn-4-yl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone
Figure imgf000064_0002
To a solution of (2-Morpholin-4-yl-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)- piperazin- 1-yl] -methanone (preparation described in example 57, 150 mg, 0.323 mmol) in methanol (3 ml) was added Pd/C 10 % (6. 9 mg) . The mixture was stirred under an atmospheric pressure of hydrogen at room temperature for 1 hour. Catalyst was filtered and the filtrate was concentrated in vacuo. The residue was chromatographed over silicagel (Eluent: Heptane/Ethylacetate (0-100% in 20 minutes)) to provide the title compound (111 mg, 79% yield) as a yellow solid, MS (m/e): 435.2 (M+H+, 100%). Example 178
(2-Morpholin-4-yl-5-te1xazol-l-yl-phenyl)-[4-(4-frifluoromethyl-phenyl)-piperazin-l- yl] -methanone
A suspension of (5-Amino-2-morpholin-4-yl-phenyl)-[4-(4-trifluoromethyl-phenyl)- piperazin- 1-yl] -methanone (50 mg, 0.115 mmol) in Acetic acid (1 ml) was heated to 75°C under nitrogen and then triethylorthoformate (36.76 ul, 0.34 mmol) was slowly added. After 1 hour, sodium azide (22.4 mg, 0.34 mmol) was added portionwise and the reaction mixture was stirred at 75°C for lh30. The reaction mixture was cooled to room temperature, diluted with water and basified with IN NaOH solution. The aqueous phase was extracted with ethyl acetate. The organic phases were combined, dried over Na2SO4, filtered and evaporated to dryness. The residue was chromatographed on silica gel: Eluent: Heptane/Ethylacetate 0% to 60% (10 minutes) to provide the titie compound (29 mg, 52%) as yellow solid, MS (m/e): 488.2 (M+H+, 100%)
Example AU
3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-chloro-N-methyl- benzenesulfonamide
Figure imgf000065_0001
The title compound was prepared according to the procedure described for example K/ step2 from l-(3-Fluoro-4-piperazin-l-yl-phenyl)-ethanone and 2-Chloro-5- methylsulfamoyl-benzoic acid (CAS: 68901-09-7; BE 620741) (69%, light yellow foam, MS (m/e): 452.1 (M-H, 100%)
Example 179
3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-N-methyl-4-morpholin-4-yl- benzenesulfonamide
The title compound was prepared according to the procedure described for example 1 from 3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-chloro-N-methyl- benzenesulfonamide and morpholine (58%, light yellow solid, MS (m/e): 503.1 (M-H, 100%)
Example AV
3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-chloro-N,N-dimethyl- benzenesulfonamide
Figure imgf000066_0001
The title compound was prepared according to the procedure described for example K/ step2 from l-(3-Fluoro-4-piperazin-l-yl-phenyl)-ethanone and 2-Chloro-5- dimethylsulfamoyl-benzoic acid (CAS: 37088-27-0; BE 620741) (64%, light yellow foam, MS (m/e): 468.1 (M+H+, 100%)
Example 180
3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-N,N-dimethyl-4-morpholin-4- yl-benzenesulfonamide
The title compound was prepared according to the procedure described for example 1 from 3- [4-(4-Acetyl-2-fluoro-phenyl)-piperazine- 1-carbonyl] -4-chloro-N,N-dimethyl- benzenesulfonamide and morpholine (60%, light yellow solid, MS (m/e): 519.2 (M+H, 100%)
Example AW
3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-morphorin-4-yl-benzoic acid
Figure imgf000066_0002
A suspension of 3- [4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-morpholin- 4-yl-benzonitrile (example 196, 469 mg, 1.07 mmol) in ethanol (6 ml) and NaOH 2N (6 ml) was heated to 85°C for 17 hours. The reaction mixture was cooled to room temperature, diluted with water and acidified with 2N HCl. The resulting solid was filtered, washed with water and dried to provide the title compound (0.47 g, 96%) as an orange solid. Example 181
3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-morpholm-4-yl-benzamide
The title compound was prepared according to the procedure described for example K/step2 from 3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl] -4-morpholin-4- yl-benzoic acid and ammonia (10%, white solid, MS (m/e): 455.2 (M+H, 100%) Example 182
3- [4- (4- Acetyl-2-fluoro-phenyl) -piperazine- 1-carbonyl] -N-methyl-4-morpholin-4-yl- benzamide
The title compound was prepared according to the procedure described for example K/step2 from 3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl] -4-morpholin-4- yl-benzoic acid and methylamine (43%, white solid, MS (m/e): 469.3 (M+H, 100%)
Example 183
3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-N,N-dimethyl-4-morpholin-4- yl-benzamide
The title compound was prepared according to the procedure described for example K/step2 from 3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-morpholin-4- yl-benzoic acid and dimethylamine (44%, yellow solid, MS (m/e): 483.2 (M+H, 100%)
Example 184
[4- (2-Chloro-4-trifluoromethyl-phenyl)-piperazin- 1-yl] - (2-morpholin-4-yl-5-nitro- phenyl) -methanone
The title compound was prepared according to the procedure described for example 46 from l-(2-Chloro-4-trifluoromethyl-phenyl)-piperazine and 2-Morpholin-4-yl-5-nitro- benzoyl chloride (74%, yellow solid, MS (m/e): 499.2 (M+H, 100%) Exa ple AX
4-(4-Trifluoromethoxy-phenyl)-piperazine-l-carboxylic acid tert-butyl ester
Figure imgf000068_0001
To a mixture of cesium carbonate (1.88 g, 5.7 mmol), palladium(II)acetate (46.1 mg, 0.205 mmol), rac-2,2'-Bis(diphenylphosphino)-l, -binaphthyl (192 mg, 0.31 mmol), tert-Butyl-1-piperazine carboxylate (928mg, 4.93 mmol) and l-Bromo-4- (trifluoromethoxy)benzene (lg, 4.11 mmol) was added degazed toluene (10 ml). The mixture was heated to 100°C for 4 hours. The mixture was cool to room temperature, diluted with ethylacetate, filtered and the solvent was removed in vacuo. The crude oil was chromatographed over silica gel: eluent: heptane/ethylacetate 0-10% over 20 minutes to provide the title compound (180 mg, 13%) as a yellow solid, MS (m/e): 347.4 (M+H, 100%). Example AY l-(4-Trifluoromethoxy-phenyl)-piperazine
Figure imgf000068_0002
The title compound was prepared according to the procedure described for example D step 2 from 4-(4-trifluoromethoxy-phenyl)-piperazine-l-carboxylic acid tert-butyl ester (44%, brown oil, MS (m/e): 247.1(M+H, 100%) Example 185
(2-MorphoUn-4-yl-5-rdtro-phenyl)-[4-(4-txifluoromethoxy-phenyl)-piperazin-l-yl]- methanone
The title compound was prepared according to the procedure described for example 46 from l-(4-Trifluoromethoxy-phenyl)-piperazine and 2-Morpholin-4-yl-5-nitro-benzoyl chloride (74%%, yellow solid, MS (m/e): 481.2(M+H, 100%) Example 186
2- [4- (2-Morpholin-4-yl-5-nitro-benzoyl)-piperazin- 1-yl] -5-txifluoromethyl- benzonitrile
The title compound was prepared according to the procedure described for example 46 from 2-Piperazin-l-yl-5-trifluoromethyl-benzonifrile and 2-Morpholin-4-yl-5-nitro- benzoyl chloride (69%, yellow solid, MS (m/e): 490.2 (M+H, 100%)
Example AZ
4-(4-Meτ anesulfonyl-phenyl)-piperazine-l-carboxylic acid tert-butyl ester
The title compound was prepared according to the procedure described for example AX from 4-bromophenyl methyl sulfone and N-Boc-piperazine (31%, white solid, MS (m/e): 241.2(M-Boc, 100%)
Example BA
l-(4-Methanesulfonyl-phenyl)-piperazine
Figure imgf000069_0001
The title compound was prepared according to the procedure described for example D step 2 from 4-(4-Methanesulfonyl-phenyl)-piperazine-l-carboxylic acid tert-butyl ester (99%, brown solid, MS (m/e): 241.2(M+H, 100%)
Example 187
[4-(4-Methanesulfonyl-phenyl)-piperazin-l-yl]-(2-morpho]in-4-yl-5-nitro-phenyl)- methanone The title compound was prepared according to the procedure described for example 46 from l-(4-Methanesulfonyl-phenyl)-piperazine and 2-Morpholin-4-yl-5-nitro-benzoyl chloride (76%, yellow solid, MS (m/e): 475.1 (M+H, 100%)
Example BB
4-(3-Fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carboxylic acid tert-butyl ester
Figure imgf000070_0001
To a mixture of sodium tert-butoxide (0.68 g, 6.9 mmol), palladium(II)acetate (11 mg, 0.05 mmol), 2-(di-t-butylphosphino)biphenyl (149 mg, 0.49 mmol), tert-Butyl-1- piperazine carboxylate (1.1 g, 5.9 mmol) and 4-chloro-2-fluorobenzotrifluoride (1 g, 4.94 mmol) was added degazed toluene ( 10 ml). The mixture was heated to 80 °C overnight. The mixture was cool to room temperature, diluted with ether, filtered and the filtrate was concentrated in vacuo. The residue was chromatographed over silica gel: eluent: Heptane/Ethylacetate 0-10% over 15 minutes to provide the titie compound (1.05 g, 61%) as a white solid, MS (m/e): 349.2 (M+H, 100%).
Example BC l-(3-Fluoro-4-trifluoromethyl-phenyl)-piperazine
Figure imgf000070_0002
The title compound was prepared according to the procedure described for example D step 2 from 4-(3-Fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carboxylic acid tert- butyl ester (98%, brown solid, MS (m/e): 249.2(M+H, 100%)
Example 188
[4- (3-Fluoro-4-trifluoromethyl-phenyl)-piperazin- 1-yl] - (2-morpholin-4-yl-5-nitro- phenyl)-methanone The titie compound was prepared according to the procedure described for example 46 from l-(3-Fluoro-4-trifluoromethyl-phenyl)-piperazine and 2-Morpholin-4-yl-5-nitro- benzoyl chloride (62%, yellow solid, MS (m/e): 483.2 (M+H, 100%)
Example BD
l-{4-[4-(2-Fluoro-5-nitro-benzoyl)-piperazin-l-yl]-phenyl}-ethanone
Figure imgf000071_0001
The titie compound was prepared according to the procedure described for example K step 2 from 4'-piperazino-acetophenone and 2-fluoro-5-nitrobenzoic acid (16%, yellow solid, MS (m/e): 372.1 (M+H, 100%) Example 189
l-{4-[4-(2-Morpholin-4-yl-5-nitro-benzoyl)-piperazin-l-yl]-phenyl}-ethanone
The titie compound was prepared according to the procedure described for example 1 from l-{4- [4-(2-Fluoro-5-nitro-benzoyl)-piperazin-l-yl] -phenyl} -ethanone and morpholine (85%, yellow solid, MS (m/e): 439.3 (M+H, 100%) Example BE
(2-Fluoro-5-nitro-phenyl)- [4- (2-fluoro-phenyl)-piperazin- 1-yl] -methanone
Figure imgf000071_0002
The titie compound was prepared according to the procedure described for example 46 from 2-Fluoro-5-nitro-benzoyl chloride and l-(2-fluorophenyl)-piperazine (52%, orange solid, MS (m/e): 348.1 (M+H, 100%) Example 190
[4-(2-Fluoro-phenyl)-piperazm-l-yl]-(2-moη)holin-4-yl-5-nitro-phenyl)-methanone
The title compound was prepared according to the procedure described for example 1 from (2-Fluoro-5-nitro-phenyl)-[4-(2-fluoro-phenyl)-piperazin-l-yl]-methanone and morpholine (87%, yellow solid, MS (m/e): 415.2 (M+H, 100%)
Example BF
(2-Fluoro-5-nitro-phenyl)-(4-phenyl-piperazin-l-yl)-methanone
Figure imgf000072_0001
The title compound was prepared according to the procedure described for example 46 from 2-Fluoro-5-nitro-benzoyl chloride and 1-phenyl-piperazine (70%, orange solid, MS (m/e): 330.1 (M+H, 100%)
Example 191
(2-Morpholin-4-yl-5-nitro-phenyl)-(4-phenyl-piperazin-l-yl)-methanone
The title compound was prepared according to the procedure described for example 1 from (2-Fluoro-5-nitro-phenyl)-(4-phenyl-piperazin-l-yl)-methanone and morpholine (87%, yellow solid, MS (m/e): 397.3 (M+H, 100%)
Example 192
[4- (4-Chloro-phenyl)-piperazin- 1-yl] - (2-morpholin-4-yl-5-nitro-phenyl)-methanone
The title compound was prepared according to the procedure described for example 46 from 2-morpholin-4-yl-5-nitro-benzoyl chloride and 4-chloro-phenyl-piperazine (orange solid), MS (m/e): 449.2 (M+H, 100%).
Example BG
l-{4-[4-(5-Amino-2-moι^holin-4-yl-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone
Figure imgf000073_0001
The title compound was prepared according to the procedure described for example AT from l-{4- [4-(2-Morpholin-4-yl-5-nitro-benzoyl)-piperazin-l-yl] -3-fluoro-phenyl}- ethanone (72%, yeUow solid, MS (m/e): 427.2 (M+H, 100%) Example 193
N-{3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-morpholin-4-yl-phenyl}- methanesulfonamide
To a solution of l-{4-[4-(5-Amino-2-morpholin-4-yl-benzoyl)-piperazin-l-yl]-3-fluoro- phenyl} -ethanone (50 mg, 0.12 mmol) and triethylamine (33 ul, 0.234 mmol) in dioxane (1.5 ml) was added a solution of methanesulfonyl chloride (15 mg, 0.13 mmol) in dioxane (0.5 ml). The mixture was stirred at room temperature for 3 hours. The reaction mixture was stirred in water. The yellow solid was filtered, washed with water and dissolved in CH2C12. The solution was dried over Na2S04, filtered and the solvent was removed in vacuo. The residue was chromatographed over silica gel eluent: Heptane/ethyl acetate 0%-100% (5 minutes) to provide the titie compound (35 mg, 59%) as a yellow solid MS (m/e): 505.3 (M+H, 100%)
Example BH 5-Bromo-2-morpholin-4-yl-benzoic acid
Figure imgf000073_0002
The titie compound was prepared according to the procedure described for example B stepl from 5-Bromo-2-fluorobenzoic acid and morpholine except that the mixture was heated at 130 °C for 48 hours (77%, white solid), 1-H-NMR (300 MHz, CDC13) δ= 8.45 (d), 7.74 (dxd, 7.33 (d)
Example Bl
5-Bromo-2-morpholin-4-yl-benzoyl chloride
Figure imgf000074_0001
The title compound was prepared according to the procedure described for example B step2 from 5-Bromo-2-morpholin-4-yl-benzoic acid (100%, yellow oil, MS (m/e): 305.0 (M+H, 100%)
Example BJ
l-{4-[4-(5-Bromo-2-morpholin-4-yl-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone
Figure imgf000074_0002
The title compound was prepared according to the procedure described for example 46 from 5-Bromo-2-morpholin-4-yl-benzoyl chloride and l-(3-Fluoro-4-piperazin-l-yl- phenyl) -ethanone (94%, yellow foam, MS (m/e): 490.3 (M+, 100%)
Example 194
l-{4-[4-(5-Acetyl-2-morpholin-4-yl-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone
To a suspension of l-{4-[4-(5-Bromo-2-morpholin-4-yl-benzoyl)-piperazin-l-yl]-3- fluoro-phenyl}-ethanone (160 mg, 0.33 mmol) in toluene (2 ml) were added
PdCl2(PPh3)2 (5 mg, 0.0065 mmol) and tributyl(l-ethoxyvinyl)tin (125 ul, 0.36 mmol). The mixture was heated to 100°C for 6 hours. The mixture was cooled in an ice bath and 2N HCl (0.55 ml) was added. The mixture was stirred at room temperature overnight. The mixture was filtered. The organic layer was separated and 10% aqueous KF solution was added. The mixture was stirred at room temperature for 3 hours and filtered. The organic layer was dried over Na2SO4, filtered and the solvent was removed in vacuo. The crude gum was chromatographed on silica gel, eluent: heptane/ethylacetate 0%-50% (10 minutes) to provide the titie compound (15 mg, 10%) as a white solid MS (m/e): 454.2 (M+H, 100%).
Example BK
5-Methylsulfanyl-2-morpho]in-4-yl-benzoic acid
Figure imgf000075_0001
A mixture of 2-Chloro-5-(methylthio)-benzoic acid (lg, 4.7 mmol), morpholine (620ul, 7.1 mmol), potassium carbonate (1.05 g, 7.6 mmol) and Copper (24 mg, 0.38 mmol) in pentanol (6 ml) was stirred for lh at room temperature. The mixture was heated to 100°C and stirred for 40 minutes. The solvent was evaporated. The residue was taken up in water and acidified to pH 2. The aqueous layer was extracted twice with ethylacetate. The organic layers were combined, dried over Na2SO4, filtered and the solvent was removed in vacuo. The crude oil was chromatographed over silicagel: eluent: heptane/ethylacetate 0-20% over 15 minutes to provide the titie compound as a brown solid (120 mg, 10%), MS (m/e): 252.1 (M-H, 100%)
Example 195
l-{3-Fluoro-4-[4-(5-methylsulfanyl-2-morpholin-4-yl-benzoyl)-piperazin-l-yl]- phenyl}-ethanone
The titie compound was prepared according to the procedure described for example K step 2 from 5-Methylsulfanyl-2-morpholin-4-yl-benzoic acid and l-(3-Fluoro-4- piperazin-l-yl-phenyl)-ethanone (8%, white solid), MS (m/e): 458.2 (M+, 100%)
Example 196 3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-morphoUn-4-yl-benzonitrile
The titie compound was prepared according to the procedure described for example 1 from 3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-bromo-benzonirrile (example L) and morpholine (71%, white solid), MS (m/e): 437.2 (M+H, 100%) Example 197
1 -{3-Fluoro-4- [4- (5-methanesulfonyl-2-morpholin-4-yl-benzoyl)-piperazin- 1 -yl] - phenyl}-ethanone
The title compound was prepared according to the procedure described for example 1 from l-{4-[4-(2-Chloro-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone (example K) and morpholine (57%, white solid), MS (m/e): 490.2 (M+H, 100%)
Example BL
3- [4- (4- Acetyl-2-fluoro-phenyl)-piperazine- 1 -carbonyl] -4-chloro-benzenesulfonamide
Figure imgf000076_0001
The titie compound was prepared according to the procedure described for example K/ step2 from l-(3-Fluoro-4-piperazin-l-yl-phenyl)-ethanone and 2-Chloro-5-sulfamoyl- benzoic acid (CAS: 97-04-1; Basu; D.-G.; J.Indian Chem.Soc; 16; 1939; 100, 106) (42%, white solid), MS (m/e): 438.1 (M-H, 100%)
Example 198
3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-morpholin-4-yl- benzenesulfonamide
The titie compound was prepared according to the procedure described for example 1 from 3-[4-(4-Acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-chloro- benzenesulfonamide and morpholine (39%, yellow solid), MS (m/e): 489.4 (M-H, 100%) Example 199
l-{3-Fluoro-4-[4-(5-imidazol-l-yl-2-mo]^ho]in-4-yl-benzoyl)-piperazin-l-yl]-phenyl}- ethanone
In a tube were added successively l-{4-[4-(5-Bromo-2-morpholin-4-yl-benzoyl)- piperazin-l-yl]-3-fluoro-phenyl}-ethanone (example BJ, 0.05 g, 0.1 mmol), imidazole (8.4 mg, 0.12 mmol), cesium carbonate (70 mg, 0.21 mmol), Cul ( 4 mg, 0.02 mmol), 1,10-phenanthroline (7.3 mg, 0.04 mmol) and dioxane (0.2 ml). The mixture was heated under argon at 120°C for 12 hours. The reaction mixture was cooled to room temperature and quenched with water/ethyl acetate. The aqueous layer was extracted twice with ethylacetate. The organic layers were combined, dried over Na2SO4, filtered and the solvent was removed in vacuo. The crude oil was chromatographed over silicagel: eluent: CH2Cl2/methanol: 0-5% to provide the titie compound as a brown solid (20 mg, 40%), MS (m/e): 478.4 (M+H, 100%) Example 200
[4-(2,4-Difluoro-phenyl)-piperazin-l-yl]-(2-morpholin-4-yl-5-nitro-phenyl)- methanone
The title compound was prepared according to the procedure described for example 46 from 2-Morpholin-4-yl-5-nitro-benzoyl chloride and l-(2,4-difluorophenyl) -piperazine (87%, yellow solid, MS (m/e): 433.4 (M+H, 100%)
Example BM
4-(2-Chloro-4-fluoro-phenyl)-piperazine-l-carboxy]ic acid tert-butyl ester
Figure imgf000077_0001
The titie compound was prepared according to the procedure described for example AX from l-bromo-2-chloro-4-fluorobenzene and N-Boc-piperazine (10%, off white solid, MS (m/e): 315.1(M+H, 100%) Example BN
l-(2-Chloro-4-fluoro-phenyl)-piperazine
Figure imgf000078_0001
The title compound was prepared according to the procedure described for example D step 2 from 4-(2-Chloro-4-fluoro-phenyl)-piperazine- 1-carboxylic acid tert-butyl ester
(91%, light yellow oil, MS (m/e): 215.2(M+H, 100%)
Example 201
[4-(2-Chloro-4-fluoro-phenyl)-piperazin-l-yl]-(2-morpholin-4-yl-5-nitro-phenyl)- methanone
The title compound was prepared according to the procedure described for example 46 from 2-Morpholin-4-yl-5-nitro-benzoyl chloride and l-(2-Chloro-4-fluoro-phenyl)- piperazine (70%, yellow solid, MS (m/e): 449.2 (M+H, 100%)
Example BO
(2-Chloro-5-methanesulfonyl-phenyl)- [4- (4-trifluoromethyl-phenyl)-piperazin- 1-yl] - methanone
Figure imgf000078_0002
To a solution of 2-Chloro-5-methanesulfonyl-benzoic acid (102mg, 0.43 mmol) in dimethylformamide (20 ml) were successively added TBTU (153mg, 0.48 mmol), N- ethyldiisopropylamine (0.28 ml, 2.17 mmol) and l-(4-trifluromethylphenyl)piperazine (ABCR F07741NB, [30459-17-7], 100 mg, 0.43 mmol). The reaction was then stirred at room temperature for two hours, then concentrated in vacuo and purified by column chromatography (SiO2, 50g, heptane/ethylacetate = 0 to 100%), to give the title compound as a colorless gum (170 mg, 0.38 mmol). MS (m/e): 464.3 (M+NH4 +, 100%) Example 202
5-Methanesulfonyl-2-moι^hom -4-yl-pheny^ 1-yl] -methanone
To a solution of (2-Chloro-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)- piperazin- 1-yl] -methanone (0.28 mmol, 130 mg) was added morpholine (0.5 ml). The reaction mixture was then stirred at 100°C for 48 hours before being concentrated in vacuo. The residue was then purified by column chromatography (SiO2, 20 g, Heptane/EtOAc 0-100%) to give the title compound as a white solid (118 mg, 85 %). MS (m/e): 497.5 (M+H\ 100%). Example BP
rflc-3-Methyl-4-(4-trifluoromethyl-phenyl)-piperazine-l-carboxylic acid tert-butyl ester
Figure imgf000079_0001
To a solution of 3-Methyl-piperazine-l-carboxylic acid tert-butyl ester (1.0 g, 5.3 mmol) and of l-Bromo-4-trifluoromethyl-benzene (1.0 g, 4.4 mmol) in toluene (10 ml) were added sodium-tert butylate (0.6 g, 6.2 mmol), 2-(dicyclohexylphosphino)biphenyl (31 mg, 89 mmol), and tris(dibenzylideneacetone)dipalladium-chloroform complex (23 mg, 22 mmol). The reaction mixture was then stirred for 16 hours at 80 °C. After allowing to cool to room temperature the reaction mixture was concentrated in vacuo and purified by column chromatography (Si02, 70g, heptane/ethyl acetate 0-30%) to give the titie compound as a light brown solid (0.47 g, 31 %). MS (m/e): 345.2 (M+H+, 100%).
Example BQ
2-Iodo-5-methanesulfonyl-benzoic acid
Figure imgf000079_0002
(a 2-Amino-5-methanesulfonyl-benzoic acid
Figure imgf000080_0001
A mixture of 4.26 mmol 2-chloro-5-methanesulfonyl-benzoic acid (see example K, stepl), 0.39 mmol Copper powder and 10 ml ammonium hydroxide 25% was heated at 125-130°C with stirring for 18 hours. Mixture was cooled to room temperature and filtered. The solid was washed with methanol. The filtrate was concentrated in vacuo. The residue was acidified with HCl IN to pH=2. The obtained solid was washed with water and dried (HV, 50°C, 1 hour) to yield the titie compound. MS (m/e): 214.1 (M-H, 100%)
(b) 2-Iodo-5-methanesulfonyl-benzoic acid
Figure imgf000080_0002
To a suspension of 3.0 mmol 2-amino-5-methanesulfonyl-benzoic acid in a mixture of 1.7 ml sulfuric acid and 1.7 ml water was added dropwise a solution of 3.92 mmol sodium nitrite in 1.7 ml water at such rate that the temperature did not exceed 3°C. The mixture was stirred at 0°C for 1 hour. A solution of 3.0 mmol KI in 1.7 ml water was added dropwise at 0°C. The brown suspension was allowed to warm to rt and stirred for 30 minutes. Excess iodine was destroyed by addition of a few drops of a sodium hydrogenosulfite solution. The solid was filtered, washed with water and dried (HV, 50°C, 1 hour) to yield the titie compound. MS (m/e): 325.0 (M-H, 100%) Example BR
rαc-(2-Iodo-5-methanesulfonyl-phenyl)-[3-methyl-4-(4-trifluoromethyl-phenyl)- piperazin- 1-yl] -methanone
Figure imgf000081_0001
To a solution of røc-3-Mefhyl-4- (4- frifluoromethyl-phenyl) -piperazine- 1-carboxylic acid tert-butyl ester (95 mg, 0.27 mmol) in dichloromethane (2 ml) was added trifluoroacetic acid (1 ml) and the reaction mixture was stirred at room temperature for 30 min. After such time the reaction mixture was concentrated in vacuo, and the residue was dissolved in dimethylformamide (3 ml). To the solution were added 2-Iodo-5-methanesulfonyl- benzoic acid (81 mg, 0.25 mmol), N-ethyldiisopropylamine (0.29 ml, 1.7 mmol), and TBTU (99 mg, 0.3 mmol). The reaction mixture was then allowed to stir at room temperature for 2 hours. The reaction mixture was then concentrated in vacuo and the residue was purified by column chromatography (Si02, 20g, Heptane/EtOAc 0-100%) to give the titie compound as a light brown solid (135 mg, 90 %). MS (m/e): 553.1 (M+H+).
Example 203
rac- ( 5-Methanesulfonyl-2-morpholin-4-yl-phenyl) - [ 3-methyl-4- (4-trifluoromethyl- phenyl)-piperazin-l-yl]-methanone
(2-Iodo-5-melhanesmfonyl-phenyl)-[3-methyl-4-(4-trifluoromethyl-phenyl)-piperazin- 1-yl] -methanone (50 mg, 0.09 mmol) was poured into morpholine (2.0 ml) and the reaction mixture was stirred for 24 h at 100°C before being concentrated in vacuo. The residue was then purified by column chromatography (SiO2, 20g, Heptane/EtOAc 0- 100%) to give the title compound as a light brown solid (43.5 mg, 94 %). MS (m/e): 512.3 (M+H+).
Example BS
røc-4-(2-Iodo-5-methanesulfonyl-benzoyl)-3-methyl-piperazine-l-carboxylic acidtert- butyl ester
Figure imgf000081_0002
To a solution of røc-3-Methyl-piperazine-l-carboxylic acid tert-butyl ester (350 mg, 1.75 mmol) in dimethylformamide (3 ml) were added 2-Iodo-5-methanesulfonyl-benzoic acid (540 mg, 1.67 mmol), IV-ethyldiisopropylamine (1.8 ml, 10.5 mmol), and TBTU (630 mg, 1.92 mmol). The reaction mixture was then allowed to stir at room temperature for 16 hours. The reaction mixture was then concentrated in vacuo and the residue was purified by column chromatography (SiO2, 20g, Heptane/EtOAc 0-100%) to give the title compound (400 mg, 45 %). MS (m/e): 526.2 (M+NH4 +).
Example BT
rαc-4-(5-Methanesuhconyl-2-moι^hoπn-4-yl-benzoyl)-3-methyl-piperazine-l-carboxyric acid tert-butyl ester
Figure imgf000082_0001
rac-4-(2-Iodo-5-methanesulfonyl-benzoyl)-3-methyl-piperazine-l-carboxylic acid tert- butyl ester (400 mg, 0.78 mmol) was poured into morpholine (5.0 ml) and the reaction mixture was stirred for 15 h at 100°C before being concentrated in vacuo. The residue was then purified by column chromatography (SiO2, 20g, dichloromethane/methanol = 0- 5%) to give the titie compound as a colorless foam (322 mg, 88 %). MS (m/e): 468.3 (M+H+).
Example 204
rαc-(5-Methanesulfonyl-2-morphoKn-4-yl-phenyl)-[2-methyl-4-(4-trifluoromethyl- phenyl)-piperazin-l-yl]-methanone
To a solution of c-4-(5-Methanesulfonyl-2-morpholin-4-yl-benzoyl)-3-methyl- piperazine-1-carboxylic acid tert-butyl ester (250 mg, 0.54 mmol) in dichloromethane (2 ml) was added trifluoroacetic acid (1 ml) and the reaction mixture was stirred at room temperature for 30 min. After such time the reaction mixture was concentrated in vacuo, and the residue was dissolved in toluene (5 ml). To the solution were added l-Bromo-4- trifluoromethyl-benzene (0.15 ml, 1.1 mmol), sodium-tert butylate (128 mg, 1.4 mmol), 2-(dicyclohexylphosphino)biphenyl (3.8.mg, 0.011 mmol), and tris(dibenzylideneacetone)dipallaclium-chloroform complex (5.5 mg, 0.005 mmol). The reaction mixture was then stirred for 16 hours at 80 °C. After allowing to cool to room temperature the reaction mixture was concentrated in vacuo and purified by column chromatography (SiO2, 70g, dichloromethane/methanol 0-5%) to give the title compound (83 mg, 30 %). MS (m/e): 512.3 (M+H+)
Table 1
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
4-[4-(2-Morpholin-4-yl-5-nitro-benzoyl)-piperazin-l-yl]-benzoic acid butyl ester The title compound was prepared according to the procedure described for example 46 from 4-Piperazin- 1-yl-benzoic acid butyl ester (CAS: 86620-18-0) and 2-Morpholin-4- yl-5-nitro-benzoyl chloride (example B) (yield :16 %, MS (m/e): 497.3 (M+H, 100%)
Example BU
rac-2-(3-Hydroxymethyl-pyrrohdin-l-yl)-5-melhanesulfonyl-benzoic acid
Figure imgf000124_0001
The titie compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid (Example Y) from 2- Chloro-5-methanesulfonyl-benzoic acid and rac-pyrrolidin-3-yl-methanol and obtained in 39 % yield. MS (m/e): 298.1 (M-H, 100%).
Example BV
5-Methanesulfonyl-2-piperidin- 1 -yl-benzoic acid
Figure imgf000124_0002
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1 -yl-benzoic acid (Example Y) from 2- Chloro-5-methanesulfonyl-benzoic acid and piperidine and obtained in 78 % yield. MS (m/e): 282.0 (M-H+ 100%)
Example BW
rac-2-(3-Hydroxy-piperidm-l-yl)-5-methanesulfonyl-benzoic acid
Figure imgf000125_0001
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesιzlfonyl-2-pvrrolidin-l-yl-benzoic acid (Example Y) from 2- Chloro-5-methanesulfonyl-benzoic acid and rac-3-hydroxy-piperidine and obtained in 9 % yield. MS (m/e): 298.1 (M-H 100%).
Example BX
rac-2-(3-Hydroxymethyl-pyrroUdin-l-yl)-5-methylsulfamoyl-benzoic acid
Figure imgf000125_0002
The titie compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid (Example S) from 2-
Chloro-5-methylsulfamoyl-benzoic acid and rac-pyrrolidin-3-yl-methanol and obtained in 25 % yield. MS (m/e): 313.0 MH- (100%).
Example BY
5-Methylsulfamoyl-2-piρeridin-l-yl-benzoic acid
Figure imgf000125_0003
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid (Example S) from 2- Chloro-5-methylsulfamoyl-benzoic acid and piperidine and obtained in 48 % yield. MS (m/e): 297.4 MH- (100%). Example BZ rac-2- (3-Hydroxy-piperidin- 1 -yl)-5-methylsulfamoyl-benzoic acid
Figure imgf000126_0001
The title compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin-l-yl-benzoic acid (Example S) from 2- Chloro-5-methylsulfamoyl-benzoic acid and rac-3-hydroxy-piperidine and obtained in 15 % yield. MS (m/e): 312.9 (MH" 100%).
Example CA 2-Pyrrolidin-l-yl-5-sulfamoyl-benzoic acid
Figure imgf000126_0002
The titie compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin-l-yl-benzoic acid (Example S) from 2- Chloro-5-sulfamoyl-benzoic acid (CAS: 97-04-1; Basu; D.-G.; JJndian Chem.Soc; 16; 1939; 100, 106) and pyrrolidine and obtained in 19% yield. MS (m/e): 269.4 (MH" 100%).
Example CB
2-Morpholin-4-yl-5-sulfamoyl-benzoic acid
Figure imgf000127_0001
The titie compound was synthesised according to the procedure described for the synthesis of 5-Methanesulfonyl-2-pyrrolidin- 1-yl-benzoic acid (Example S) from 2- Chloro-5-sulfamoyl-benzoic acid (CAS: 97-04-1; Basu; D.-G.; JTndian Chem.Soc; 16; 1939; 100, 106) and morpholine and obtained in 85% yield. MS (m/e): 285.1 (MH" 100%).
According to the procedure described for the synthesis of Example 123 further derivatives have been synthesised from acid derivatives and piperazine derivatives and comprise Examples 206-279 in Table 2.
Table 2
Figure imgf000127_0002
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
Figure imgf000137_0001
Figure imgf000138_0001
Figure imgf000139_0001
Figure imgf000140_0001
Figure imgf000141_0001
Figure imgf000142_0001
Figure imgf000143_0001
Figure imgf000144_0001
Figure imgf000145_0002
Example CC
3,4-Difluoro-N-methyl-5-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]- benzenesulfonamide
Figure imgf000145_0001
(a) 5-Chlorosulfonyl-2,3-difluoro-benzoic acid
To 2,3-difluoro-benzoic acid (3g) was added to a solution of chlorosulfonic acid and the reaction mixture was stirred for 2 hours at room temperature. After such time, the reaction mixture was poured onto ice. The resulting solid precipitate was then filtered off and dried in vacuo to yield the titie compound as a light grey solid (4.8 g, mp = 109- 114°C, MS (El): 256.0 (M+) and was used directly in the next step without any further purification. fb~)-2,3-Difluoro-5-methylsulfamoyl-benzoic acid
To a solution of 5-chlorosulfonyl-2,3-difluoro-benzoic acid (400 mg) in dichloromethane (5 mL) at -10°C was added a solution of methylamine in ethanol (8M). The reaction mixture was then stirred at -10°C for 5 minutes and poured over IN NaOH solution. The aqueous phase was extracted with diethyl ether twice and then acidified with a concentrated solution of HCl. The aqueous phase was then extracted 3 times with a mixture of dichoromethane:ethanol (9:1) and the combined organic layer were dried over sodium sulfate and concentrated in vacuo to yield the title compound as a light brown solid (390 mg, mp=191-194°C, MS (m/e): 250.1 (M-H, 100%).
(c 3,4-Difluoro-N-methyl-5-[4-(4-trifluoromethyl-phenyl -piperazine-l-carbonyl]- benzenesulfonamide
The title compound was prepared in analogy to Example BO by reaction of 2,3-Difluoro- 5-methylsulfamoyl-benzoic acid and l-(4-trifluromethylphenyl)piperazine (ABCR F07741NB, [30459-17-7]) to yield the title compound as a light yellow amorpous solid, (m/e): 462.1 (M-H, 100%).
Example CD
2,4-Difluoro-N-me yl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]- benzenesulfonamide
Figure imgf000146_0001
The title compound was prepared in analogy to Example CC using 3-chlorosulfonyl-2,6- difluoro-benzoic acid [142576-91-8] to yield the title compound as a light brown solid (m/e): 462.3 (M-H, 100%).
Example 280
(5-Methanesmfonyl-2-tWomorphoHn-4-yl-phenyl)-[4-(4-trifluoromeιhyl-phenyl)- piperazin- 1 -yl] -methanone
The titie compound was prepared according to the procedure described for example 202 from (2-Cl loro-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l- yl] -methanone (example BO) and thiomorpholine to yield the title compound as a pale yellow solid. MS (m/e): 514.5 (M+H, 100%).
Example 281
3-Fluoro-N-methyl-4-morpholin-4-yl-5- [4- (4-trifluoromethyl-phenyl)-piperazine- 1- carbonyl] -benzenesulfonamide The title compound was prepared according to the procedure described for example 202 from 3,4-Difluoro-N-methyl-5-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]- benzenesulfonamide (example CC) and morpholine to yield the title compound as a colourless foam, MS (m/e): 531.1 (M+H, 100%). Example 282
2-Fluoro-N-memyl-4-morpholm-4-yl-3-[4-(4-frifluoromethyl-phenyl)-piperazine-l- carbonyl] -benzenesulfonamide
The title compound was prepared according to the procedure described for example 202 from 2,4-Difluoro-N-methyl-3- [4-(4-trifluoromethyl-phenyl)-piperazine- 1-carbonyl] - benzenesulfonamide (example CD) and morpholine to yield the titie compound as a colourless foam, MS (m/e): 529.3 (M+H, 100%).
Example CE 2,3-Difluoro-4-piperazin-l -yl-benzonitrile- trifluoro-acetic acid
Figure imgf000147_0001
(a) 4-(4-Cyano-2,3-difluoro-phenyl)-piperazine-l-carboxyric acid tert-butyl ester
To a solution of iV-Boc-Piperazine (0.65 g) in DMA (20 mL) was slowly added a solution of 2,3,4-trifluorobenzonitrile (0.49 g) in DMA (10 mL). The reaction mixture was stirred for 2 hours at 80°C. After such time the solvent was removed in vacuo and purified by column chromatography (SiO2) to yield the title compound as white solid (0.76 g).
(b) 2,3-Difluoro-4-piperazin-l-yl-benzonitrile- trifluoro-acetic acid
To a solution of 4-(4-Cyano-2,3-difluoro-phenyl)-piperazine-l-carboxylic acid tert-butyl ester (0.72 g) in dichloromethane (5 mL) was added trifluoroacetic acid and the reaction mixture was stirred at room temperature for 30 minutes. After such time the reaction mixture was concentrated in vacuo to yield the title compound (0.63 g). MS (m/e): 224.3 (M+H+, 100%). Example CF 2,5-Difluoro-4-piperazin- l-yl-benzonitrile-trifluoro-acetic acid
Figure imgf000148_0001
Example CF was prepared in analogy to Example CE using 2,4,5-trifluorobenzonitrile. MS (m/e): 224.3 (M+H+, 100%).
Example CG
3,5-Difluoro-4-piperazin-l -yl-benzonitrile trifluoro-acetic acid
Figure imgf000148_0002
Compound CG was prepared in analogy to compound CE using 3,4,5- trifluorobenzonitrile. MS (m/e): 224.1 (M+H+, 100%).
Example CH
2,6-Difluoro-4-piperazin-l-yl-benzonitrile trifluoro-acetic acid
Figure imgf000148_0003
Compound CH was prepared in analogy to compound CE using 2,4,6- trifluorobenzonitrile. MS (m/e): 224.1 (M+H+, 100%).
Example CI
4-Piperazin-l-yl-6-frifluorometnyl-pyrimidine trifluoro-acetic acid
Figure imgf000149_0001
Compound CI was prepared in analogy to compound CE using 4-chloro-6- trifluoromethyl-pyrimidine [37552-81-1]. MS (m/e): 233.1 (M+H+).
Example CJ
2-Piperazin-l-yl-5-trifluoromethyl-pyrimidine
Figure imgf000149_0002
(a) 2-("4-Benzyl-piperazin-l-yl)-5-trifluoromethyl-pyrimidine
To a solution of (3-Dimethylamino-2-trifluoromethyl-allylidene)-dimethyl-ammonium chloride ([176214-18-9], 0.60 g) in acetonitrile (10 mL) was added 4-Benzyl-piperazine- 1-carboxamidine hydrochloride ([7773-69-5], 0.66 g) and triethylamine (0.87 mL) and the reaction mixture was stirred for 3 hours at room temperature. After such time the reaction mixture was concentrated in vacuo and purified by column chromatography to yield the title compound as a light yellow solid (0.79 g). MS (m/e): 323.4 (M+H+).
(b) 2-Piperazin-l-yl-5-trifluoromethyl-pyrimidine
To a solution of 2-(4-Benzyl-piperazin-l-yl)-5-trifluoromethyl-pyrimidine (0.63 g) in methanol was added Palladium-C (Degussa E101N; 5%) and the reaction mixture was heated at 60°C under hydrogen atmosphere. The reaction mixture was then allowed to cool down to room temperature, the catalyst was filtered of and solvent was removed in vacuo to yield the title compound as a colorless solid (0.41 g). MS (m/e): 233.1 (M+H+).
According to the procedure described for the synthesis of Example 123 further derivatives have been synthesised from acid derivatives and piperazine derivatives and comprise Examples 283-289 in Table 3. Table 3
Figure imgf000150_0001
Figure imgf000151_0001
Example CK
(2-Iodo-5-methanesulfonyl-phenyl)-[4-(4-frifluoromethyl-phenyl)-piperazin-l-yl]- methanone
Figure imgf000151_0002
Example CK was prepared in analogy to Example 123 from 2-Iodo-5-methanesulfonyl- benzoic acid (example BQ) and l-(4-Trifluoromethyl-phenyl)-piperazine (commercial). MS (m/e): 539.1 (M+H+, 100%). Example CL
3-Fluoro-4- [4- (2-iodo-5-methanesulfonyl-benzoyl)-ρiperazin- 1-yl] -benzonitrile
Figure imgf000152_0001
Example CL was prepared in analogy to Example 123 from 2-Iodo-5-methanesulfonyl- benzoic acid (example BQ) and 3-Fluoro-4-piperazin-l -yl-benzonitrile (WO9625414). MS (m/e): 514.0 (M+H+, 100%).
Example CM
[4- (2-Fluoro-4-methanesulfonyl-phenyl)-piperazin- 1 -yl] - (2-iodo-5-methanesulfonyl- phenyl)-methanone
Figure imgf000152_0002
Example CM was prepared in analogy to Example 123 from 2-Iodo-5-methanesulfonyl- benzoic acid (example BQ) and l-(2-Fluoro-4-methanesulfonyl-phenyl)-piperazine (commercial). MS (m/e): 567.0 (M+H+, 100%).
Example CN
[4-(2-Fluoro-4-lxifluoromethyl-phenyl)-piperazin-l-yl]-(2-iodo-5-methanesulfonyl- phenyl)-methanone.
Figure imgf000152_0003
Example CN was prepared in analogy to Example 123 from 2-Iodo-5-methanesulfonyl- benzoic acid (example BQ) and l-(2-Fluoro-4-trifluoromethyl-phenyl)-piperazine (example H). MS (m/e): 574.2 (M+NH4 +, 100%). Example CR
(5-Bromo-2-morphomι-4-yl-phenyl)-[4-(4-trifluoromet-hyl-phenyl)-piperazin-l-yl]- methanone
Figure imgf000153_0001
Example CR was prepared in analogy to Example 46 from 5-Bromo-2-morpholin-4-yl- benzoyl chloride (example Bl) and l-(4-Trifluoromethyl-phenyl)-piperazine (commercial). MS (m/e): 500.1 (M+H+, 100%).
Example 290
(2-Imidazol-l-yl-5-melhanesulfonyl-phenyl)-[4-(4-frifluoromethyl-phenyl)-piperazin- 1-yl] -methanone
The title compound was prepared according to the procedure described for example 199 from (2-Iodo-5-methanesulfonyl-phenyl)- [4-(4-trifluoromethyl-phenyl)-piperazin- 1- yl] -methanone (compound CK) and imidazole (20%, light grey solid , MS (m/e): 479.2 (M+H, 100%) Example 291
5-Methanesulfonyl-2- (2-methyl-imidazol- l-yl)-phenyl] - [4- (4-trifluoromethyl-phenyl)- piperazin- 1-yl] -methanone
The title compound was prepared according to the procedure described for example 199 from (2-Iodo-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l- yl] -methanone (compound CK) and 2-methyl-imidazole ( 10% yield, yellow solid , MS (m/e): 493.1 (M+H, 100%)
Example 292
[5-MeΛanesulfonyl-2-(4-methyl-irr dazol-l-yl)-phenyl]-[4-(4-1xifluoromethyl-phenyl)- piperazin- 1-yl] -methanone The title compound was prepared according to the procedure described for example 199 from (2-Iodo-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l- yl] -methanone (compound CK) and 4-Methyl-lH-imidazole (32% yield, white solid , MS (m/e): 493.4 (M+H, 100%) Example 293
[[5-(2-Cyclopropyl-imidazol-l-yl)-2-morphomι-4-yl-phenyl]-[4-(4-trifluoromethyl- phenyl)-ρiperazin- 1-yl] -methanone
The title compound was prepared according to the procedure described for example 199 from (5-Bromo-2-morpholin-4-yl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l- yl] -methanone (compound CR) and 2-Cyclopropyl-lH-imidazole (CAS: 89532-38-7 ) (16% yield, white solid , MS (m/e): 526.3(M+H, 100%)
Example 294
(5-Metlιanesmfonyl-2-pyrazol-l-yl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l- yl] -methanone
In a tube were added successively (2-Iodo-5-methanesulfonyl-phenyl)- [4-(4- trifluoromethyl-phenyl) -piperazin- 1-yl] -methanone (compound CK, 0.1 g, 0.19 mmol), pyrazole (15 mg, 0.223 mmol), potassium carbonate (51 mg, 0.37 mmol), Cul ( 7 mg, 0.037 mmol), Trans- 1,2-diaminocyclohexane (9 ul, 0.07 mmol) and dioxane (0.4 ml). The mixture was heated under argon at 120°C for 24 hours. The reaction mixture was cooled to room temperature and quenched with water/dichloromethane. The aqueous layer was extracted twice with dichloromethane. The organic layers were combined, dried over Na2SO , filtered and the solvent was removed in vacuo. The crude oil was chromatographed over silicagel: eluent: heptane/ethylacetate: 0-5% to provide the titie compound as a light grey powder (19 mg, 21%), MS (m/e): 479.1 (M+H, 100%)
Example 295
[5-Methanesmfonyl-2-(3-memyl-pyrazol-l-yl)-phenyl]-[4-(4-trifluoromethyl-phenyl)- piperazin- 1-yl] -methanone
The title compound was prepared according to the procedure described for example 294 from (2-Iodo-5-methanesulfonyl-phenyl)- [4-(4-trifluoromethyl-phenyl)-piperazin-l- yl] -methanone (compound CK) and 3-Methyl-lH-pyrazole (15%yield, white solid , MS (m/e): 493.5 (M+H, 100%)
Example 296
[5-Memanes fonyl-2-(4-methyl-pyrazol-l-yl)-phenyl]-[4-(4-txifluoromethyl-phenyl)- piperazin- 1-yl] -methanone
The title compound was prepared according to the procedure described for example 294 from (2-Iodo-5-methanesulfonyl-phenyl)- [4- (4- trifluoromethyl-phenyl) -piperazin- 1- yl] -methanone (compound CK) and 4-Methyl-lH-pyrazole (43 %yield, white solid , MS (m/e): 493.1 (M+H, 100%)
Example 297
3-Fluoro-4-{4-[5-methanesulfonyl-2-(4-methyl-pyrazol-l-yl)-benzoyl]-piperazin-l-yl}- benzonitrile
The titie compound was prepared according to the procedure described for example 294 . from 3-Fluoro-4-[4-(2-iodo-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-benzonitrile (compound CL) and 4-Methyl-lH-pyrazole (20% yield, white foam , MS (m/e): 468.3 (M+H, 100%)
Example 298
[4- (2-Fluoro-4-methanesulfonyl-phenyl)-piperazin- 1 -yl] - [5-methanesulfonyl-2-(4- methyl-pyrazol-l-yl)-phenyl]-methanone
The title compound was prepared according to the procedure described for example 294 from [4-(2-Fluoro-4-methanesulfonyl-phenyl)-piperazin-l-yl]-(2-iodo-5- methanesulfonyl-phenyl)-methanone (compound CM) and 4-Methyl-lH-pyrazole (29% yield, yeUo foam, MS (m/e): 521.3(M+H, 100%) Example 299
[4- (2-Fluoro-4-trifluoromethyl-phenyl)-piperazin- 1 -yl] - [5-methanesulfonyl-2- (4- methyl-pyrazol- l-yl)-phenyl] -methanone The titie compound was prepared according to the procedure described for example 294 from [4- (2-Fluoro-4-trifluoromethyl-phenyl)-piperazin- 1 -yl] - (2-iodo-5- methanesulfonyl-phenyl)-methanone (compound CN) and 4-Methyl-lH-pyrazole (30% yield, light brown solid, MS (m/e): 511.2(M+H, 100%) Example 300
(5-Methanesulfonyl-2-[l,2,4]triazol-l-yl-phenyl)-[4-(4-trifluoromethyl-phenyl)- piperazin- 1-yl] -methanone
In a tube were added successively (2-Iodo-5-methanesulfonyl-phenyl)-[4-(4- trifluoromethyl-phenyl) -piperazin- 1-yl] -methanone (compound CK, 0.1 g, 0.19 mmol), 1,2,4-triazole (11 mg, 0.155 mmol), potassium phosphate (71 mg, 0.326 mmol), Cul ( 7 mg, 0.037 mmol), (lR,2R)-diaminomethylcyclohexane (2.3 mg, 0.015 mmol) and DMF (1 ml). The mixture was heated under argon at 120°C for 24 hours. The reaction mixture was cooled to room temperature and quenched with water/dichloromethane. The aqueous layer was extracted twice with dichloromethane. The organic layers were combined, dried over Na2SO , filtered and the solvent was removed in vacuo. The crude oil was chromatographed over silicagel: eluent: heptane/ethylacetate: 0-100% to provide the title compound as a light grey solid (5 mg, 6%), MS (m/e): 480.4 (M+H, 100%)
Example 301
(2-Cyclobutylamino-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone
A solution of (2-Iodo-5-methanesulfonyl-phenyl)-[4-(4-trifluoromefhyl-phenyl)- piperazin- 1-yl] -methanone (compound CK, 0.05 g, 0.09 mmol) and of cyclobutylamine (0.1 ml) in dimethylacetamide was heated in a microwave oven (180 deg) for 10 min before being concentrated in vacuo. The residue was disolve in ethyl acetate, washed with water dried over sodiumsulfate, filtered and concentrated. The residue was purified by column chromatography (Si0 , 5 g, Heptane/EtOAc 0-50%) to give the title compound as a white foam (24 mg, 54%). MS (m/e): 482.5 (M+H+, 100%).
Example 302
[2-(Cyclopropylmethyl-amino)-5-me anesιUfonyl-phenyl]-[4-(4-trifluoromethyl- phenyl)-piperazin- 1-yl] -methanone The title compound was prepared according to the procedure described for example 301 from (2-Iodo-5-met anes fonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l- yl] -methanone (compound CK) and Cyclopropanemethylamine (40% yield, white foam, MS (m/e): 482.5 (M+H, 100%) Example 303
(2-Isobutylammo-5-methanesulfonyl-phenyl)^ 1 -yl] -methanone
The title compound was prepared according to the procedure described for example 301 from (2-Iodo-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l- yl] -methanone (compound CK) and and Isobutylamine (49% yield, off white foam, MS (m/e): 484.5 (M+H, 100%)
Example 304
rac-{5-Methanesmfonyl-2-[(tefrahydro-furan-2-ylme1-hyl)-amino]-phenyl}-[4-(4- trifluoromethyl-phenyl)-piperazin-l-yl]-methanone
The title compound was prepared according to the procedure described for example 301 from (2-Iodo-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l- yl] -methanone (compound CK) and tetrahydrofurfurylamine (28% yield, MS (m/e): 512.4 (M+H, 100%)
Example CO l-(6-Trifluoromethyl-pyridin-3-yl)-piperazine
Figure imgf000157_0001
The compound was prepared in analogy to example H from 5-Bromo-2-frifluoromethyl- pyridine [436799-32-5]. MS (m/e): 232.1 (M+H+, 100%) Example CP l-(3-Fluoro-5-frifluoromethyl-pyridin-2-yl)-piperazine
Figure imgf000158_0001
The compound was prepared in analogy to example CE from 2,3-Difluoro-5- trifluoromethyl-pyridine (EP0104715). MS (m/e): 250.2 (MH+, 100%)
Example CQ l-(6-Methyl-pyridin-3-yl)-piperazine
Figure imgf000158_0002
The compound was prepared in analogy to example H from 5-Bromo-2-methyll- pyridine (commercial). MS (m/e): 178.1 (M+H+, 100%) Example CS 5-Piperazin-l-yl-2-frifluoromethyl-pyrimidine
Figure imgf000158_0003
(a) 5-Chloro-2-trifluoromethyl-pyrimidine
To a solution of 38 mmol trifluoroacetamidine in 70 ml acetonitrile was added 37.92 mmol ((Z)-2-Chloro-3-dimethylamino-allylidene)-dimethyl-ammonium hexafluoro phosphate (CAS: 291756-76-8) followed by 45.5 mmol triethylamine. The yellow solution was stirred at room temperature for 5 hours, then poured onto water and extracted 3 times with ether. The combined extracts were dried over sodium sulfate, filtered and distilled at 760 mm Hg to provide the title compound. MS (m/e): 182.2 (M+, 100%)
(b) 4-(2-Trifluoromethyl-pyrimidin-5-y -piperazine-l-carboxylic acid tert-butyl ester
0.26 mmol 5-Chloro-2-trifluoromethyl-pyrimidine was added to 0.26 mmol piperazine- 1-carboxylic acid tert-butyl ester in 1.5 ml dimethylacetamide and the reaction mixture was stirred at 150°C for 10 min. in a microwave oven. After such time the reaction mixture was concentrated and the residue was then purified by column chromatography (SiO2, Heptane/EtOAc) to yield the title compound. MS (m/e): 333.2 (M+H+, 100%)
(c) 5-Piperazin-l-yl-2-trifluoromethyl-pyrimidine
The titie compound was prepared in analogy to Example H from 4-(2-trifluoromethyl- pyrimidin-5-yl)-piperazine-l-carboxylic acid tert-butyl ester MS (m/e): 233.0 (M+H+, 100%)
Example CT 3-Piperazin-l-yl-6-trifluoromethyl-pyridazine
Figure imgf000159_0001
The title compound was prepared in analogy to Example CS (b-c) from 3-Chloro-6- trifluoromethyl-pyridazine (CAS: 258506-68-2). MS (m/e): 233.0 (M+H+, 100%)
Example CU
Dimethyl-(4-piperazin-l-yl-[l,3,5]triazin-2-yl)-arnine
Figure imgf000159_0002
(a) 4-(4-Chloro-[l,3,5]triazin-2-yl)-piperazine-l-carboxylic acid tert-butyl ester
A solution of 11 mmol of 2,4-dichlorotriazine (WO 02/083654) in 20ml of acetonitrile was chilled and treated with 11 mmol of triethylamine and 11 mmol of N-BOC- piperazine. The reaction mixture was stirred for 2 hours at 0° C then for 2 hours at room temperature. Addition of 100ml brine and extraction with ethyl acetate yielded the crude product which was purified through trituration in ethyl acetate. MS (m/e): 300.3 (MH+, 100%)
(b) 4-(4-Dimethylamino-[l,3,5ltriazin-2-yl)-piperazine-l-carboxylic acid tert-butyl ester A solution of 2 mmol of 4-(4-Chloro-[l,3,5]triazin-2-yl)-piperazine-l-carboxylic acid tert-butyl ester in 15 ml of 2M dimethylamine in methanol was stirred at room temperature for 1 hour. Concentration and purification by chromatography (SiO2; ethyl acetate / cyclohexane 1:1) yielded the title compound as a colorless solid. MS (m/e): 309.1 (MH+, 100%)
(c Dimethyl-(4-piperazin-l-yl- l,3,5]triazin-2-v -amine
A solution of 1 mmol of 4-(4-Dimethylamino-[l,3,5]triazin-2-yl)-piperazine-l- carboxylic acid tert-butyl ester in 10 ml dichloromethane was chilled and treated with 14 mmol of trifluoroacetic acid. The reaction mixture was heated to 40° C for 30 min. After cooling, 50ml of 2M aqueous sodium hydroxide is added. The organic layer was separated, dried and concentrated to yield the title compound as a yellowish oil. MS (m/e): 267.0 (M+CH3COO+, 100%)
Example CV 5'-Trifluoromethyl-3,4,5,6-tetrahydro-2H- [ l,2']bipyrazinyl
Figure imgf000160_0001
(a) 2-Bromo-5-trifluoromethyl-pyrazine
To a suspension of 0.423 mmol copper (II) bromide in THF (1 ml) was added dropwise 0.51 mmol tert-butylnitrite at 0°C within 2 minutes. 0.37 mmol 5-Trifluoromethyl- pyrazin-2-ylamine (CAS: 69816-38-2; WO9518097) in solution in THF (0.5 ml) was added dropwise within 5 minutes at 0°C. The mixture was stirred at 0°C for 1 hour, at room temperature for 21 hours and quenched with water. The aqueous phase was extracted with ether. The combined extracts were dried over sodium sulfate and filtered and concentrated at atmospheric pressure. The residue was then purified by column chromatography (Si02, ether) to yield the title compound.
(bl 5'-Trifluoromethyl-3,4,5,6-tetrahvdro-2H- \ 1,2'lbipyrazinyl
The title compound was prepared in analogy to Example CS (b-c) from 2-Bromo-5- trifluoromethyl-pyrazine MS (m/e): 233.0 (M+H+, 100%) According to the procedure described for the synthesis of Example 123 further derivatives have been synthesised from acid derivatives and piperazine derivatives and comprise Examples 305-318 in Table 4.
Table 4
Figure imgf000161_0001
Figure imgf000162_0001
Figure imgf000163_0001
Tablet Formulation (Wet Granulation)
Item Ingredients mg/tablet 5mg 25]mg 100 mg 500
1. Compound of formula I 5 25 100 500
2. Lactose Anhydrous DTG 125 105 30 150
3. Sta-Rx 1500 6 6 6 30
4. Microcrystalline Cellulose 30 30 30 150
5. Magnesium Stearate 1 1 1 1 Total 167 167 167 831
Manufacturing Procedure
1. Mix items 1, 2, 3 and 4 and granulate with purified water.
2. Dry the granules at 50°C.
3. Pass the granules through suitable milling equipment. 4. Add item 5 and mix for three minutes; compress on a suitable press.
Capsule Formulation
Item Ingredients mg/capsule
Figure imgf000164_0001
Compound of formula I 5 25 100 500 Hydrous Lactose 159 123 148 — Corn Starch 25 35 40 70 Talc 10 15 10 25 Magnesium Stearate 1 2 2 5 Total 200 200 300 600
Manufacturing Procedure
1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes.
2. Add items 4 and 5 and mix for 3 minutes.
3. Fill into a suitable capsule.

Claims

Claims
1. A compound of formula
Figure imgf000165_0001
wherein
Ar is unsubstituted or substituted aryl or 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups are substituted by one or more substituents selected from the group consisting of hydroxy, halogen, NO2, CN, (C1-C6)-alkyl, ( -C6)-alkyl substituted by halogen, (CrC6)-alkoxy, (C1-C6)-alkoxy substituted by halogen, NR7R8, C(O)R9 or SO2R10;
R1 is hydrogen or (Cι-C6)-alkyl;
R2 and R2 are independentiy from each other hydrogen, (CR2)n-hydroxy for R being hydrogen or -C^-alkyl, or are (C C6)-aIkyl, (C2-C6)-alkenyl, (CrC6)-alkyl substituted by halogen, (CH2)n-(C3-C6)-cycloalkyl, (CH2)n-heterocycloalkyl, (CH2)n-O-(CrC0)-alkyl or (CH2)n-aryl or R2 and R2 form together with the N atom to which they are attach a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O, which rings are unsubstituted or substituted by (CH2)n-hydroxy, (C C6)-alkyl, (C C6)-alkoxy, (CH2)n-0-(C1-C6)-alkyl, or form together with the N atom a 5-membered heteroaryl group, optionnally containing in addition to the N atom one, two or three further nitrogen atoms and wherein the heteroaryl group is optionally substituted by (Cι-C6)-alkyl;
R3, R4 and R6 are independentiy from each other hydrogen, halogen, (C C6)-alkyl or (Cr )-alkoxy; R5 is N02, CN, C(O)R9, S-(C C6)-alkyl, SO2R10 or is NRπR12;
R7 and R8 are independently from each other hydrogen, (CH2)n-(C3-C6)-cycloalkyl or (C1-C6)-alkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
R9 is hydroxy, (CrC6)-alkyl, (C3-C6)-cycloalkyl, (C1-C6)-alkoxy or NR7R8;
R10 is (Cι-C6)-alkyl, (CH2)„-(C3-C6)-cycloalkyl or NR7R8;
R11 and R12 are independently from each other hydrogen, C(O)-(CrC6)-alkyl, SO2-(CrC6)-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, (Cj-C6)-alkyl or (CH2)„(C3-C6)-cycloalkyl;
n is 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof, with the proviso that l-[5-(aminosulfonyl)-2-(4-morpholinyl)benzoyI] -4-phenyl-piperazine, l-(4-methoxyphenyl)-4-[2-(4-morpholinyl)-5-nitrobenzoyl]-piperazine, l-[2-(4-morpholinyl)-5-nitrobenzoyl]-4-[2-nitro-4-(trifluoromethyl)phenyl]- piperazine, 1 - (4-methoxyphenyl) -4- [ 5-nitro-2- ( 1 -pyrrolidinyl)benzoyl] -piperazine, l-[2-[4-(2-hydroxyethyl)-l-piperazinyl]-5-nitrobenzoyl]-4-(4-methoxyphenyl)- piperazine,
1 - [2-fluoro-4- ( 1 -oxopropyl)phenyl] -4- [ 5-nitro-2- ( 1 -piperidinyl)benzoyl] -piperazine,
1 - [2-fluoro-4- ( 1 -oxopropyl)phenyl] -4- [5-nitro-2- ( l-pyrrolidinyl)benzoyl] -piperazine, 1- [2-fluoro-4-( l-oxopropyl)phenyl] -4- [2-(4-methyl-l-piperidinyl)-5-nitrobenzoyl] - piperazine,
1- [2-fluoro-4-( l-oxopropyl)phenyl] -4- [2-(4-methyl-l-piperazinyl)-5-nitrobenzoyl] - piperazine,
1- [2-fluoro-4-( l-oxopropyl)phenyl] -4-[2-(4-morpholinyl)-5-nitrobenzoyl] -piperazine, l-[5-[[methyl(phenylmethyl)amino]sulfonyl]-2-(4-morpholinyl)benzoyl]-4-(4- nitrophenyl) -piperazine and l-(4-acetyl-2-fluorophenyl)-4-[2-(4-morphoUnyl)-5-nitrobenzoyl]- piperazine, are excluded.
2. A compounds of formula
Figure imgf000167_0001
wherein
Ar is unsubstituted or substituted aryl or 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups are substituted by one or more substituents selected from the group consisting of hydroxy, halogen, NO2, CN, (Cr )-alkyl, (Ci- )-alkyl substituted by halogen, (C1-C6)-alkoxy, (CrC6)-alkoxy substituted by halogen, NR7R8, C(O)R9 or SO2R10;
R1 is hydrogen or (Ci-C6)-alkyl;
R2 and R2 are independently from each other hydrogen, hydroxy, ( -Ce) -alkyl, (C3-C6)-alkenyl, (C2-C6)-alkyl substituted by halogen, (C3-C6)-cycloalkyl, heterocycloalkyl, ( -C6) -alkyl- ( C3-C6) -cycloalkyl, ( -C6) -alkyl-heterocycloalkyl, (C1.C6)-alkyl-C(O)-R9, (CrC6)-alkyl-CN, (C2-C6)-alkyl-O-R13, (C2-C6)-alkyl- NR7R8, aryl or 6-membered heteroaryl containing one, two or three nitrogen atoms, ( -Cδ^alkyl-aryl or ( -C6)-alkyl-5 or-6-membered heteroaryl containing one, two or three heteroatoms, selected from the group consisting of oxygen, sulphur or nitrogen, wherein aryl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen, (Cι-C6)-alkyl or ( -C^-alkoxy; or R2 and R2 form together with the N atom to which they are attach a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O, which rings are unsubstituted or substituted by hydroxy, (CrC6) -alkyl, (C C6)-alkoxy, (C1-C6)-alkyl-O-R13, or form together with the N atom a 5-membered heteroaryl group, optionnally containing in addition to the N atom one, two or three further nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, (C1-C6)-alkyl, (CrC6)-alkyl substituted by halogen or (C3-C6)-cycloalkyl;
R3, R4 and R6 are independentiy from each other hydrogen, hydroxy, halogen, CN, (CrC6)-alkyl, (C1-C6)-alkoxy or NR7R8;
R5 is NO2, CN, C(O)R9, S-(C1-C6)-alkyl, SO2R10 or is NRnR12;
R7 and R8 are independently from each other hydrogen, (C1-C6)-alkyl-(C3-C6)-cycloalkyl, (C1-C6)-alkyl, or (C3-C6)-cycloalkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
R9 is hydroxy, (C C6)-alkyl, (C3-C6)-cycloalkyl, ( -CeJ-alkoxy or NR7R8;
R10 is (Cι-Ce)-alkyl, (C3-C6)-cycloalkyl, (Cι-C6)-alkyl-(C3- )-cycIoalkyl or NR7R8;
R1-1 and R12 are independently from each other hydrogen, C(0)-(Cι-C6)-aT yl, SO2-(C1-C6)-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, (Cι-C6)-alkyl, ( -C^-alkyl substituted by halogen or (C3-C6)-cycloalkyl;
R13 is hydrogen, (Cι-C6)-alkyl or (C3-C6)-cycloalkyl; and pharmaceutically acceptable acid addition salts thereof, with the proviso that
1 - [ 5- (aminosulfonyl) -2- (4-morpholinyl)benzoyl] -4-phenyl-piperazine, l-(4-methoxyphenyl)-4-[2-(4-morpholinyl)-5-nitiObenzoyl]-piperazine, l-[2-(4-morpholinyl)-5-nitrobenzoyl]-4-[2-nitro-4-(trifluoromethyl)phenyl]- piperazine, 1 - (4-methoxyphenyl)-4- [ 5-nitro-2- ( 1 -pyrrolidinyl)benzoyl] -piperazine, l-[2-[4-(2-hydroxyethyl)-l-piperazinyl]-5-nitrobenzoyl]-4-(4-methoxyphenyl)- piperazine, l-[2-fluoro-4-(l-oxopropyl)phenyl]-4-[5-nitro-2-(l-piperidinyl)benzoyl] -piperazine, l-[2-fluoro-4-(l-oxopropyl)phenyl]-4-[5-nitro-2-(l-pyrrolidinyl)benzoyl]-piperazine, l-[2-fluoro-4-(l-oxopropyl)phenyl]-4-[2-(4-methyl-l-piperidinyl)-5-nitrobenzoyl]- piperazine,
1- [2-fluoro-4-( l-oxopropyl)phenyl] -4-[2-(4-methyl-l-piperazinyl)-5-nitrobenzoyl] - piperazine,
1- [2-fluoro-4-( l-oxopropyl)phenyl] -4-[2-(4-morpholinyl)-5-nitrobenzoyl] -piperazine, 1- [5- [ [methyl(phenylmethyl)amino]sulfonyl] -2-(4-morpholinyl)benzoyl] -4-(4- nitrophenyl)-piperazine and l-(4-acetyl-2-fluorophenyl)-4- [2-(4-morpholinyl)-5-nitrobenzoyl] - piperazine, are excluded.
3. A compound of formula 1-1 according to claim 1
Figure imgf000169_0001
wherein
R' is hydroxy, halogen, NO2, CN, (C1-C6)-alkyl, (Cι-C6)-alkyl substituted by halogen, (Cι-C6)-alkoxy, (C C6)-alkoxy substituted by halogen, NR7R8, C(O)R9 or SO2R10; m is 0, 1, 2 or 3;
R1 is hydrogen or (CrC6)-alkyl;
R2 and R2 are independently from each other hydrogen, (CR2)n-hydroxy for R being hydrogen or C1-C6)-alkyl, or are (C1-C6)-alkyl, (C2-C6)-alkenyl, (C1-C6)-alkyl substituted by halogen, (CH2)n-(C3-C6)-cycloalkyl, (CH2)n-heterocycloalkyl, (CH2)n-O-(C1-C6)-alkyl or (CH2)n-aryl;
R3, R4 and R6 are independentiy from each other hydrogen, halogen, (Ci-Q -alkyl or (Cr )-alkoxy;
R5 is NO2, CN, C(O)R9, S-(C C6)-alkyl, SO2R10 or is NRπR12;
R7 and R8 are independently from each other hydrogen, (CH2)π-(C3-C6)-cycloalkyl or (Cι-C6)-alkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
R9 is hydroxy, (CrC6)-alkyl, (C3-C6)-cycloalkyl, (C C6)-alkoxy or NR7R8;
R10 is (Q-Q -alkyl, (CH2)n-(C3-C6)-cycloalkyl or NR7R8;
R11 and R12 are independently from each other hydrogen, C(O)-(CrC6)-alkyl, SO2-(C1-C6)-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, (Q-Q -alkyl or (CH2)n(C3-C6)-cycloalkyl;
n is 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof.
4. A compound of formula 1-1 according to claim 3, which compounds are
l-(4-{4-[2-(cyclopropylmethyl-amino)-5-nitro-benzoyl]-piperazin-l-yl}-3-fluoro- phenyl)-ethanone, l-{4-[4-(2-cyclohexylamino-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone, l-{4-[4-(2-diethylamino-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}-ethanone, l-{3-fluoro-4-[4-(2-isobutylamino-5-nitro-benzoyl)-piperazin-l-yl]-phenyl}-ethanone, l-{4-[4-(2-cyclobutylamino-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone, l-{4-[4-(2-cyclobutylamino-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone, l-{4-[4-(2-cyclopentylamino-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone or l-(4-{4-[2-(allyl-methyl-amino)-5-nitro-benzoyl]-piperazin-l-yl}-3-fluoro-phenyl)- ethanone.
5. A compound of formula 1-2 according to claim 1
Figure imgf000171_0001
wherein
R' is hydroxy, halogen, N02, CN, (Q-Q)-alkyl, (Q-C6)-alkyl substituted by halogen, (Q-C6)-alkoxy, (Q-C6)-alkoxy substituted by halogen, NR7R8, C(O)R9 or SO2R10; m is 0, 1, 2 or 3;
R1 is hydrogen or (Q-Q)-alkyl;
Figure imgf000171_0002
is a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O, which rings are unsubstituted or substituted by (CH2)n-hydroxy, (Q-Q)-alkyl, (Q-Q)-alkoxy, (CH2)n-O-(Q-C6)-alkyl, or form together with the N atom a 5-membered heteroaryl group, optionnally containing in addition to the N atom one, two or three further nitrogen atoms and wherein the heteroaryl group is optionally substituted by (Q- Q)-alkyl;
R3, R4 and R6 are independentiy from each other hydrogen, halogen, (Q-Q)-alkyl or (Q-C6)-alkoxy;
Rb is NO2, CN, C(O)Ry, S-(Q-Q)-alkyl, SO2Rιυ or is NR ) lUlR-r> 1122;.
R7 and R8 are independently from each other are hydrogen, (CH2)n-(C3-Q)-cycloalkyl or (Q-Q) -alkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
R9 is hydroxy, (Q-Q)-alkyl, (C3-C6)-cycloalkyl, (Q-Q)-alkoxy or NR7R8;
R10 is (Q-C6)-alkyl, (CH2)n-(C3-Q)-cycloalkyl or NR7R8; R11 and R12 are independently from each other hydrogen, C(O)-(Q-Q)-alkyl, SO2-(Q-C6)-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, (Q-Q)-alkyl or (CH2)„(C3-C6)-cycloalkyl;
n is 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof.
6. A compound of formula 1-2 according to claim 5, which compounds are
l-{4-[4-(2-morpholin-4-yl-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}-ethanone, l-{3-fluoro-4-[4-(5-nitro-2-pyrrolidin-l-yl-benzoyl)-piperazin-l-yl]-phenyl}-ethanone, 1 -{ 3-fluoro-4- [4- (5-nitro-2-piperidin- 1 -yl-benzoyl) -piperazin- 1 -yl] -phenyl} -ethanone, l-{4-[4-(2-azepan-l-yl-5-nitro-benzoyl)-piperazin-l-yl] -3-fluoro-phenyl}-ethanone, l-(3-fluoro-4-{4-[2-(2-methyl-piperidin-l-yl)-5-nitro-benzoyl]-piperazin-l-yl}- phenyl) -ethanone, 1- (3-fluoro-4- {4- [2- (4-methyl-piperidin- 1 -yl) -5-nitro-benzoyl] -piperazin- 1 -yl} - phenyl) -ethanone, l-(3-fluoro-4-{4-[2-(3-methyl-piperidin-l-yl)-5-nitro-benzoyl]-piperazin-l-yl}- phenyl)-ethanone, l-(3-fluoro-4-{4-[2-(2-methyl-pyrrolidin-l-yl)-5-nitro-benzoyl]-piperazin-l-yl}- phenyl) -ethanone, l-(4-{4-[2-(2,5-dihydro-pyrrol-l-yl)-5-nitro-benzoyl]-piperazin-l-yl}-3-fluoro-phenyl)- ethanone, l-{3-fluoro-4-[4-(5-nitro-2-thiomorpholin-4-yl-benzoyl)-piperazin-l-yl]-phenyl}- ethanone, l-(3-fluoro-4-{4-[2-(3-hydroxy-piperidin-l-yl)-5-nitro-benzoyl]-piperazin-l-yl}- phenyl)-ethanone, l-{4- [4-(2-azepan-l-yl-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -3-fluoro-phenyl}- ethanone, l-{3-fluoro-4-[4-(5-methanesulfonyl-2-pyrrolidin-l-yl-benzoyl)-piperazin-l-yl]- phenylj-ethanone, N-methyl-4-pyrrolidin-l-yl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]- benzenesulfonamide, N-methyl-4-morpholin-4-yl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]- benzenesulfonamide,
3-[4-(4-acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-N-methyl-4-pyrrolidin-l-yl- benzenesulfonamide, l-(3-fluoro-4-{4-[2-(3-hydroxymethyl-pyrrolidin-l-yl)-5-nitro-benzoyl]-piperazin-l- yl} -phenyl) -ethanone, 2-[4-(2-morpholin-4-yl-5-nitro-benzoyl)-piperazin-l-yl]-5-trifluoromethyl- benzonitrile, 3 -fluoro-4- [4- ( 5-methanesulfonyl-2-piperidin- 1 -yl-benzoyl) -piperazin- 1 -yl] - benzonitrile,
2-fluoro-4-[4-(5-methanesulfonyl-2-piperidin-l-yl-benzoyl)-piperazin-l-yl]- benzonitrile, [4- (2-fluoro-4-trifluoromethyl-phenyl) -piperazin- 1 -yl] - (5-methanesulfonyl-2-piperidin- 1 -yl-phenyl) -methanone, [4-(3-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-(5-methanesulfonyl-2-piperidin- 1 -yl-phenyl) -methanone, 3 - [4- (4-cyano-phenyl) -piperazine- 1 -carbonyl] -N-methyl-4-pyrrolidin- 1 -yl- benzenesulfonamide, 3- [4- (4-cyano-2-fluoro-phenyl) -piperazine- 1-carbonyl] -N-methyl-4-pyrrolidin- 1 -yl- benzenesulfonamide,
3-[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]-N-methyl-4- pyrrolidin-1-yl-benzenesulfonamide, 3-[4-(3-fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]-N-methyl-4- pyrrolidin-1-yl-benzenesulfonamide, 3-[4-(4-acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-N-methyl-4-piperidin-l-yl- benzenesulfonamide, 3-[4-(4-cyano-phenyl)-piperazine-l-carbonyl]-N-methyl-4-piperidin-l-yl- benzenesulfonamide, 3 - [4- (4-cyano-2 -fluoro-phenyl) -piperazine- 1 -carbonyl] -N-methyl-4-piperidin- 1 -yl- benzenesulfonamide,
3-[4-(4-cyano-3-fluoro-phenyl)-piperazine-l-carbonyl]-N-methyl-4-piperidin-l-yl- benzenesulfonamide, N-methyl-4-piperidin-l-yl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]- benzenesulfonamide, 3-[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]-N-methyl-4- piperidin- 1 -yl-benzenesulfonamide, 3-[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]-N-methyl-4- piperidin-1-yl-benzenesulfonamide, 3-[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]-N-methyl-4- morpholin-4-yl-benzenesulfonamide or 3-[4-(3-fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]-N-methyl-4- morpholin-4-yl-benzenesulfonamide.
7. A compound of formula 1-3 according to claim 1
Figure imgf000174_0001
wherein
hetaryl is a 6-membered heteroaryl, containing one, two or three nitrogen atoms, optionally substituted by one or more substituents selected from the group consisting of hydroxy, halogen, NO2, CN, (Q-Q)-alkyl, (Q-C6)-alkyl substituted by halogen, (Q-C6)-alkoxy, (Q-C6)-alkoxy substituted by halogen, NR7R8, C(O)R9 or SO2R10;
R1 is hydrogen or (Q-Q)-alkyl; R2 and R2 are independently from each other hydrogen, (CR2)n-hydroxy for R being hydrogen or Q-C6)-alkyl, or are (Q-C6)-alkyl, (C2-Q)-alkenyl, (C C6)-alkyl substituted by halogen, (CH2)n-(C3-Q)-cycloalkyl, (CH2)n-heterocycloalkyl, (CH2)„-O-(Q-C6)-alkyl or (CH2)n-aryl or
R3, R4 and R6 are independentiy from each other hydrogen, halogen, (Q-Q)-alkyl or (Q-C6)-alkoxy;
R5 is NO2, CN, C(O)R9, S-(Q-C6) -alkyl, SO2R10 or is NRnR12;
R7 and R8 are independently from each other are hydrogen, (CH2)n-(Q-Q)-cycloalkyl or (Q-C6)-alkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
R9 is hydroxy, (Q-Q) -alkyl, (C3-C6)-cycloalkyl, (Q-C6)-alkoxy or NR7R8;
R10 is (Q-C6)-alkyl, (CH2)n-(C3-Q)-cycloalkyl or NR7R8;
R11 and R12 are independentiy from each other hydrogen, C(O)-(Q-Q)-alkyl, S02-(Q-Q)-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, (Q-Q)-alkyl or (CH2)n(C3-C6)-cycloalkyl;
n is 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof.
8. A compound of formula 1-4 according to claim 1
Figure imgf000175_0001
wherein hetaryl is a 6-membered heteroaryl, containing one, two or three nitrogen atoms, optionally substituted by one or more substituents selected from the group consisting of hydroxy, halogen, NO2, CN, (Q-Q)-alkyl, (Q-Q)-alkyl substituted by halogen, (Q-Q)-alkoxy, (Q-Q)-alkoxy substituted by halogen, NR7R8, C(O)R9 or SO2R10;
R1 is hydrogen or (Q-Q) -alkyl;
Figure imgf000175_0002
* is a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O, which rings are unsubstituted or substituted by (CH2)n-hydroxy, (Q-Q)-alkyl, (C1-C6)-alkoxy, (CH2)n-0-(C1-C6)-alkyl, or form together with the N atom a 5-membered heteroaryl group, optionnally containing in addition to the N atom one, two or three further nitrogen atoms and wherein the heteroaryl group is optionally substituted by (Q- Q)-alkyl;
R3, R and R6 are independently from each other hydrogen, halogen, (Q-Q)-alkyl or (Q-Q)-alkoxy;
R5 is NO2, CN, C(O)R9, S-(Q-Q)-alkyl, SO2R10 or is NRUR12;
R7 and R8 are independently from each other hydrogen, (CH2)n-(C3-Q)-cycloalkyl or (Q-Q)-alkyl, or form together with the N atom to which they are attached a heterocycloalkyl ring, optionally containing in addition to the N atom a further heteroatom, selected from the group consisting of N, S or O;
R9 is hydroxy, (Q-Q)-alkyl, (Q-Q^cycloalkyl, (Q-C6)-alkoxy or NR7R8;
R10 is (Q-Q)-alkyl, (CH2)„-(C3-C6)-cycloalkyl or NR7R8;
R11 and R12 are independently from each other hydrogen, C(O)-(Q-Q)-alkyl, S02-(Q-Q)-alkyl, or form together with the N-atom a 5-membered heteroaryl group optionally containing in addition to the N atom one, two or three nitrogen atoms and wherein the heteroaryl group is optionally substituted by halogen, (Q-Q)-alkyl or (CH2)n(C3-Q)-cycloalkyl;
n is 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof.
9. A compound of formula 1-4 according to claim 8, which compounds are
3-[4-(3-fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]-N-methyl-4- morpholin-4-yl-benzenesulfonamide (2-morpholin-4-yl-5-nitro-phenyl)-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]- methanone [4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-(2-morpholin-4-yl-5- nitro-phenyl)-methanone 6-[4-(2-morpholin-4-yl-5-nitro-benzoyl)-piperazin-l-yl]-nicotinonitrile [4-(3-chloro-pyridin-2-yl)-piperazin-l-yl]-(2-morpholin-4-yl-5-nitro-phenyl)- mefhanone
(2-morpholin-4-yl-5-nitro-phenyl)-[4-(4-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]- methanone
(2-morpholin-4-yl-5-nitro-phenyl)-[4-(6-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]- methanone [4-(5-bromo-pyrimidin-2-yl)-piperazin-l-yl]-(2-morpholin-4-yl-5-nitro-phenyl)- mefhanone [4-(6-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l -yl] -(2-morpholin-4-yl-5- nitro-phenyl) -methanone (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(2-trifluoromethyl-pyrimidin-4-yl)- piperazin- 1-yl] -methanone (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(6-trifluoromethyl-pyrimidin-4-yl)- piperazin- 1-yl] -methanone
(5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(5-trifluoromethyl-pyrimidin-2-yl)- piperazin- 1 -yl] -methanone 6-[4-(5-methanesulfonyl-2-morphoHn-4-yl-benzoyl)-piperazin-l-yl]-nicotinonitrile (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(5-trifluoromethyl-pyridin-2-yl)- piperazin- 1-yl] -methanone
[4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-(5-methanesulfonyl-2- morpholin-4-yl-phenyl)-methanone [4-(5-chloro-pyridin-2-yl)-piperazin-l-yl]-(5-methanesulfonyl-2-morpholin-4-yl- phenyl) -methanone (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(6-trifluoromethyl-pyridin-3-yl)- piperazin- 1-yl] -methanone [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-(5-methanesulfonyl-2- morpholin-4-yl-phenyl) -methanone (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(6-methyl-pyridin-3-yl)-piperazin-l- yl] -methanone
( 5 -methanesulfonyl-2-morpholin-4-yl-phenyl) - [4- ( 5 -methyl-pyridin-2-yl) -piperazin- 1 - yl] -methanone (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(4-trifluoromethyl-pyridin-2-yl)- piperazin- 1 -yl] -methanone (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(6-trifluoromethyl-pyridin-2-yl)- piperazin- 1 -yl] -methanone (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(2-trifluorometiιyl-pyrimidin-5-yl)- piperazin- 1 -yl] -methanone (5-methanesulfonyl-2-morpholin-4-yl-phenyl)-[4-(6-trifluoromethyl-pyridazin-3-yl)- piperazin- 1-yl] -methanone [4-(4-dimethylamino-[l,3,5]triazin-2-yl)-piperazin-l-yl]-(5-methanesulfonyl-2- morpholin-4-yl-phenyl) -methanone or (5-metiιanesulfonyl-2-morpholin-4-yl-phenyl)-(5'-trifluoromethyl-2,3,5,6-tetrahydro- [ 1 ,2' ] bipyrazinyl-4-yl) -methanone.
10. Processes for preparation of compounds of formula I and their pharmaceutically acceptable salts, which process comprises a) reacting a compound of formula
N Ar' R,
with a compound of formula
Figure imgf000178_0001
to a compound of formula
Figure imgf000178_0002
wherein Z is OH or halogen and the other substituents are as defined in claim 1, or b) reacting a compound of formula
Figure imgf000179_0001
with a compound of formula
R2R2NH
to a compound of formula
Figure imgf000179_0002
wherein X is halogen and the other substituents are as defined in claim 1, c) reacting a compound of formula
Figure imgf000179_0003
with a compound of formula
ArX
to a compound of formula
Figure imgf000179_0004
wherein X is halogen and the other substituents are as defined in claim 1, c) reacting a compound of formula
Figure imgf000180_0001
with hydrogen on Pd/C to a compound of formula
Figure imgf000180_0002
wherein the substituents are as defined in claim 1, d) reacting a compound of formula
Figure imgf000180_0003
with a compound of formula
R14AX to a compound of formula
Figure imgf000180_0004
wherein X is halogen, A is -C(O)- or -SO2-, R14 is (Cι- )-alkyl and the other substituents are as defined in claim 1, e) reacting a compound of formula
Figure imgf000181_0001
with a compound of formula
R15C(OEt)3
to a compound of formula
Figure imgf000181_0002
wherein R15 is hydrogen, halogen, (Q-Q)-alkyl, (Q-C6)-alkyl substituted by halogen or (C3-Q)-cycloalkyl and the other substituents are as defined in claim 1, f) reacting a compound of formula
Figure imgf000181_0003
with a base
to a compound of formula
Figure imgf000182_0001
wherein the substituents are as defined in claim 1, g) reacting a compound of formula
Figure imgf000182_0002
with a compound of formula
R7R8NH
to a compound of formula
Figure imgf000182_0003
wherein the substituents are as defined in claiml, h) reacting a compound of formula
Figure imgf000182_0004
with a compound of formula
Figure imgf000183_0001
to a compound of formula
Figure imgf000183_0002
wherein R is (C1-C6)-alkyl, R16 is (C C6)-alkyl or (C3-C6)-cycloalkyl and the other substituents are as defined in claim 1, j) reacting a compound of formula
Figure imgf000183_0003
with a compound of formula
Figure imgf000183_0004
to a compound of formula
Figure imgf000184_0001
wherein X is CH or N and the heteroaryl ring is selected from the group consisting of imidazole, pyrazole or triazole, R15 is hydrogen, halogen, (Q-C6)-alkyl, (Q-Q)-alkyl substituted by halogen or (C3-Q)-cycloalkyl and the other substituents are as defined in claim 1,
and if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.
11. A compound according to claim 1, whenever prepared by a process as claimed in claim 10 or by an equivalent method.
12. A medicament containing one or more compounds as claimed in claim 1 or containing
1 - [ 5- (aminosulfonyl) -2- (4-morpholinyl)benzoyl] -4-phenyl-piperazine, l-(4-methoxyphenyl)-4-[2-(4-morpholinyl)-5-nitrobenzoyl] -piperazine, l-[2-(4-morpholinyl)-5-nitrobenzoyl]-4-[2 nitro-4-(trifluoromethyl)phenyl]- piperazine, l-(4-methoxyphenyl)-4- [5-nitro-2-( l-pyrrolidinyl)benzoyl] -piperazine, 1 - [2- [4- (2-hydroxyethyl) - 1 -piperazinyl] -5-nitrobenzoyl] -4- (4-methoxyphenyl) - piperazine, 1- [2-fluoro-4-( l-oxopropyl)phenyl] -4-[5-nitro-2-( l-piperidinyl)benzoyl] -piperazine, 1- [2-fluoro-4-( l-oxopropyl)phenyl] -4-[5-nitro-2-( l-pyrrolidinyl)benzoyl] -piperazine, 1 - [2-fluoro-4-( l-oxopropyl)phenyl] -4- [2-(4-methyl- l-piperidinyl)-5-nitrobenzoyl] - piperazine, 1- [2-fluoro-4-( l-oxopropyl)phenyl] -4- [2-(4-methyl-l-piperazinyl)-5-nitrobenzoyl] - piperazine,
1 - [2-fluoro-4-( l-oxopropyl)phenyl] -4- [2-(4-morpholinyl)-5-nitrobenzoyl] -piperazine, l-[5-[[methyl(phenylmethyl)amino]sulfonyl]-2-(4-morpholinyl)benzoyl]-4-(4- nitrophenyl) -piperazine, l-(4-acetyl-2-fluorophenyl)-4- [2-(4-morpholinyl)-5-nitrobenzoyl] - piperazine, l-{4-[4-(2-morpholin-4-yl-5-nitro-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}-ethanone and [4-(4-methoxy-phenyl)-piperazin-l-yl]-(2-morpholin-4-yl-5-nitro-phenyl)-methanone. and pharmaceutically acceptable excipients.
13. A medicament according to claim 12 for the treatment of illnesses based on the glycine uptake inhibitor.
14. A medicament according to claims 12 and 13, wherein the illnesses are psychoses, pain, disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
15. The use of a compound as claimed in claim 1 and of l-[5-(aminosulfonyl)-2-(4-morpholinyl)benzoyl]-4-phenyl-piperazine, l-(4-methoxyphenyl)-4-[2-(4-morpholinyl)-5-nitrobenzoyl] -piperazine, 1- [2-(4-morpholinyl)-5-nitrobenzoyl] -4- [2-nitro-4-(trifluoromethyl)phenyl] - piperazine, l-(4-methoxyphenyl)-4-[5-nitro-2-(l-pyrrolidinyl)benzoyl] -piperazine, l-[2-[4-(2-hydroxyethyl)-l-piperazinyl]-5-nitrobenzoyl]-4-(4-methoxyphenyl)- piperazine, l-[2-fluoro-4-(l-oxopropyl)phenyl]-4-[5-nitro-2-(l-piperidinyl)benzoyl] -piperazine, 1 - [2-fluoro-4- ( 1 -oxopropyl)phenyl] -4- [5-nitro-2- ( 1 -pyrrolidinyl)benzoyl] -piperazine, l-[2-fluoro-4-(l-oxopropyl)phenyl]-4-[2-(4-methyl-l-piperidinyl)-5-nitrobenzoyl]- piperazine, 1- [2-fluoro-4-( l-oxopropyl)phenyl] -4- [2-(4-methyl-l-piperazinyl)-5-nitrobenzoyl] - piperazine, l-[2-fluoro-4-(l-oxopropyl)phenyl]-4-[2-(4-morpholinyl)-5-nitrobenzoyl] -piperazine, l-[5-[[methyl(phenylmethyl)amino]sulfonyl]-2-(4-morpholinyl)benzoyl]-4-(4- nitrophenyl)-piperazine, l-(4-acetyl-2-fluorophenyl)-4-[2-(4-morpholinyl)-5-nitrobenzoyl]- piperazine, l-{4- [4-(2-morpholin-4-yl-5-nitro-benzoyl)-piperazin-l-yl] -3-fluoro-phenyl}-ethanone and [4-(4-methoxy-phenyl)-piperazin-l-yl]-(2-morpholin-4-yl-5-nitro-phenyl)-methanone for the manufacture of medicaments for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
16. The invention as herein before described. ***
PCT/EP2004/009665 2003-09-09 2004-08-30 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses WO2005023260A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
DE602004009323T DE602004009323T2 (en) 2003-09-09 2004-08-30 1- (2-AMINO-BENZOYL) -PIPERAZINE DERIVATIVES AS A GLYCIN INHIBITION FOR THE TREATMENT OF PSYCHOSES
NZ545454A NZ545454A (en) 2003-09-09 2004-08-30 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
PL04764631T PL1663232T3 (en) 2003-09-09 2004-08-30 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
MXPA06002727A MXPA06002727A (en) 2003-09-09 2004-08-30 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses.
BRPI0414209A BRPI0414209B8 (en) 2003-09-09 2004-08-30 1-(2-amino-benzol)-piperazine derivatives, their preparation processes and their use, and medicine
EP04764631A EP1663232B1 (en) 2003-09-09 2004-08-30 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
DK04764631T DK1663232T3 (en) 2003-09-09 2004-08-30 Benzimidazole derivatives as human chymase inhibitors
CN2004800321632A CN1874777B (en) 2003-09-09 2004-08-30 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
JP2006525694A JP4563386B2 (en) 2003-09-09 2004-08-30 1- (2-Amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychosis
CA2537292A CA2537292C (en) 2003-09-09 2004-08-30 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
AU2004269889A AU2004269889B2 (en) 2003-09-09 2004-08-30 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
IL173768A IL173768A0 (en) 2003-09-09 2006-02-16 1-(2-amino-benzol)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
NO20060768A NO20060768L (en) 2003-09-09 2006-02-17 1- (2-Amino-benzene) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03019686.9 2003-09-09
EP03019686 2003-09-09

Publications (1)

Publication Number Publication Date
WO2005023260A1 true WO2005023260A1 (en) 2005-03-17

Family

ID=34259149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/009665 WO2005023260A1 (en) 2003-09-09 2004-08-30 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses

Country Status (23)

Country Link
US (2) US7427612B2 (en)
EP (1) EP1663232B1 (en)
JP (1) JP4563386B2 (en)
KR (1) KR100774630B1 (en)
CN (1) CN1874777B (en)
AR (1) AR045602A1 (en)
AT (1) ATE374610T1 (en)
AU (1) AU2004269889B2 (en)
BR (1) BRPI0414209B8 (en)
CA (1) CA2537292C (en)
DE (1) DE602004009323T2 (en)
DK (1) DK1663232T3 (en)
ES (1) ES2294529T3 (en)
IL (1) IL173768A0 (en)
MX (1) MXPA06002727A (en)
NO (1) NO20060768L (en)
NZ (1) NZ545454A (en)
PL (1) PL1663232T3 (en)
PT (1) PT1663232E (en)
RU (1) RU2354653C2 (en)
TW (1) TWI295287B (en)
WO (1) WO2005023260A1 (en)
ZA (1) ZA200601990B (en)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103000A1 (en) * 2004-04-20 2005-11-03 Glaxo Group Limited N-`4-4(4-morpholinyl) phenyl!-`(4-piperidinyl) methyl! carboxamide derivatives and their use as glycine transporter inhibitors
WO2006061135A1 (en) * 2004-12-09 2006-06-15 F. Hoffmann-La Roche Ag Phenyl-piperazin methanone derivatives
WO2006063709A1 (en) * 2004-12-15 2006-06-22 F.Hoffmann-La Roche Ag Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer’s disease
WO2006067430A1 (en) * 2004-12-23 2006-06-29 Glaxo Group Limited 2-amino-1-phenylethylcarboxamide derivatives
WO2006072435A1 (en) * 2005-01-06 2006-07-13 F.Hoffmann-La Roche Ag Sulfanyl substituted phenyl methanones as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
WO2006072436A1 (en) * 2005-01-07 2006-07-13 F. Hoffmann-La Roche Ag [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
WO2006094843A1 (en) * 2005-03-11 2006-09-14 Glaxo Group Limited Piperazine derivatives as glyt1 inhibitors
WO2006094842A1 (en) * 2005-03-11 2006-09-14 Glaxo Group Limited Acylated piperidihes as glycine transporter inhibitors
US7462617B2 (en) * 2003-09-09 2008-12-09 Hoffmann-La Roche Inc. Substituted acylpiperazine derivatives
WO2009051112A1 (en) 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
US7595314B2 (en) * 2003-09-09 2009-09-29 Hoffmann-La Roche Inc. Benzoyl-piperazine derivatives
WO2009146648A1 (en) 2008-06-04 2009-12-10 中国中化集团公司 Amide compounds, preparation methods and uses thereof
US7745642B2 (en) 2004-12-23 2010-06-29 Glaxo Group Limited Glycine transport inhibitors
US7767677B2 (en) * 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CN101007794B (en) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,N'-disubstituted piperazine derivative, and its preparation method and medicinal composition and uses
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US8026360B2 (en) 2004-09-20 2011-09-27 Xenon Pharmaceuticals Inc. Substituted pyridazines as stearoyl-CoA desaturase inhibitors
WO2011136292A1 (en) * 2010-04-27 2011-11-03 田辺三菱製薬株式会社 Novel amide derivative and use thereof as medicine
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US8420670B2 (en) 2007-08-22 2013-04-16 Abbott Laboratories 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
JP2013107881A (en) * 2011-10-26 2013-06-06 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition containing novel amide derivative as active ingredient
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
US8563617B2 (en) 2009-02-16 2013-10-22 AbbVie Deutschland GmbH & Co. KG Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US8642587B2 (en) 2009-02-16 2014-02-04 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
US8653100B2 (en) 2008-04-01 2014-02-18 Abbvie Inc. Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
US8846741B2 (en) 2011-11-18 2014-09-30 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586942B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586945B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US10562884B2 (en) 2018-06-05 2020-02-18 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525398A (en) * 2004-12-23 2008-07-17 グラクソ グループ リミテッド Glycine transport inhibitor
US7485637B2 (en) * 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
MX2007008616A (en) * 2005-01-18 2007-09-11 Hoffmann La Roche 2, 5-disubstituted phenyl methanone derivatives as glycine transporter 1 (glyt-i) inhibitors for the treatment of neurological and neuropsychiatry disorders.
ES2332529T3 (en) * 2005-01-26 2010-02-08 F. Hoffmann-La Roche Ag DERIVATIVES OF PHENYL-METANONE AND ITS EMPLOYMENT AS INHIBITORS OF GLICINE TRANSPORTER 1.
EP1848694B1 (en) * 2005-02-07 2009-11-25 F. Hoffmann-Roche AG Heterocyclic substituted phenyl methanones as inhibitors of the glycine transporter 1
GB0505085D0 (en) * 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
WO2009102761A1 (en) 2008-02-12 2009-08-20 Bristol-Myers Squibb Company 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type i inhibitors
DK2470182T3 (en) * 2009-08-24 2014-07-21 Neuralstem Inc SYNTHESIS OF A NEUROSTIMULATING PIPERAZINE
US8153653B2 (en) * 2010-06-22 2012-04-10 Hoffmann-La Roche Inc. Amido-tropane derivatives
WO2015164520A1 (en) 2014-04-24 2015-10-29 Dart Neuroscience, Llc Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c] pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c] pyridine compounds as glyt1 inhibitors
TWI601712B (en) 2014-11-05 2017-10-11 達特神經科學（開曼）有限責任公司 Substituted azetidinyl compounds as glyt1 inhibitors
CN114409621B (en) * 2022-02-09 2023-09-08 江苏省原子医学研究所 Targeted dopamine D 3 Diagnosis and treatment medicine for receptor and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933802A (en) * 1973-05-28 1976-01-20 Ciba-Geigy Corporation New sulphamoylbenzoic acid amides
US4244871A (en) * 1976-03-18 1981-01-13 Richter Gedeon Vegyeszeti Gyar Rt Sulfonamido-benzoic acid derivatives
EP0171636A1 (en) * 1984-08-14 1986-02-19 RAVIZZA S.p.A. Pharmacologically active piperazino derivatives and the process for their preparation
WO1999044596A2 (en) * 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Glycine transport inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100774622B1 (en) * 2003-08-11 2007-11-08 에프. 호프만-라 로슈 아게 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors
JP4563387B2 (en) * 2003-09-09 2010-10-13 エフ．ホフマン−ラ ロシュ アーゲー 1-Benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychosis
DK1663232T3 (en) * 2003-09-09 2008-02-04 Hoffmann La Roche Benzimidazole derivatives as human chymase inhibitors
US7191925B2 (en) * 2003-09-16 2007-03-20 Aris Sandra M Clean carry apparatus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933802A (en) * 1973-05-28 1976-01-20 Ciba-Geigy Corporation New sulphamoylbenzoic acid amides
US4244871A (en) * 1976-03-18 1981-01-13 Richter Gedeon Vegyeszeti Gyar Rt Sulfonamido-benzoic acid derivatives
EP0171636A1 (en) * 1984-08-14 1986-02-19 RAVIZZA S.p.A. Pharmacologically active piperazino derivatives and the process for their preparation
WO1999044596A2 (en) * 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Glycine transport inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1 January 2004 (2004-01-01), XP002308403, Database accession no. 2004:591813 *
DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1 January 2004 (2004-01-01), XP002308404, Database accession no. 2004:660630 *
DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1 January 2004 (2004-01-01), XP002308405, Database accession no. 2003: 2872406 CHEMCATS *
DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 23 April 2003 (2003-04-23), XP002308402, Database accession no. 2003: 2142911 CHEMCATS *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 6 June 2003 (2003-06-06), XP002308481, Database accession no. CAS RN: 524034-40-0 *

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462617B2 (en) * 2003-09-09 2008-12-09 Hoffmann-La Roche Inc. Substituted acylpiperazine derivatives
US7595314B2 (en) * 2003-09-09 2009-09-29 Hoffmann-La Roche Inc. Benzoyl-piperazine derivatives
WO2005103000A1 (en) * 2004-04-20 2005-11-03 Glaxo Group Limited N-`4-4(4-morpholinyl) phenyl!-`(4-piperidinyl) methyl! carboxamide derivatives and their use as glycine transporter inhibitors
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7767677B2 (en) * 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US8026360B2 (en) 2004-09-20 2011-09-27 Xenon Pharmaceuticals Inc. Substituted pyridazines as stearoyl-CoA desaturase inhibitors
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
WO2006061135A1 (en) * 2004-12-09 2006-06-15 F. Hoffmann-La Roche Ag Phenyl-piperazin methanone derivatives
US7241761B2 (en) 2004-12-09 2007-07-10 Hoffmann-La Roche Inc. Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups
US7429585B2 (en) 2004-12-09 2008-09-30 Hoffmann-La Roche Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups
US7375226B2 (en) 2004-12-15 2008-05-20 Hoffman-La Roche Inc. Bi- and tricyclic substituted phenyl methanones
WO2006063709A1 (en) * 2004-12-15 2006-06-22 F.Hoffmann-La Roche Ag Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer’s disease
US7745642B2 (en) 2004-12-23 2010-06-29 Glaxo Group Limited Glycine transport inhibitors
WO2006067430A1 (en) * 2004-12-23 2006-06-29 Glaxo Group Limited 2-amino-1-phenylethylcarboxamide derivatives
WO2006072435A1 (en) * 2005-01-06 2006-07-13 F.Hoffmann-La Roche Ag Sulfanyl substituted phenyl methanones as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
WO2006072436A1 (en) * 2005-01-07 2006-07-13 F. Hoffmann-La Roche Ag [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
US7220744B2 (en) 2005-01-07 2007-05-22 Hoffman-La Roche Inc. Monocyclic substituted phenyl methanones
WO2006094842A1 (en) * 2005-03-11 2006-09-14 Glaxo Group Limited Acylated piperidihes as glycine transporter inhibitors
WO2006094843A1 (en) * 2005-03-11 2006-09-14 Glaxo Group Limited Piperazine derivatives as glyt1 inhibitors
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
CN101007794B (en) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,N'-disubstituted piperazine derivative, and its preparation method and medicinal composition and uses
US8420670B2 (en) 2007-08-22 2013-04-16 Abbott Laboratories 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
WO2009051112A1 (en) 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
US8329691B2 (en) 2007-10-15 2012-12-11 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
US8957089B2 (en) 2008-04-01 2015-02-17 AbbVie Deutschland GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
US8653100B2 (en) 2008-04-01 2014-02-18 Abbvie Inc. Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
WO2009146648A1 (en) 2008-06-04 2009-12-10 中国中化集团公司 Amide compounds, preparation methods and uses thereof
US8563617B2 (en) 2009-02-16 2013-10-22 AbbVie Deutschland GmbH & Co. KG Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8642587B2 (en) 2009-02-16 2014-02-04 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
US9096619B2 (en) 2009-02-16 2015-08-04 AbbVie Deutschland GmbH & Co. KG Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9067871B2 (en) 2009-02-16 2015-06-30 AbbVie Deutschland GmbH & Co. KG Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2011136292A1 (en) * 2010-04-27 2011-11-03 田辺三菱製薬株式会社 Novel amide derivative and use thereof as medicine
KR101800044B1 (en) 2010-04-27 2017-11-21 미쓰비시 타나베 파마 코퍼레이션 Novel amide derivative and use thereof as medicine
US8816079B2 (en) 2010-04-27 2014-08-26 Mitsubishi Tanabe Pharma Corporation Amide derivative and use thereof as medicine
AU2011246095A8 (en) * 2010-04-27 2016-10-27 Mitsubishi Tanabe Pharma Corporation Novel amide derivative and use thereof as medicine
AU2011246095B2 (en) * 2010-04-27 2016-10-20 Mitsubishi Tanabe Pharma Corporation Novel amide derivative and use thereof as medicine
US9227930B2 (en) 2010-08-13 2016-01-05 Abbvie Inc. Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9238619B2 (en) 2010-08-13 2016-01-19 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2013107881A (en) * 2011-10-26 2013-06-06 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition containing novel amide derivative as active ingredient
US8846741B2 (en) 2011-11-18 2014-09-30 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586942B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586945B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US10562884B2 (en) 2018-06-05 2020-02-18 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US10604507B2 (en) 2018-06-05 2020-03-31 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US10766877B2 (en) 2018-06-05 2020-09-08 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US10981894B2 (en) 2018-06-05 2021-04-20 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US11566015B2 (en) 2018-06-05 2023-01-31 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

Also Published As

Publication number Publication date
NO20060768L (en) 2006-06-06
ES2294529T3 (en) 2008-04-01
MXPA06002727A (en) 2006-06-05
NZ545454A (en) 2009-11-27
US20050070539A1 (en) 2005-03-31
DE602004009323T2 (en) 2008-07-10
DE602004009323D1 (en) 2007-11-15
CA2537292C (en) 2013-04-02
TW200526600A (en) 2005-08-16
AU2004269889A1 (en) 2005-03-17
CA2537292A1 (en) 2005-03-17
RU2354653C2 (en) 2009-05-10
BRPI0414209B1 (en) 2019-03-19
KR100774630B1 (en) 2007-11-08
PL1663232T3 (en) 2008-05-30
US7427612B2 (en) 2008-09-23
JP2007505060A (en) 2007-03-08
ATE374610T1 (en) 2007-10-15
IL173768A0 (en) 2006-07-05
EP1663232A1 (en) 2006-06-07
JP4563386B2 (en) 2010-10-13
CN1874777B (en) 2012-07-04
EP1663232B1 (en) 2007-10-03
BRPI0414209B8 (en) 2021-05-25
DK1663232T3 (en) 2008-02-04
PT1663232E (en) 2007-12-12
US7595314B2 (en) 2009-09-29
BRPI0414209A (en) 2006-10-31
KR20060037464A (en) 2006-05-03
RU2006111583A (en) 2007-10-27
US20090192136A1 (en) 2009-07-30
AU2004269889B2 (en) 2009-07-23
AR045602A1 (en) 2005-11-02
CN1874777A (en) 2006-12-06
TWI295287B (en) 2008-04-01
ZA200601990B (en) 2007-05-30

Similar Documents

Publication Publication Date Title
EP1663232A1 (en) 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
CA2538135C (en) 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
JP4252598B2 (en) Piperazine having an OR-substituted phenyl group and their use as a GLYT1 inhibitor
US20080287455A1 (en) Sulfanyl substituted phenyl methanones

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480032163.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004764631

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 173768

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 545454

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 06019309

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2537292

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004269889

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 815/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006/01990

Country of ref document: ZA

Ref document number: 12006500491

Country of ref document: PH

Ref document number: 1020067004792

Country of ref document: KR

Ref document number: 200601990

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/002727

Country of ref document: MX

Ref document number: 2006525694

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004269889

Country of ref document: AU

Date of ref document: 20040830

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004269889

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006111583

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020067004792

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004764631

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0414209

Country of ref document: BR

WWG Wipo information: grant in national office

Ref document number: 2004764631

Country of ref document: EP